Skip to content
FrontierPicks

Dossiers · 942 published · 942 with a kill line · 8 archetypes · 40 themes

Thesis. Kill line. Catalyst. Per ticker.

Each dossier compresses thirty days of news, four quarters of earnings transcripts, and narrative-cluster classification into one read: thesis, kill line, archetype, conviction, catalyst calendar. Generated by a frontier model, dated, and graded against the line it published.

Watch lists

Conviction mix

  1. Supreme 14 · 1%
  2. High 28 · 3%
  3. Medium 298 · 32%
  4. Low 602 · 64%

Archetype mix

  1. Compounder 139 · 15%
  2. Cyclical recovery 122 · 13%
  3. Theme leader 62 · 7%
  4. Special situation 258 · 27%
  5. Earnings inflection 228 · 24%
  6. Retail squeeze 48 · 5%
  7. Defensive 85 · 9%

Freshness · last analysed

  1. ≤ 7 days 915 · 97%
  2. ≤ 30 days 27 · 3%

conviction highmediumlownone

942 shown

No dossiers match your filters.

Held

29
HPE Hewlett Packard Enterprise Company fresh HIGH Hewlett Packard Enterprise's AI and networking earnings transition supports a repricing thesis that requires intact growth guidance and the first weekly close above $54.44 after the 2026-09-30 Investor Day. A weekly close below $50… Special situation · AI datacenter infrastructure catalyst · AMD Advanced Micro Devices, Inc. fresh MEDIUM Advanced Micro Devices’ Helios story depends on OpenAI bringing the platform online in the fourth quarter of 2026. Confirmed operation would settle the deployment case; a weekly close below $456 or activation postponed beyond that quarter… Cyclical recovery · AI chips & memory analysed · IRDM Iridium Communications Inc fresh MEDIUM Iridium Communications’ merger-discount thesis now has completed financing behind it; acquisition completion before a weekly close below $43.50 settles the case. Rocket Lab’s 2026-09-15 funding announcement advances the transaction, while… Earnings inflection · Space economy catalyst · MRCY Mercury Systems Inc fresh MEDIUM Defense-electronics turnaround still re-rating on record bookings and a promised FCF turn, but the stock has given back ~20% from its $128.45 ATH and now chops near the analyst median (~$103) into a binary ~Aug 10-18 Q4/full-year print.… Special situation · Defense & aerospace catalyst · MU Micron Technology, Inc. fresh MEDIUM Micron Technology's contracted memory revenue supports an earnings-durability thesis tested on 2026-09-30 against June's $50.0 billion ±$1.0 billion revenue guidance and an 86% adjusted gross-margin benchmark. A weekly close below $958… Cyclical recovery · AI chips & memory catalyst · NTAP NetApp, Inc. fresh MEDIUM NetApp's AI storage recovery requires delivery of September guidance before a weekly close below $164 breaks the thesis. Fiscal-Q2 revenue of at least $2.025 billion and non-GAAP gross margin of at least 67.0%, with the annual revenue… Special situation · AI datacenter infrastructure catalyst · OKTA Okta, Inc. fresh MEDIUM Identity-security re-rating in its second, sell-side-led leg; the upgrade wave is still building nearly two months post-print — Wells Fargo lifted its target to $150 from $100 on 2026-07-20, collapsing the low-end dispersion. Cyber theme… Defensive · Cybersecurity catalyst · OSCR Oscar Health, Inc. fresh MEDIUM Oscar Health's higher earnings outlook and quantified 2027 pricing support a post-Investor-Day rerating. A weekly close above $32.76 before a weekly close below $29.83 would complete the price-confirmation test; the September 18, 2026… Earnings inflection · Managed care & health services analysed · RXO RXO, Inc. fresh MEDIUM Freight-cycle recovery intact; sell-side has fully caught up into a $20–35 battleground — bears $20 (Goldman 07-16, Susquehanna 07-14), bulls $30–35 (BMO $35 initiation 07-14, Stifel/Truist/Citi $30). Narrative matured from mispriced to… Compounder · Freight & logistics · Cyclical industrials analysed · SIMO Silicon Motion Technology Corporation fresh MEDIUM Silicon Motion's enterprise-storage expansion needs third-quarter 2026 revenue of at least $519 million to validate the recovery before a weekly close below $230 breaks it. September 15 supply and customer-ramp commentary supports the… Cyclical recovery · AI chips & memory catalyst · SNDK Sandisk Corporation fresh MEDIUM Sandisk’s contracted-revenue story has regained its post-Investor Day price level, leaving fiscal Q1 2027 delivery as the unresolved test. Revenue of at least $10.3 billion and non-GAAP gross margin of at least 83% would complete the case… Cyclical recovery · AI chips & memory catalyst · TXG 10x Genomics, Inc. fresh MEDIUM 10x Genomics' Atera recovery now needs deliveries and revenue confirmation after clearing its earlier price hurdle. Approximately 40 second-half 2026 shipments and full-year revenue of $610–630 million would substantiate the case before a… Special situation · Medtech & diagnostics catalyst · XMTR Xometry, Inc. fresh MEDIUM Xometry's AI manufacturing thesis requires enterprise adoption to deliver its August 4 guidance before a weekly close below $85. Third-quarter revenue of at least $234 million and adjusted EBITDA of at least $16 million, with the 33–34%… Theme leader · AI datacenter infrastructure analysed · ARCB ArcBest Corporation fresh LOW ArcBest’s cost-reduction rebound failed its published price condition at the 2026-09-18 weekly close of $128.73. Third-quarter results still test recurring savings and preservation of the second-quarter 90.8% adjusted Asset-Based operating… Special situation · Freight & logistics · Cyclical industrials catalyst · ATEX Anterix Inc. fresh LOW Anterix’s utility-spectrum conversion thesis failed its published price test when the 2026-09-18 weekly close of $76.99 breached $85.31. A new utility agreement with disclosed payments and a weekly recovery above $85.31 would support a… Defensive · Industrial power & grid catalyst · CNC Centene Corporation fresh LOW Centene's margin-repair case requires sustained earnings guidance and a weekly close above $68.72 by its 2026-10-27 results. September's reaffirmation supports the earnings leg, but a weekly close below $65 or withdrawal or reduction of… Earnings inflection · Managed care & health services analysed · DAVE Dave Inc. fresh LOW Dave Inc.'s growth-and-credit-quality recovery case is invalidated by the September 18, 2026 weekly close of $337.82 below its published $358 boundary. JPMorgan's September 15 initiation adds favorable coverage but does not reverse that… Compounder · Fintech & consumer credit catalyst · DELL Dell Technologies Inc. fresh LOW Dell Technologies’ AI-server thesis requires roughly $19 billion of next-quarter revenue and infrastructure operating margin of at least 15.0%. The next quarterly results settle that case; September 21, 2026 index inclusion does not… Cyclical recovery · AI datacenter infrastructure catalyst · HNGE Hinge Health, Inc. fresh LOW Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating… Compounder · Managed care & health services analysed · HUM Humana Inc. fresh LOW Humana's Medicare Advantage margin-recovery story faces a renewed price test: an adjusted daily close above $409.80 before a daily close below $383. The September 1, 2026 earnings reaffirmation supports stability, while October Star… Compounder · Managed care & health services catalyst · JBHT J.B. Hunt Transport Services, Inc. fresh LOW J.B. Hunt’s freight-recovery thesis was invalidated by the 2026-09-18 weekly close below $265. The estimated 2026-10-15 report tests whether intermodal pricing and profit growth can support a separate recovery case after September’s cost… Compounder · Freight & logistics · Cyclical industrials catalyst · LSTR Landstar System, Inc. fresh LOW Landstar System's truckload repricing must produce further earnings improvement. The 2026-10-27 results settle the case if truck revenue per load grows year over year and earnings per share exceed the second quarter's $1.44 before a weekly… Defensive · Freight & logistics catalyst · MRVL Marvell Technology, Inc. fresh LOW Custom-silicon ASIC royalty story intact, but the AI-semi theme is mid-correction — chips posted their worst month vs software on record (7/17) with money rotating into energy. Buying a falling sector with no confirmed higher low is the… Cyclical recovery · AI chips & memory catalyst · SEZL Sezzle Inc. fresh LOW Sezzle's profitable-growth recovery thesis requires a daily close above $129.87 before a weekly close below $114 invalidates it. The 2026-09-18 adjusted close of $116.55 lost the August shelf again, reversing the intermediate repair… Compounder · Fintech & consumer credit analysed · SNX TD SYNNEX Corporation fresh LOW TD SYNNEX's Hyve expansion supports an AI hardware earnings story, tested by revenue above $19.0 billion and adjusted diluted EPS above $4.75 on 2026-09-24. A weekly close below $255 invalidates the September price structure; stronger… Theme leader · AI datacenter infrastructure catalyst · STX Seagate Technology Holdings PLC fresh LOW Maturing AI-storage supercycle with sell-side still chasing: Wells Fargo upgrade to Overweight $1,100 (7/10) and Citi Street-high $1,240 (7/13). But the DRAM ETF is down ~30% and Seagate's Q4 FY26 print ~2026-07-22 is a binary about two… Cyclical recovery · AI chips & memory catalyst · UMC United Microelectronic Corp. fresh LOW Silicon-photonics pivot re-rated the ADR ~3x, but the July blowoff to $28.96 round-tripped -26% to $21.25 in days while sell-side finally upgraded (Macquarie Outperform 2026-07-14) — late-stage distribution behaviour. The 2026-07-29 Q2… Special situation · Semi foundry & equipment catalyst · WDC Western Digital Corporation fresh LOW The 29% bounce off the 2026-07-28 low stalled: WDC closed $527.22 on 2026-08-03, −3.23% on a day its sector rose 0.58%, back under a rising 50-day at $562.65. Consensus (~$3.69B / $3.31–$3.35) still sits above the company's own $3.65B… Cyclical recovery · AI chips & memory analysed · XPO XPO, Inc. fresh LOW XPO, Inc.'s shipment-and-margin thesis failed its price test when the 2026-09-18 weekly close of $174.25 breached $185. The 2026-10-29 results still test shipment growth and management's guidance for an adjusted less-than-truckload… Compounder · Freight & logistics · Cyclical industrials catalyst ·

Watchlist

200
APGE Apogee Therapeutics, Inc. fresh SUPREME Apogee Therapeutics’ $135.11-per-share cash-acquisition thesis resolved with AbbVie’s completion on 2026-09-03. The 2026-09-14 Form 15 advances administrative closure, leaving no unresolved APGE acquisition catalyst. Earnings inflection · M&A & special situations · Precision biotech & therapeutics catalyst · ATAI AtaiBeckley Inc. fresh SUPREME AtaiBeckley's Lilly acquisition thesis resolved with completion on 2026-09-11, ending the pending-merger case. Remaining contingent payments depend on disclosed clinical and regulatory milestones; Nasdaq suspended ATAI effective 2026-09-14. Earnings inflection · M&A & special situations · Precision biotech & therapeutics analysed · DSGR Distribution Solutions Group, Inc. fresh SUPREME Distribution Solutions Group’s $35.00 cash acquisition remains a completion thesis, with the minority vote and closing settling the case. HSR clearance occurred on 2026-08-20; a daily close below $33.50 invalidates the price thesis. Earnings inflection · M&A & special situations analysed · ATKR Atkore Inc. fresh HIGH Atkore's $95.00 cash-merger thesis now turns on the October 7 shareholder vote and remaining approvals after September 14 US antitrust clearance. Completion before a weekly close below $88 constitutes success; termination negates the case. Earnings inflection · M&A & special situations · Industrial power & grid catalyst · BWMN Bowman Consulting Group Ltd. HIGH Bowman Consulting Group’s $43.00 cash acquisition makes merger completion the central thesis. The case resolves with payment of the announced consideration before a daily close below $40.50; the 2026-09-13 go-shop deadline narrows… Earnings inflection · Cyclical industrials catalyst · CBZ CBIZ, Inc. fresh HIGH CBIZ’s signed $55.00 cash merger makes completion the central thesis; closing settles the case, while a daily close below $52 invalidates it. The expected 2026-09-10 antitrust milestone has elapsed, but its outcome and a shareholder-vote… Earnings inflection · M&A & special situations analysed · CLSK CleanSpark, Inc. fresh HIGH Spring's binary resolved bullish: CleanSpark signed a $6.6B, 20-year Georgia data-center lease (2026-07-14) with an unnamed "global technology company," converting the BTC-miner-to-AI-infrastructure pivot from speculation into contracted… Special situation · Bitcoin miners · AI datacenter infrastructure catalyst · HZO MarineMax, Inc. HIGH MarineMax’s $53.00-per-share cash merger prices completion of the Safe Harbor transaction on the announced end-2026 timetable. Closing would settle the case; a weekly close below $50, termination or failure to complete by 2026-12-31 would… Earnings inflection · M&A & special situations catalyst · ITGR Integer Holdings Corporation HIGH Integer Holdings Corporation’s $127.00 cash acquisition by KKR remains a completion thesis, strengthened by the 2026-09-03 merger proxy. Completion by year-end 2026 would settle the case; a daily close below $118 invalidates it. Earnings inflection · M&A & special situations · Medtech & diagnostics catalyst · LPG Dorian Lpg Ltd HIGH Dorian LPG’s contracted freight surge supports September-quarter TCE above June’s record $75,926 per available day. Reported results settle the case; a weekly close below $47 invalidates the equity thesis first. Compounder · Freight & logistics catalyst · PSNL Personalis, Inc. fresh HIGH The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus… Earnings inflection · Medtech & diagnostics · Oncology & immunology catalyst · RVMD Revolution Medicines, Inc. fresh HIGH Regulatory-clock narrative re-accelerating: the rolling NDA under the FDA National Priority Voucher is "nearing completion" (2026-07-07) and the EMA opened a phased CHMP review the same day, while the Street ceiling walked from ~$186 to… Compounder · Precision biotech & therapeutics · Oncology & immunology catalyst · VREX Varex Imaging Corporation HIGH Varex Imaging Corporation’s $18.90 cash acquisition by Teledyne remains a completion thesis. The 2026-09-08 preliminary proxy advances the process; payment resolves the case, while a daily close below $17.50 invalidates it. Earnings inflection · Medtech & diagnostics catalyst · AAMI Acadian Asset Management Inc. MEDIUM Acadian Asset Management’s repricing depends on client inflows sustaining higher fees and margins. Positive third-quarter flows, management fees of at least $176.5 million and an economic net income operating margin of at least 40.3% would… Special situation · Cybersecurity analysed · ABCL AbCellera Biologics Inc. fresh MEDIUM AbCellera's monthly hot-flash antibody thesis requires the 2026-10-01 presentation to preserve the Phase 2 efficacy case and a subsequent weekly close above $12.73; a weekly close below $9.75 invalidates it. Earnings inflection · Precision biotech & therapeutics catalyst · ABSI Absci Corporation fresh MEDIUM Absci Corporation’s valuation rests on ABS-201 delivering human hair-growth efficacy in the guided second half of 2026. Separation from placebo would validate the case; a weekly close below $7.50, absent efficacy or a missed readout window… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics analysed · ADPT Adaptive Biotechnologies Corporation MEDIUM clonoSEQ MRD pure-play inflecting to self-funding growth (MRD rev +53% YoY, profitability turning); June 15 Immune Medicine separation adds a value-unlock leg. But the tape just broke to fresh 52-wk highs (~$22.92) above the $20–22… Defensive · Medtech & diagnostics catalyst · AEHR Aehr Test Systems MEDIUM Aehr Test Systems’ AI burn-in orders support a revenue-ramp thesis; the next results must preserve fiscal 2027 guidance of $130–150 million. The recovery case requires a weekly close above Lake Street’s $110 target before a weekly close… Cyclical recovery · Semi foundry & equipment analysed · AGCO AGCO Corporation MEDIUM AGCO Corporation's valuation reflects a 2027 farm-equipment recovery that remains unconfirmed by reported demand. A weekly close above the $139.71 market high recorded as of 2026-09-04 and Q3 results meeting July guidance would confirm the… Compounder · Cyclical industrials catalyst · AGM Federal Agricultural Mortgage Corporation fresh MEDIUM Federal Agricultural Mortgage Corporation's infrastructure lending supports an earnings-led re-rating. The next quarterly report tests whether spread income grows with volume; a weekly close above $240.02 fulfills the price case, while a… Theme leader · Biofuels & low-carbon fuels · AI datacenter infrastructure catalyst · ALVO Alvotech MEDIUM Alvotech's recovery prices in Q4 2026 FDA approvals after the Reykjavik inspection closure announced on 2026-07-29. AVT05 and AVT06 approvals within that window would confirm the regulatory-repair case; another manufacturing-related… Earnings inflection · Binary-catalyst biotech catalyst · APPN Appian Corporation fresh MEDIUM Appian’s AI orchestration re-rating needs Q3 revenue of at least $214 million and cloud subscriptions of at least $133 million to confirm management’s August guidance. A weekly close below $34 or a miss against either revenue floor… Theme leader · AI enterprise software analysed · AQST Aquestive Therapeutics, Inc. MEDIUM Aquestive Therapeutics' recovery thesis rests on an Anaphylm resubmission by 2026-09-30, following its August usability results. A filing announcement before a weekly close below $4.47 would satisfy the near-term case; missing the deadline… Earnings inflection · Precision biotech & therapeutics catalyst · ASST Strive, Inc. MEDIUM Strive, Inc.'s bitcoin-treasury premium thesis depends on increasing bitcoin per diluted common share. A company-reported year-to-date Bitcoin Yield above the 40.8% reading dated 2026-08-28 would confirm the case before a weekly close… Compounder · Crypto exchanges & financials analysed · ASTH Astrana Health Inc. MEDIUM Astrana Health’s full-risk care story depends on meeting Q3 revenue and profit guidance while preserving its raised annual profit outlook. That operational result must arrive before a weekly close below $34 invalidates the recovery thesis. Defensive · Managed care & health services analysed · ATRC AtriCure, Inc. fresh MEDIUM AtriCure’s profitability and clinical-expansion story now has to sustain its re-rating after September 21 index inclusion. A weekly close at or above Needham’s $64 target would complete the price case; a weekly close below $47 would… Compounder · Medtech & diagnostics catalyst · AVAH Aveanna Healthcare Holdings Inc. fresh MEDIUM Aveanna Healthcare’s earnings recovery supports further revaluation if its next report raises annual adjusted EBITDA guidance above the greater-than-$365 million outlook set on 2026-08-13. A weekly close below $11.75 or an unchanged or… Special situation · Managed care & health services analysed · BBNX Beta Bionics, Inc. fresh MEDIUM Beta Bionics’ new case is Mint commercialization after the September revenue cut broke the iLet growth thesis. Full U.S. launch within management’s Q1 2027 window would confirm the case; a weekly close below $17.25 would invalidate it. Earnings inflection · Medtech & diagnostics catalyst · BULL Webull Corporation MEDIUM June dormant-to-leader flip is confirming: the ~$7.52 breakout resolved up on the 2026-07-21 surge, Rosenblatt lifted its target to $13 (2026-07-16), and June ops printed 28.2M users / $800M net deposits. Theme accelerating; read is a… Retail squeeze · Crypto exchanges & financials catalyst · BWLP BW LPG Limited fresh MEDIUM BW LPG Limited’s contracted freight earnings support dividend continuation; its 2026-11-24 report must show Q3 realised shipping TCE above Q2’s $74,000 per day and a dividend of at least $0.95 per share. A weekly close below $22.00… Compounder · Freight & logistics · Oil, energy & geopolitical analysed · CDNA CareDx, Inc. MEDIUM CareDx’s reimbursement repricing depends on its next quarterly report sustaining the $490–500 million revenue outlook issued on 2026-07-30. Canaccord’s 2026-09-02 initiation renewed attention, but a weekly close below $44 would invalidate… Earnings inflection · Medtech & diagnostics analysed · CLDT Chatham Lodging Trust fresh MEDIUM Chatham Lodging Trust’s raised earnings outlook depends on sustained Silicon Valley hotel demand. The case resolves if third-quarter results preserve the August 4 guidance and regional outperformance before a weekly close below $12.00. Theme leader · AI datacenter infrastructure catalyst · CLF Cleveland-Cliffs Inc. fresh MEDIUM Cleveland-Cliffs’ tariff-supported cash-flow recovery needs another positive quarter and a weekly close above $12.50. A weekly close below $11.62 would invalidate the recovery, while unresolved labor terms remain the nearest operating… Special situation · Cyclical industrials · Industrial power & grid catalyst · CLMT Calumet, Inc. fresh MEDIUM Calumet’s lower-cost aviation-fuel expansion supports its re-rating if year-end 2026 production exceeds an annual 80 million gallons within the disclosed $137 million remaining-capital plan. The final loan draw reported on 2026-09-14… Special situation · Biofuels & low-carbon fuels catalyst · CMBT CMB.TECH NV fresh MEDIUM CMB.TECH's vessel-disposal and cash-return story supports further upside if the proposed October distribution is delivered. The case requires payment of $0.64 per share and a weekly close above $20.41 by 2026-10-31, before a weekly close… Special situation · Oil, energy & geopolitical · Freight & logistics catalyst · CMPS COMPASS Pathways Plc MEDIUM Compass Pathways’ September 9 COMP360 durability update renews the regulatory revaluation case ahead of its company-guided Q4 2026 submission. A weekly close above the September 11 series’ $15.17 52-week high would confirm the price… Earnings inflection · Precision biotech & therapeutics catalyst · CNH CNH INDUSTRIAL N.V. MEDIUM CNH Industrial's farm-equipment recovery is being priced ahead of earnings after September's analyst upgrades. The next quarterly report tests margin recovery, while a weekly close below $12.50 invalidates the re-rating leg. Compounder · Cyclical industrials catalyst · COIN Coinbase Global, Inc. fresh MEDIUM Coinbase’s recovery now rests on agency-led crypto market access after the Senate setback. Confirmation requires a weekly close above the historical $196.07 reference and third-quarter subscription-and-services revenue within the published… Compounder · Crypto exchanges & financials catalyst · CRDL Cardiol Therapeutics Inc. Class A MEDIUM Cardiol Therapeutics’ enrollment-led re-rating requires MAVERIC completion by 2026-09-30 and a weekly close above $2.29 before a weekly close below $1.75. The 2026-09-10 preliminary shelf introduces financing capacity, but the announcement… Earnings inflection · Precision biotech & therapeutics catalyst · CRM Salesforce, Inc. fresh MEDIUM De-rated Dow software incumbent on two dated legs: the $1.6B VA agentic ELA (2026-07-24) and Reuters' 2026-08-13 report of Silver Lake–Workday take-private talks, which put a private-market floor under mega-cap SaaS. Six target revisions… Special situation · AI enterprise software analysed · CRSR Corsair Gaming, Inc. MEDIUM Corsair Gaming's margin-recovery story is approaching its $14.35 annual high; a weekly close above that level would confirm the recovery leg. A weekly close below the market's $10.93 August anchor would invalidate it, while the next… Special situation · Prediction markets & betting · Consumer discretionary rotation catalyst · CRWD CrowdStrike Holdings, Inc. fresh MEDIUM Fal.Con (2026-08-31 to 09-03) delivered real product — Falcon Guardian, Falcon IQ, GPT-5.6 Cyber in Falcon, Anthropic marketplace distribution — and nine broker actions through 2026-09-04 including Truist $300, yet CRWD closed $213.10 on… Compounder · Cybersecurity · AI enterprise software analysed · CRWV CoreWeave, Inc. fresh MEDIUM Post-print repricing is holding but fading: the 2026-08-12 gap to $107.73 is unfilled after closes of $106.29 and $105.26, RSI 71.1. Q2 printed $128M adjusted operating income against a $30–90M guide, and the $2.6B facility closed… Compounder · GPU cloud & neoclouds · AI datacenter infrastructure catalyst · CVI CVR ENERGY, INC. MEDIUM CVR Energy’s refining thesis is that Hormuz disruption lifts reported margins above second-quarter 2026’s $9.94 per throughput barrel. Third-quarter results test that inference; a weekly close below $39 invalidates the price structure. Compounder · Oil, energy & geopolitical catalyst · CXW CoreCivic, Inc. MEDIUM CoreCivic's facility sales support a real-estate monetization thesis; another completed sale by third-quarter results must confirm its next leg while operating contracts remain intact. A weekly close below $31 invalidates the price thesis. Compounder · Housing, homebuilders & proptech catalyst · CYRX CryoPort, Inc. MEDIUM Q2 (2026-08-06) split the read: revenue $49.0M beat $48.21M and FY26 guide affirmed at $192–196M with adjusted EBITDA crossing to +$0.4M, but commercial CGT growth halved to +9% YoY from +26%. The narrative leg is now the profitability… Cyclical recovery · Rare disease & gene therapy · Precision biotech & therapeutics catalyst · DCTH Delcath Systems, Inc. fresh MEDIUM Delcath Systems’ self-funded liver-treatment expansion must sustain its raised revenue outlook. Confirmation requires maintained $104–108 million guidance at the next quarterly report and a weekly close above $17.36 before a weekly close… Defensive · Oncology & immunology analysed · DINO HF Sinclair Corporation MEDIUM HF Sinclair’s refining-margin and separation story now has fresh UBS support. The case requires the next quarterly report to sustain second-quarter adjusted refinery gross margin of $25.95 per produced barrel sold on comparable throughput,… Compounder · Oil, energy & geopolitical catalyst · DK Delek US Holdings, Inc. MEDIUM Delek US's refining recovery supports the August breakout, but September's distillate build weakens the scarcity leg. Q3 throughput and expense delivery must confirm the earnings case before a weekly close below $64 invalidates the… Compounder · Oil, energy & geopolitical catalyst · DPRO Draganfly Inc. MEDIUM Draganfly's policy-led drone re-rating now has a Canadian defence contract behind it, announced on 2026-09-11. A weekly close above the historical $6.23 reference would confirm price recovery; a weekly close below $4.70 would invalidate… Retail squeeze · Defense & aerospace catalyst · EGO Eldorado Gold Corporation MEDIUM Eldorado Gold’s Skouries expansion thesis now hinges on fourth-quarter 2026 commercial production after first concentrate on September 8. Delivery before a weekly close below $40 would validate the case; a delay into 2027 would contradict… Compounder · Critical materials & rare earths catalyst · ETON Eton Pharmaceuticals, Inc. MEDIUM Eton Pharmaceuticals’ re-rating rests on repeatable rare-disease product revenue. Confirmation requires third-quarter product sales to match or exceed the $37.568 million reported on 2026-08-13 and annual revenue guidance above $145… Defensive · Precision biotech & therapeutics catalyst · EWTX Edgewise Therapeutics, Inc. MEDIUM Edgewise Therapeutics’ cardiovascular re-rating rests on EDG-7500 entering Phase 3 in Q4 2026 and price expanding above its reference high. Initiation by 2026-12-31 and a weekly close above $48.35 would confirm the case; a weekly close… Special situation · Precision biotech & therapeutics analysed · FA First Advantage Corporation MEDIUM Aug 6 flipped the frame: Q2 revenue $448.8M/+14.9% vs $415.0M consensus, adj EPS $0.35 vs $0.28, and the first FY guide raise of the cycle ($1.67–1.71B). Needham upgraded to Buy/$28, RBC to $24 — targets moved above spot for the first… Special situation · M&A & special situations catalyst · FBIZ First Business Financial Services, Inc. fresh MEDIUM First Business Financial Services’ earnings re-rating depends on Q3 sustaining its 3.78% margin and exceeding $19.8 million in pre-tax pre-provision earnings. The thesis fails on a weekly close below $68 or deterioration below those Q2… Defensive · Small-cap value rotation · Squeeze & momentum setups catalyst · FIGS FIGS, Inc. MEDIUM The post-print shelf resolved upward: the 2026-08-28 close of $15.42 sits 8.1% above the 2026-08-07 mark of $14.26 and 9.9% under the $17.12 52-week high, with no company-dated news since the 2026-08-07 target revisions. The re-rating off… Defensive · Managed care & health services catalyst · FRNM Freenome, Inc. MEDIUM Freenome's approved blood-test story depends on Abbott launching SimpleScreen CRC and demonstrating reimbursed testing. Carelon's 2026-11-15 guideline strengthens the pathway; a weekly close below $14 or no US launch by 2026-12-31… Earnings inflection · Binary-catalyst biotech analysed · FROG JFrog Ltd. fresh MEDIUM Software-supply-chain-security plus AI-agent "trust layer" narrative keeps re-rating: the analyst cluster now leads price above $100 (UBS Buy $110 Jul 2, Truist Buy $105 Jul 9), confirming the continuation tell flagged in June.… Theme leader · Cybersecurity · AI enterprise software analysed · FSM Fortuna Mining Corp. MEDIUM Fortuna Mining’s gold-supported cash generation funds its mine-growth story, but the September 11 retreat weakens the recovery case. A weekly close above $13.66 before a weekly close below $11.00 would confirm the equity thesis. Compounder · Critical materials & rare earths catalyst · FTK Flotek Industries, Inc. fresh MEDIUM Legacy oilfield chemistry re-rating into a power/measurement business: Data Analytics hit 51% of gross profit in Q2 2026, the 2026-08-03 PREPA award adds ~$400M of 10-year expected backlog, and the 2026-08-04 guide went to $340–350M from… Special situation · Oil, energy & geopolitical catalyst · FTNT Fortinet, Inc. fresh MEDIUM Q2 (2026-07-29) resolved up — revenue $2.047B vs ~$1.89B, product +52% YoY, FY26 guide raised to $8.020–8.180B — but price has gone nowhere since: $161.95 on 07-31, $160.01 on 08-14, still 4.9% under the $168.29 high. The 44-analyst mean… Theme leader · Cybersecurity · AI datacenter infrastructure analysed · GEO The GEO Group, Inc. MEDIUM The GEO Group’s detention-contract story depends on year-end 2026 activation, with normalized earnings expected in early 2027. A weekly close above $32.77 would confirm the price leg; a weekly close below $28 or a disclosed activation… Compounder · Travel & leisure · Managed care & health services catalyst · GHRS GH Research PLC MEDIUM Eli Lilly's up-to-$3.8B AtaiBeckley buy (2026-07-16) put a large-cap price on 5-MeO-DMT for depression; GHRS is now the last independent pure-play, with best-in-class inhaled GH001 Phase 2b data, that the sector is repricing as the next… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · GTLB GitLab Inc. fresh MEDIUM GitLab's consumption-pricing story needs coding-agent usage to lift revenue above its September guidance. Fiscal Q3 revenue above $283 million and a paid-consumption run-rate above September's $40 million reference would confirm the case… Theme leader · AI enterprise software catalyst · HAE Haemonetics Corporation fresh MEDIUM Haemonetics’ CSL agreement supports a plasma-recovery thesis, but November must supply a quantified revenue contribution and transition timetable. Citi’s September 17 upgrade strengthens analyst support; a weekly close below $91… Special situation · Medtech & diagnostics catalyst · HALO Halozyme Therapeutics, Inc. MEDIUM Halozyme's royalty-led earnings re-rating rests on the 2026-08-06 guidance increase. A weekly close above the $110.76 high identified on September 11 would confirm another price leg before a weekly close below $98 invalidates it; Argus's… Cyclical recovery · Precision biotech & therapeutics catalyst · HNI HNI Corporation fresh MEDIUM HNI Corporation’s Steelcase integration could sustain earnings growth despite weak organic sales, but the September 18 close broke the prior shelf. The next quarterly report tests delivery against July’s raised outlook; a weekly close… Special situation · Cyclical industrials · Housing, homebuilders & proptech catalyst · HNST The Honest Company, Inc. MEDIUM The Honest Company’s margin re-rating depends on Q3 confirming organic growth and profitability excluding tariff refunds. Confirmation requires organic growth of at least 5%, underlying adjusted gross margin of at least 43.8% and unchanged… Special situation · Consumer discretionary rotation catalyst · HOOD Robinhood Markets, Inc. MEDIUM Robinhood Markets' September repricing now includes prediction-market infrastructure alongside on-chain finance. Stronger August activity and a weekly close above $124.72 would confirm continuation; a weekly close below $107 would… Compounder · Crypto exchanges & financials catalyst · HP Helmerich & Payne, Inc. MEDIUM Helmerich & Payne’s crude-led drilling recovery needs fourth-quarter rig activity and margins to meet guidance and adjusted earnings to turn positive. Those results would confirm the operating case; a weekly close below $40 invalidates the… Cyclical recovery · Oil, energy & geopolitical catalyst · HTFL Heartflow, Inc. MEDIUM Heartflow’s diagnostic revenue growth supports a continuation thesis after its August guidance increase. A weekly close above the $50.43 reference high would confirm the price leg before a weekly close below $42 invalidates it; the next… Compounder · Medtech & diagnostics analysed · IAG IAMGold Corporation MEDIUM IAMGOLD’s margin-expansion case depends on Côté lowering costs as gold support weakens. Q3 all-in sustaining costs within the published $2,000–$2,150 per-ounce range and retained annual production guidance would confirm the case before a… Compounder · Critical materials & rare earths catalyst · IBTA Ibotta, Inc. fresh MEDIUM Ibotta's rally prices a repeatable recovery in digital-promotions revenue; Q3 revenue above $86 million with year-over-year growth would confirm the next leg, unless a weekly close below $33 invalidates it first. Defensive · Crypto exchanges & financials · Consumer discretionary rotation analysed · IOVA Iovance Biotherapeutics, Inc. fresh MEDIUM Iovance Biotherapeutics' Amtagvi ramp supports a higher 2026 revenue outlook; a company-issued range above $350–370 million by 2026-09-30 would confirm it. An unchanged range or a missed update deadline would invalidate the revision thesis. Compounder · Oncology & immunology analysed · IREN IREN Limited MEDIUM IREN Limited’s recovery rests on converting contracted AI cloud capacity into operating revenue by 2026-12-31. Management’s $4 billion operating-ARR target settles the conversion case, while a weekly close below $35 invalidates the… Special situation · GPU cloud & neoclouds catalyst · KARO Karooooo Ltd. fresh MEDIUM Karooooo's record subscriber additions support a continuation thesis, resolved by a weekly close above $68.71 before a weekly close below $62. The next quarterly report tests whether the July-reported subscriber momentum persists. Compounder · Emerging markets · EV & autonomous mobility catalyst · LFST LifeStance Health Group, Inc. fresh MEDIUM LifeStance Health's margin recovery faces a repeatability test after September's shareholder offering: Q3 must meet August guidance and the annual outlook must hold. A weekly close below $11.00 invalidates the market thesis. Special situation · Managed care & health services catalyst · LIFE Ethos Technologies Inc. fresh MEDIUM Ethos Technologies’ guidance-durability re-rating depends on meeting its third-quarter outlook despite the TruStage disruption. Revenue of at least $160 million and preservation of the $727–731 million full-year outlook would substantiate… Defensive · Precision biotech & therapeutics · AI datacenter infrastructure analysed · LMND Lemonade, Inc. MEDIUM The $50 shelf has held six weeks: $53.14 on 2026-09-02, RSI(14) 50.6, three reference closes since 2026-08-21 inside a $0.41 band. The state cadence restarted — Florida car 2026-08-26, Kansas renters 2026-09-01, Missouri car plus… Theme leader · AI datacenter infrastructure · EV & autonomous mobility catalyst · MANE Veradermics, Incorporated MEDIUM Veradermics’ oral minoxidil story depends on Study ‘304’ replicating the reported hair-growth benefit by year-end 2026. Failed replication, a weekly close below $85, or the reporting window expiring without results would invalidate the… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech analysed · META Meta Platforms, Inc. MEDIUM Meta Platforms’ AI monetisation story gained a consumer product with Muse’s 2026-09-08 launch. Disclosed external AI revenue or contract value by the 2026-10-28 results would validate the commercial leg; a weekly close below $545 would… Compounder · Mega-cap AI platforms catalyst · MGNI Magnite, Inc. fresh MEDIUM Magnite's connected-TV growth now has an AI advertising catalyst; a weekly close above $25.92 and reaffirmed 2026 guidance at the next quarterly report would validate the next leg. A weekly close below $21 invalidates the price structure. Theme leader · AI enterprise software analysed · MGTX MeiraGTx Holdings plc fresh MEDIUM The $400M Oberland royalty deal (2026-07-07) took dilution and runway risk off the table and spiked MGTX to a new 52-week high of $15.35 before a fade to ~$12.44 — a non-dilutive re-rate of a three-program AAV gene-therapy pipeline, but… Earnings inflection · Rare disease & gene therapy · Precision biotech & therapeutics analysed · MTW The Manitowoc Company, Inc. MEDIUM Manitowoc's crane-order recovery supports its re-rating if Q3 backlog holds at least $1,050.1 million and raised 2026 profit guidance survives. A weekly close below $18 invalidates the price thesis; the Q3 reporting date remains… Defensive · Cyclical industrials catalyst · NAVN Navan, Inc. fresh MEDIUM Q2 FY2027 prints 2026-09-09 with the first positive non-GAAP operating-income guide ($13.5–14.5M) on the line. Four target raises in 21 days — BofA $26→$34 on 09-02, Morgan Stanley $33 on 09-04 — landed while the shares fell from the… Earnings inflection · AI enterprise software · Travel & leisure analysed · NET Cloudflare, Inc. MEDIUM Cloudflare’s AI security and agent-infrastructure story supports a recovery toward its recorded $330.83 high. The case plays out on a weekly close above that level by the listed 2026-10-29 results date and fails on a weekly close below… Cyclical recovery · AI enterprise software · AI datacenter infrastructure catalyst · NIQ NIQ Global Intelligence plc MEDIUM NIQ Global Intelligence’s deleveraging re-rating needs a weekly recovery above $19.24 and Q3 delivery against August guidance. A weekly close below $16.00 breaks the price case, while September’s Optiq rollout has yet to establish… Special situation · AI enterprise software catalyst · NVCT Nuvectis Pharma, Inc. MEDIUM Nuvectis Pharma’s expanded-pipeline valuation depends on US development of its Haisco compounds. The case requires announced IND submissions for both assets and a weekly close above the $28.53 trailing high by 2026-12-31, before a weekly… Defensive · Oncology & immunology · Precision biotech & therapeutics catalyst · OMER Omeros Corporation MEDIUM Omeros Corporation’s YARTEMLEA launch supports a further re-rating if Q3 2026 net sales exceed Q2’s $28.5 million before a weekly close below $16.00. The 2026-10-01 hospital reimbursement change adds a later adoption test; it cannot… Compounder · Precision biotech & therapeutics catalyst · OPRT Oportun Financial Corporation MEDIUM Oportun Financial Corporation's margin-repair re-rating needs a weekly close above the $8.09 market high and Q3 results meeting its 2026-08-05 guidance. A weekly close below $7.00 or Q3 adjusted EBITDA below $43 million invalidates the… Special situation · Fintech & consumer credit analysed · ORKA Oruka Therapeutics, Inc. MEDIUM Supply overhang cleared: the 2026-07-01 Fairmount $300M block at $84.43 was absorbed and price closed $92.70 on 07-17 (+11.6%), 5% off the 52-week high, with 19.85% short interest still rising. Long-acting I&I re-rated by the $10.9B… Earnings inflection · Binary-catalyst biotech · Oncology & immunology catalyst · PBF PBF ENERGY INC. MEDIUM PBF Energy’s new high prices in sustained refining profits; Q3 adjusted earnings of at least $6.22 per share would confirm the case unless a weekly close below $75.48 first breaks the breakout. Compounder · Oil, energy & geopolitical catalyst · PCTY Paylocity Holding Corporation MEDIUM Post-print re-rating leg: the 2026-08-04 Q4 FY26 beat ($1.84 adj. EPS vs $1.61 est.) triggered five price-target raises in 48 hours and a $150.42 close on 2026-08-07, +35.5% over three months. The buy is multiple recovery in mid-cap HCM… Theme leader · Cybersecurity catalyst · PGNY Progyny, Inc. MEDIUM Progyny’s distribution expansion supports a recovery toward Citizens’ $33 target; Q3 revenue tests whether demand stabilizes. A weekly close below $24 or Q3 revenue at or below $335 million would invalidate the recovery case. Special situation · Managed care & health services analysed · PLPC Preformed Line Products Company MEDIUM The July rollover read was voided by the 2026-07-29 Q2 print: sales $212.7M vs $193M consensus, EPS $4.49 vs $2.41, and a ~30% one-session repricing to a new all-time closing high of $480.77 (2026-08-11). Grid/AI-power second-order… Theme leader · Industrial power & grid analysed · PLSE Pulse Biosciences, Inc MEDIUM Pulse Biosciences’ faster trial-enrollment story depends on NANOPULSE-AF completion in early October. An announcement by 2026-10-31 before a weekly close below $44 would validate the schedule thesis; the 2026-09-09 analyst initiation adds… Earnings inflection · Medtech & diagnostics catalyst · PMTS CPI Card Group Inc. MEDIUM Levered card manufacturer re-rating on cash generation: Q2 revenue $149.2M (+15%) with net leverage cut to 2.7x from 3.6x and FY free-cash-flow guidance lifted to $45–50M on 2026-08-06. Adjusted EBITDA grew just 7% against that 15% top… Cyclical recovery · Fintech & consumer credit catalyst · PSX Phillips 66 MEDIUM Phillips 66’s repricing depends on exceptional refining margins persisting into Q3 2026. The case plays out if Q3 realized refining margin reaches at least Q2’s $24.08 per barrel before a weekly close below $239 invalidates it. Compounder · Oil, energy & geopolitical catalyst · PUBM PubMatic, Inc. MEDIUM PubMatic's AI-led advertising recovery supports a growth re-rating, conditional on Q3 revenue reaching at least $75 million and a weekly close above the August high of $17.78. A weekly close below $15.20 would invalidate the case. Special situation · AI enterprise software analysed · PYPL PayPal Holdings, Inc. MEDIUM PayPal's standalone turnaround rests on profit guidance reiterated on 2026-09-09 despite checkout pressure. The case plays out if the 2026-10-27 results preserve its approximately $5.38 annual adjusted earnings-per-share outlook before a… Special situation · Fintech & consumer credit catalyst · RCEL Avita Medical, Inc. fresh MEDIUM AVITA Medical’s wound-care turnaround depends on meeting its $86–89 million 2026 revenue guide and generating cash in the fourth quarter. Those commitments, announced on 2026-08-06, must become reported results before a weekly close below… Defensive · Medtech & diagnostics analysed · RCMT RCM Technologies, Inc. MEDIUM RCM Technologies’ energy-services re-rating requires continued Engineering growth and stable margins. Q3 revenue above the segment’s $39.5 million Q2 level and consolidated gross margin of at least 25.7% would confirm the case, provided a… Cyclical recovery · Cyclical industrials analysed · RVTY Revvity, Inc. fresh MEDIUM Revvity’s AI drug-discovery story requires instrument backlog to convert into positive Life Sciences organic growth. The next quarterly report must show that recovery while preserving August’s full-year growth outlook before a weekly close… Theme leader · Medtech & diagnostics analysed · SBET SharpLink, Inc. MEDIUM SharpLink's Ether treasury discount is the recovery thesis: The Block reported a 0.84-times net asset value multiple on 2026-09-07. The case plays out if a comparable valuation reaches net asset value before a weekly close below $7.50… Special situation · Crypto exchanges & financials catalyst · SGMT Sagimet Biosciences Inc. Series A MEDIUM Sagimet Biosciences’ funded acne-trial launch underpins a continuation case, confirmed by October 2026 screening and a weekly close above $11.06. A weekly close below $8.50 or a disclosed screening delay beyond October would invalidate it. Defensive · Precision biotech & therapeutics catalyst · SIBN SI-BONE, Inc. MEDIUM SI-BONE’s surgical-device growth and improving adjusted profitability underpin a recovery case above the August shelf. A weekly close above $21.40 would confirm renewed strength before a weekly close below $17 invalidates it; the September… Defensive · Medtech & diagnostics catalyst · SMMT Summit Therapeutics Inc. fresh MEDIUM Summit Therapeutics’ ivonescimab thesis is that quantified survival evidence converts into US approval by 2026-11-14 before a weekly close below $15.00. September’s disclosures strengthen the clinical case, but the global trial’s primary… Earnings inflection · Oncology & immunology analysed · SNAP Snap Inc. MEDIUM Snap Inc.'s margin recovery supports a potential rerating above $6; the 2026-09-16 SPECS launch tests renewed attention. The price case succeeds on a weekly close above $6 before a weekly close below $5, while Q3 results test operating… Special situation · AI enterprise software catalyst · SOPH SOPHiA GENETICS SA fresh MEDIUM SOPHiA GENETICS' cloud-genomics expansion thesis requires renewed strength above the $8.92 market high and another revenue-guidance increase at Q3 results, estimated for 2026-11-03. A weekly close below $6.84 invalidates the price thesis;… Theme leader · Medtech & diagnostics · AI enterprise software catalyst · SPCX SpaceX (Space Exploration Technologies Corp.) MEDIUM SpaceX’s compute expansion now has a price breakout behind it; September capacity delivery and the December contract start test revenue conversion. A weekly close below $146.15 invalidates the breakout thesis. Compounder · Space economy · AI datacenter infrastructure catalyst · SPT Sprout Social, Inc MEDIUM Sprout Social's margin-led recovery thesis calls for a weekly close above the market's 2026-08-28 close of $11.49 before a weekly close below $9.50. Q3 results test whether revenue and operating income meet management's 2026-08-06 guidance. Special situation · AI enterprise software catalyst · SPXC SPX Technologies, Inc. MEDIUM Q2 beat-and-raise on 2026-07-30 was the strongest print of the cycle — HVAC backlog $919M (+59% organic), 2026 data-center revenue set at $430M, capacity target lifted to $1.1B from $750M — yet the 2026-08-14 close of $217.32 sits 11.8%… Cyclical recovery · AI datacenter infrastructure analysed · SRPT Sarepta Therapeutics, Inc. MEDIUM Sarepta Therapeutics’ recovery thesis prices commercial funding of its RNA pipeline, with follow-up clinical data guided for the second half of 2026. The market re-rating case completes at a weekly close above the supplied $24.45 reference… Special situation · Precision biotech & therapeutics catalyst · SSL Sasol Limited MEDIUM Sasol Limited’s operating recovery supports price continuation after its 2026-09-01 results. A weekly close above the $14.65 annual high recorded on 2026-09-11 completes the case; a weekly close below that day’s $14.59 reference close… Compounder · Oil, energy & geopolitical analysed · SSRM SSR Mining Inc. MEDIUM SSR Mining’s post-divestiture re-rating rests on cash and repurchases, with weaker momentum after the 2026-09-04 jobs report. A weekly close above the $39.21 market high would confirm the case before a weekly close below $33 invalidates it. Compounder · Critical materials & rare earths catalyst · STLN Starling Oncology, Inc. MEDIUM Starling Oncology’s oncology-risk contracts support a margin-expansion thesis that the next quarterly results must confirm. Third-quarter adjusted EBITDA within management’s $500,000–$1.5 million range and maintained full-year guidance… Special situation · Managed care & health services analysed · TARS Tarsus Pharmaceuticals, Inc. MEDIUM Tarsus Pharmaceuticals’ eye-care expansion depends on XDEMVY sustaining growth after the Alkeus acquisition. The case requires next-quarter sales above Q2 2026’s $173.9 million and retention or an increase of both boundaries of the… Compounder · Binary-catalyst biotech catalyst · TEAM Atlassian Corporation MEDIUM The "agentic AI kills seat-based software" de-rating just reversed: Q4 FY26 (2026-08-06) put cloud +31% and $6,606M subscription ARR behind the Rovo/MCP agent story, and the stock gapped 30%+ on 2026-08-07 to close $149.07. The… Theme leader · AI enterprise software catalyst · TSEM Tower Semiconductor Ltd. MEDIUM Tower Semiconductor’s silicon-photonics expansion needs its next quarterly report to confirm the August revenue guide and July 2028 model. A weekly close below $195 would invalidate the price recovery before that operating confirmation. Cyclical recovery · Semi foundry & equipment catalyst · TVTX Travere Therapeutics, Inc. fresh MEDIUM Travere Therapeutics’ FILSPARI expansion needs another quarter of sales and patient-start growth to confirm its commercial narrative. A weekly close above $67.52 completes the price case; a weekly close below $58 invalidates it. Earnings inflection · Precision biotech & therapeutics catalyst · TWLO Twilio Inc. MEDIUM Legacy CPaaS repricing as voice/agentic-AI engagement infrastructure; sell-side re-clustered higher into the print — Cowen $245, Mizuho $240, Citizens $250 (2026-07-17/20) — but the 2026-07-30 Q2 report is now the binary deciding whether… Special situation · AI enterprise software analysed · TWST Twist Bioscience Corporation fresh MEDIUM Synthetic-DNA-as-AI-input narrative went vertical: the failed $70 breakout reclaimed and ran to a $105.47 high, +200%+ YTD with 85% of it since the 2026-05-21 analyst day. Targets now $102-$120 but price sits above the $85.50 consensus and… Theme leader · AI datacenter infrastructure catalyst · U Unity Software Inc. MEDIUM Unity Software’s advertising turnaround needs Q3 Strategic Grow revenue of at least $380 million and its promised first GAAP-profitable quarter. Those tests come from management’s 2026-08-06 outlook; a weekly close below $36 would… Special situation · AI datacenter infrastructure analysed · UGP Ultrapar Participacoes S.A. MEDIUM Ultrapar’s Ipiranga earnings and reported stake-sale talks underpin a further re-rating. A weekly close at or above UBS’s 2026-09-04 target of $7.90 would confirm the price case; a weekly close below $5.80 or confirmed termination of the… Special situation · Oil, energy & geopolitical catalyst · VLO Valero Energy Corporation MEDIUM Refiner crack spreads at a record ~$70/bbl 3-2-1 as a Hormuz/Iran supply shock idles ~10% of global refining; VLO is the pure-play margin leverage and the fundamental leg is accelerating. But sell-side (6 PT raises in 11 days) and CNBC… Compounder · Oil, energy & geopolitical catalyst · VST Vistra Corp. MEDIUM Vistra's AI-power scarcity story now depends on PJM's September procurement proceeding and a weekly close above the June resistance shelf near $153. A weekly close below $135.66 invalidates the price-repair case. Theme leader · Nuclear & uranium · AI datacenter infrastructure catalyst · VSTM Verastem, Inc. MEDIUM Verastem’s commercial launch supports a VS-7375 clinical revaluation thesis, tested by the newly scheduled 2026-10-14 efficacy update. The case requires reported tumor responses and a daily close above the 2026-09-02 reference close of… Earnings inflection · Oncology & immunology catalyst · ZLAB Zai Lab Limited MEDIUM Zai Lab's global drug-development re-rating depends on October's zoci data leading to first-line lung-cancer Phase 3 initiation by 2026-12-31. The case requires those milestones before a weekly close below $22; the partnered ALKIVIA… Earnings inflection · Oncology & immunology analysed · AESI Atlas Energy Solutions Inc. fresh LOW Frac-sand legacy pivoting to behind-the-meter gas power for AI data centers, but the story is DORMANT and the structure broken: shares fell from $16.73 (6/29) to an $11.96 close (7/24, -8.5%), losing the ~$15 base and $13 shelf on… Special situation · Oil, energy & geopolitical · Industrial power & grid catalyst · AMLX Amylyx Pharmaceuticals, Inc. fresh LOW Amylyx Pharmaceuticals’ avexitide story now depends on a year-end 2026 NDA submission and recovery above the $35.50 offering price. An announced submission and a weekly close above that level complete the case; a weekly close below $30… Earnings inflection · Precision biotech & therapeutics catalyst · AMR Alpha Metallurgical Resources, Inc. LOW Alpha Metallurgical Resources’ coal-supply-shock thesis requires stronger third-quarter realized pricing before August support breaks. Realization above the second quarter’s $118.71 per short ton would confirm transmission; a weekly close… Compounder · Oil, energy & geopolitical catalyst · ANF Abercrombie & Fitch Co. fresh LOW Abercrombie & Fitch’s margin re-rating lacks price confirmation after the 2026-09-18 close of $135.76. Continuation requires a weekly close above $152.08 before Q3 results, estimated for 2026-11-24, without first closing below $130. Special situation · Consumer discretionary rotation analysed · ASMB Assembly Biosciences, Inc. LOW Assembly Biosciences confirmed its Gilead profit-share option on 2026-09-08, but its momentum thesis failed at the September 11 close below $30. The remaining development case requires GS-1179 to enter Phase 2 by year-end 2026; a disclosed… Earnings inflection · Precision biotech & therapeutics catalyst · BB BlackBerry Limited fresh LOW Q1 FY27 gave the pivot real numbers (QNX $72.3M vs the $60-64M guide, FY27 raised to $594-621M), but the parabola broke: after a $13.59 high the stock fell ~37% to ~$8.54 on a meme unwind plus insider selling. Narrative maturing, price… Retail squeeze · AI enterprise software · AI chips & memory catalyst · BLSH Bullish LOW Bullish's regulatory repricing thesis requires successful CLARITY Act cloture followed by a weekly close above $37.10 before a weekly close below $31. The September 15, 2026 milestone is motion ripening, while the September 9 close of… Earnings inflection · Crypto exchanges & financials catalyst · BMEA Biomea Fusion, Inc. fresh LOW Biomea Fusion’s icovamenib thesis depends on lasting glucose control after limited treatment. COVALENT-211 must meet its placebo-controlled primary endpoint in the company-guided Q1 2027 window before a weekly close below $1.60 invalidates… Earnings inflection · Precision biotech & therapeutics catalyst · BMNR BitMine Immersion Technologies, Inc. LOW Premium-to-NAV funding engine is closed; the 2026-08-10 release shows capital flipping from coin to float — 7,391 ETH bought for $14.3M (smallest week of 2026) against 3.0M shares retired, with cash down to $104M from $173M. The narrative… Compounder · Crypto exchanges & financials catalyst · BTCS BTCS Inc. LOW BTCS Inc.’s Ethereum recovery thesis requires stronger DeFi earnings without renewed borrowing. The next Q3 disclosure must show gross profit above Q2 2026’s $1.5 million and debt no higher than June’s $50.4 million before a weekly close… Compounder · Crypto exchanges & financials catalyst · BXC BlueLinx Holdings Inc. fresh LOW BlueLinx's specialty-margin re-rating depends on Trex execution and price repair. Completed initial stocking followed by a weekly close above $84 would resolve the recovery case; a weekly close below $72 would invalidate it. Cyclical recovery · Housing, homebuilders & proptech analysed · CDE Coeur Mining, Inc. fresh LOW Coeur Mining’s cash-backed repair thesis requires price recovery and confirmation that reduced production guidance holds. A weekly close above the September $21.24 reference and reaffirmed guidance at the next quarterly report would… Compounder · Critical materials & rare earths catalyst · CLYM Climb Bio, Inc. fresh LOW Climb Bio's re-rating depends on Q4 2026 budoprutug patient data establishing clinical benefit. Recovery of the $17.84 adjusted annual high would confirm the price leg; a weekly close below $13.30 or a delay beyond the guided clinical… Earnings inflection · Precision biotech & therapeutics · Oncology & immunology analysed · CRCL Circle Internet Group, Inc. LOW Circle Internet Group's Arc-led infrastructure breakout failed when its 2026-09-09 close of $92.99 breached the published $95 boundary. The scheduled 2026-09-16 public launch still tests delivery, while any recovery case requires renewed… Earnings inflection · Crypto exchanges & financials catalyst · DHT DHT HOLDINGS, INC. LOW DHT Holdings’ tanker-rate story depends on strong charter bookings sustaining its September 11 high through the next results. Confirmation requires reported earnings to meet the disclosed booking benchmark and the release week to close… Compounder · Freight & logistics analysed · DSX Diana Shipping, Inc. LOW Diana Shipping's higher charter rates underpin a near-term breakout thesis, settled by a weekly close above $3.01 before a weekly close below $2.97. Those levels are the adjusted annual high and latest daily close in the September 11, 2026… Defensive · Freight & logistics catalyst · EMBC Embecta Corp. LOW Embecta Corp.’s earnings-and-debt recovery story needs price confirmation after the September retreat. A weekly close above the September 2 reference close of $5.69 would satisfy the recovery case; a weekly close below $4.60 would… Special situation · Medtech & diagnostics catalyst · ESTC Elastic N.V. LOW AI-retrieval-layer narrative accelerating: Q4 FY26 total RPO $1.98B grew 28% YoY against revenue +16%, and the 2026-07-30 OpenAI partnership re-rated the name 56.8% in three months. The 2026-08-27 Q1 FY27 print is the binary — company… Theme leader · Cybersecurity · AI enterprise software catalyst · FDMT 4D Molecular Therapeutics, Inc. LOW 4D Molecular Therapeutics’ durability thesis needs timely Q3 clinical execution to restore the advance; a weekly close above the August 21 reference of $15.83 would complete the recovery case before a weekly close below $12.50 invalidates… Earnings inflection · Precision biotech & therapeutics catalyst · FIVN Five9, Inc. fresh LOW Legacy-CCaaS AI pivot staged a sharp V-recovery: +29% off the $19.70 June swing low to $25.42, reclaiming the broken $22 shelf on a 2026-06-23 next-gen Voice AI Agents launch and an AI-first leadership overhaul. Now pressing the $26.26… Special situation · AI enterprise software catalyst · FLXS Flexsteel Industries, Inc. fresh LOW Flexsteel Industries’ operating-turnaround thesis requires a weekly close above $84.20 before a weekly close below $79.69. These are the high and reference close in the September 18, 2026 market snapshot; weaker quarterly margins limit… Special situation · Housing, homebuilders & proptech catalyst · FRO Frontline Plc LOW Frontline's tanker-rate boom supports an earnings-persistence thesis, conditional on retaining the September high. The 2026-11-30 results test whether third-quarter vessel earnings sustain the second-quarter benchmark before a weekly close… Compounder · Freight & logistics catalyst · FWDI Forward Industries, Inc. LOW Forward Industries' Solana treasury re-rating requires growing tokens per share and a verified recovery to net asset value. Updated disclosure must show fully diluted mNAV at or above 1.0x and SOL per share of at least 0.0754 before a… Special situation · Crypto exchanges & financials catalyst · GPRK Geopark Limited LOW GeoPark's Venezuela redevelopment deal creates a revaluation case. A weekly close above the $11.97 reference high would confirm the price thesis before a weekly close below the September 11 reference close of $11.48 invalidates it. Earnings inflection · Oil, energy & geopolitical analysed · HAFN Hafnia Limited LOW Hafnia Limited’s tanker-earnings surge supports a continuation case at its 2026-09-11 high. The 2026-11-18 results test earnings durability, while a weekly close below $9.38 invalidates the price thesis. Compounder · Freight & logistics catalyst · HBB Hamilton Beach Brands Holding Company fresh LOW Hamilton Beach Brands' tariff-refund re-rating needs durable underlying margins and renewed price strength. A weekly close above the September 11 reference high of $33.86 before a weekly close below $28.00 completes the price case;… Defensive · Consumer discretionary rotation analysed · HIVE HIVE Digital Technologies Ltd. fresh LOW BTC-miner→AI-compute re-rating has its first blue-chip proof — BUZZ HPC's $220M Bell/Cohere sovereign-AI GPU deal (~$70M ARR) on top of $35M contracted ARR — but the stock stalled ~$3.79 below its early-June highs as BTC bled ~45-50% off… Special situation · Bitcoin miners analysed · IMMX Immix Biopharma, Inc. LOW Immix Biopharma’s NXC-201 story hinges on late-September data extending the reported 95% response rate across more patients. Confirmation requires that update by 2026-09-30 before a weekly close below $11.00; company language does not… Earnings inflection · Oncology & immunology catalyst · IMRN Immuron Limited LOW Immuron’s consumer-health expansion needs a dated US PROIBS launch and disclosed commercial terms to validate its September repricing. The 2026-09-04 agreement supplies neither; a weekly close below $1.65 or an annual report without those… Retail squeeze · Binary-catalyst biotech catalyst · INBX Inhibrx Biosciences, Inc. LOW Inhibrx Biosciences’ advance prices HexAgon clinical success and a Phase 3 start within the guided quarter. The 2026-09-08 results and September start confirmation test that case; a weekly close below $104 or reported primary-endpoint… Earnings inflection · Oncology & immunology analysed · INSP Inspire Medical Systems, Inc. LOW Inspire Medical Systems' rally prices a recovery from reimbursement disruption. A weekly close at or above Stifel's September 11, 2026 target of $80 would confirm the price case, while a weekly close below the September 11 reference close… Earnings inflection · Medtech & diagnostics catalyst · JILL J.Jill, Inc. fresh LOW J.Jill's post-earnings continuation thesis failed when the 2026-09-18 weekly close of $23.94 breached its published $24.08 threshold. Third-quarter results must separately confirm management's projected sales acceleration. Defensive · Managed care & health services catalyst · KELYA Kelly Services, Inc. fresh LOW Kelly Services' staffing-recovery thesis depends on Q3 2026 meeting revenue and margin guidance before a weekly close below $15. The 2026-09-18 close of $16.14 has lost the former $16.31 shelf, weakening the price evidence ahead of that… Special situation · Freight & logistics catalyst · KFRC Kforce Inc. fresh LOW Cyclical staffing recovery is fully printed — Q1 returned to YoY growth, Q2 guided +~4% — but price ran ~24% in three weeks to a fresh all-time high near $58.6, ~38% above the $42.33 consensus PT, into the confirmed 2026-07-27 Q2 print. A… Special situation · Freight & logistics catalyst · KURA Kura Oncology, Inc. LOW The binary already fired: KOMZIFTI's 2025-11-13 approval and ~40% R/R NPM1 share are priced, and the $24–28 targets need a frontline Phase 3 that doesn't read until 2028. The tape is drifting — $10.39, lower third of the H1 range. A… Earnings inflection · Oncology & immunology · Medtech & diagnostics catalyst · MAN ManpowerGroup fresh LOW Cyclical staffing inflection confirmed by the 2026-08-07 10-Q, but sell-side marks stopped moving 2026-07-20 and the next company binary is ~2026-10-15. Retail squeeze · Cyclical industrials · Squeeze & momentum setups catalyst · MARA MARA Holdings, Inc. fresh LOW AI/HPC power-buildout re-rate is the leg being bought — the 2026-07-09 HIF deal adds up to 2 GW in Texas, lifting potential capacity toward ~4.8 GW — but the golden-cross base fully round-tripped to ~$11.4 as analysts cut across the board… Special situation · Bitcoin miners catalyst · MPC Marathon Petroleum Corporation LOW Record refining cracks are already in the tape: Q2 R&M margin $36.33/bbl vs $17.58 YoY and a 29% EPS beat on 2026-08-04, yet the stock closed 2026-08-07 at $298.20 — RSI 37.3, 6.7% under the $319.76 high — while six desks raised targets… Compounder · Oil, energy & geopolitical catalyst · MSTR Strategy Inc LOW Strategy Inc.'s bitcoin accumulation thesis needs successive purchase disclosures and STRC recovering its $100 stated amount. Those milestones must arrive before a weekly close below $123 invalidates the price structure. Compounder · Crypto exchanges & financials catalyst · MXL MaxLinear, Inc. fresh LOW The AI-optical revenue leg still compounds — Q3 guided to $210–220M against Q2's $168.8M — while the price leg makes new lows: the 2026-09-04 close of $62.74 is 51.0% below the $128.03 high with RSI(14) at 25.1, after roughly $50M of… Cyclical recovery · Analog semiconductors analysed · MYGN Myriad Genetics, Inc. fresh LOW Legacy hereditary-cancer testing house executing a diagnostics pivot; shares +40% off the June $3.99 base as Prolaris+AI launched (May 26) and Precise MRD colorectal/renal was pulled forward to Q3. Structure has repaired but now… Special situation · Medtech & diagnostics analysed · NSP Insperity, Inc fresh LOW Insperity's margin-repair re-rating requires a weekly close above $53.40 before a weekly close below $48. Third-quarter employee volumes must meet the 305,500 guidance floor and the full-year adjusted EBITDA floor must remain at least $185… Special situation · Prediction markets & betting catalyst · NVAX Novavax, Inc. LOW Novavax's Matrix-M royalty re-rating needs company-confirmed Sanofi trial timing at the 2026-09-09–2026-09-10 conferences. The near-term case fails if both pass without that timing or a weekly close falls below $9.00. Earnings inflection · Binary-catalyst biotech catalyst · OABI OmniAb, Inc. LOW OmniAb’s milestone re-rating depends on repeat partner payments lifting full-year revenue guidance above $36 million at the next results. A weekly close below $3.82 ends the price thesis; the October 6 Investor and Analyst Day provides an… Cyclical recovery · Precision biotech & therapeutics catalyst · ODD ODDITY Tech Ltd. fresh LOW Broken compounder with exactly one dated event: the 2026-09-09 pre-market Q2 print. Price ran $13.22 (2026-08-21) to $14.35 (2026-08-28) on no company disclosure since 2026-07-22, leaving it ~30% above the $11.07 consensus target of 10… Earnings inflection · Consumer discretionary rotation analysed · PANL Pangaea Logistics Solutions Ltd. LOW Dry-bulk recovery is in the P&L but not the tape: Q1 2026 (2026-05-11) adjusted EBITDA +70% YoY to $25.2M on $15,252/day TCE, yet the stock closed $7.42 on 2026-08-07, 20.1% under the $9.29 52-week high. The 2026-08-10 Q2 print is the… Earnings inflection · Freight & logistics catalyst · PAYS Paysign, Inc. LOW Paysign’s patient-affordability expansion can sustain its August re-rating if Q3 meets revenue and program guidance and retains the full-year outlook. A weekly close below $11.50 invalidates the market thesis before that confirmation. Defensive · Managed care & health services catalyst · PRPO Precipio, Inc. LOW Precipio’s diagnostics growth and renewed operating cash generation support a conditional recovery toward its recorded $32.37 high. A weekly close above that level confirms the price case; a weekly close below the 2026-09-11 reference… Defensive · Medtech & diagnostics analysed · PTEN Patterson-UTI Energy, Inc. LOW Rig-reactivation cyclical is basing, not broken: June averaged 95 US rigs (vs ~90 Q2 guide), the July EIA STEO lifted 2026 Henry Hub to $3.67, gas rigs turned up 122→126, and Piper upgraded to Overweight 07-14. Price bottomed $8.57 (07-01)… Special situation · Oil, energy & geopolitical catalyst · QRVO Qorvo, Inc. fresh LOW Qorvo trades as a fixed-ratio merger spread: 0.960 SWKS plus $32.50 cash. Skyworks' $74.02 close on 2026-09-04 implies $103.56 against Qorvo's $102.84 — about 0.70% gross, the thinnest of this coverage, after the acquirer rallied 12.5% in… Earnings inflection · Analog semiconductors catalyst · RHI Robert Half Inc. fresh LOW White-collar staffing in secular decline: Q2 EPS collapsed to $0.26 (2026-07-23) as AI automation and a frozen hiring market gut permanent-placement demand. The >5% dividend yield reads as a value-trap signal rather than a floor. No… Special situation · Managed care & health services catalyst · RPD Rapid7, Inc. fresh LOW Rapid7's cost-cutting recovery needs Q3 2026 results to meet revenue and recurring-revenue guidance while preserving the 20% Q4 adjusted operating-margin goal. A weekly close below $10.60 or withdrawal of that goal invalidates the case. Earnings inflection · Cybersecurity analysed · RUM Rumble Inc. fresh LOW The sell-the-news break is now confirmed: RUM lost the $6.46–$6.66 100/200-day shelf and closed $5.76 on 2026-07-17, -19% from the post-rebrand tape and within 25% of the $4.62 52-week low. Every moving average is overhead. The 2026-08-10… Special situation · GPU cloud & neoclouds · AI datacenter infrastructure catalyst · SDGR Schrodinger, Inc. fresh LOW Agentic-AI software leg: the 2026-08-05 Bristol Myers Squibb agreement to deploy Bunsen at scale landed with a double beat (Q2 revenue $58.889M vs $47.228M consensus) and a raised drug-discovery guide of $65–75M. ACV grew 27% while… Theme leader · AI enterprise software · Precision biotech & therapeutics catalyst · SENS Senseonics Holdings, Inc. LOW Only year-long implantable CGM, clinically de-risked at ADA 2026 with revenue +71.9% YoY TTM — and the tape has spent six weeks grinding back toward the $4.79 post-catalyst low ($5.11 on Jul 17). Accelerating fundamentals against a broken… Defensive · Medtech & diagnostics catalyst · SG Sweetgreen, Inc. fresh LOW Sweetgreen’s recovery thesis links sales stabilization to KeyBanc’s 2026-09-08 target of $9. The next quarterly results test the operating case; a daily close at or above $9 completes the price case, while a weekly close below $6.00… Retail squeeze · Consumer discretionary rotation catalyst · SID Companhia Siderurgica Nacional S.A. (CSN) fresh LOW New-CEO deleveraging story: Fabio Schvartsman replaced 24-year CEO Benjamin Steinbruch on 2026-09-03 and the ADR ran from $1.13 (09-01) to $1.22 (09-04) with RSI at 79.2, while R$42.1bn net debt and 3.49x leverage are untouched until a… Special situation · Cyclical industrials analysed · SMCI Super Micro Computer, Inc. fresh LOW Dilution leg has broken the story: the $7B raise cleared at $27.50 on June 11 and spot is $24.18, with a live $2B ATM as forward supply. DDR contract prices +32% QoQ crush a business guiding 8.2–8.4% gross margin. Falling knife under all… Retail squeeze · AI datacenter infrastructure catalyst · SMTC Semtech Corporation fresh LOW The mix-purification leg has lost its price leg: the August bounce round-tripped from a $140.35 close on 2026-08-14 to $124.09 on 2026-08-21, under the 2026-07-17 flush close. The binary moved forward — Q2 FY27 prints 2026-08-25 after the… Cyclical recovery · Analog semiconductors catalyst · TEM Tempus AI, Inc. LOW Tempus AI's proposed Personalis acquisition supports a cancer-vaccine sequencing recovery thesis. A daily close above the August 21 reference close of $72.69 would confirm the price case before a weekly close below $58 invalidates it;… Cyclical recovery · Medtech & diagnostics catalyst · TITN Titan Machinery Inc. LOW Titan Machinery’s farm-equipment recovery re-rating requires falling total inventory and preserved earnings guidance at its next quarterly report. A weekly close below $23 would invalidate the market thesis before confirmation. Compounder · Cyclical industrials catalyst · TNET Trinet Group, Inc. fresh LOW TriNet Group’s margin recovery depends on Q3 insurance costs holding below 89.5% without July’s nonrecurring benefit. The case resolves positively if FY2026 earnings and revenue guidance also hold before a weekly close below $65… Earnings inflection · Managed care & health services catalyst · TNK Teekay Tankers Ltd. LOW Teekay Tankers’ record freight earnings underpin a continuation thesis requiring third-quarter rates to meet July booking benchmarks before a weekly close below $100.83. The next earnings report tests that persistence; its publication date… Compounder · Freight & logistics analysed · TRMD TORM plc LOW TORM plc’s freight-earnings story supports a conditional move to Evercore ISI’s $38 target, reported on 2026-08-27. The case succeeds at a daily close at or above $38 before a daily close below the 2026-09-11 reference close of $35.08… Compounder · Freight & logistics catalyst · UPXI Upexi, Inc. LOW Upexi’s Solana-discount recovery requires positive audited net assets and a Nasdaq bid-price cure. The September 28 annual-report checkpoint is provisional, while a weekly close below $1.00 invalidates the recovery structure. Earnings inflection · Crypto exchanges & financials catalyst · W Wayfair Inc. fresh LOW Margin-inflection turnaround has stalled: after the June Evercore-driven pop, W has faded ~10% back to the ~$84–85 recovery base ahead of the binary Aug 4 Q2 print. Wedbush's Jul 16 Neutral/$104 initiation and a ~$100-capped consensus mark… Special situation · Consumer discretionary rotation analysed · WEAV Weave Communications, Inc. LOW Beaten-down vertical-SaaS front-office platform for healthcare SMBs, down ~36% YTD and basing off the $4.24 low, repositioning around AI-receptionist monetization (TrueLark, 2025). Still a ~17% grower with GAAP losses, so the re-rate is… Theme leader · AI enterprise software analysed · WGS GeneDx Holdings Corp. fresh LOW Busted-growth genomics name; the recovery off the −49% May guide-cut crash has stalled in the low-$60s, below the $74.83 200-day. The confirmed Aug 3 Q2 print (blended ARR vs the ~$3,300 baseline) is the binary — the same day as the… Earnings inflection · Medtech & diagnostics analysed · WPP WPP PLC fresh LOW WPP’s re-rating rests on revenue stabilisation after the September index-promotion case expired. The next quarterly update must improve on the 2.8% like-for-like decline and retain 12–13% margin guidance before a weekly close below $24… Special situation · Consumer discretionary rotation · AI enterprise software analysed · WT WisdomTree, Inc. fresh LOW WisdomTree’s record August assets and September 17 MoonPay agreement support a fee-growth rerating thesis. A weekly close at or above the $25.04 annual high observed September 18, 2026 confirms the price case; a weekly close below that… Defensive · Cybersecurity analysed · XNCR Xencor, Inc. LOW Xencor’s post-settlement re-rating depends on October XmAb819 data supporting a pivotal-dose choice and the planned 2027 study. A weekly close below $23.34 or withdrawal of that timetable invalidates the continuation case. Earnings inflection · Oncology & immunology analysed · XXI Twenty One Capital, Inc. LOW The one re-rate catalyst just died: Tether's Strike–Elektron three-way merger was scrapped on 2026-07-21 and CEO Jack Mallers quit, dropping XXI to a fresh all-time low near $4.46. A leveraged-Bitcoin-treasury proxy stuck below 1.0x float… Compounder · Crypto exchanges & financials catalyst ·

Recently exited

28
PANW Palo Alto Networks, Inc. fresh HIGH AI-security spend narrative accelerating with third-party confirmation: IBM missed Q2 ($17.2B vs $17.86B) on 2026-07-14 and blamed budget migration into Cybersecurity — PANW +6.4%, CRWD +10%, BUG +6% same session. New ATH close $357.53… Compounder · Cybersecurity analysed · SNOW Snowflake Inc. fresh HIGH The June digestion resolved upward, not downward — SNOW cleared the ~$244 June high and printed a fresh 52-week high at $284.99 before settling at $268.90 (2026-07-17). Q1 FY27 product revenue re-accelerated to +34% and the street is still… Cyclical recovery · AI enterprise software catalyst · ATI ATI Inc. fresh MEDIUM Titanium/superalloy aero-defense supplier digesting a June breakout above the reclaimed $183.30 ATH shelf: ~9% off the $204.09 high, RSI cooled to ~66, consensus PT $200.33 back above spot. Q2 lands 2026-08-06; peer CRS prints 2026-07-30… Defensive · Defense & aerospace analysed · NBIS Nebius Group N.V. fresh MEDIUM GPU-neocloud narrative re-accelerated after NVIDIA disclosed a 9.3% stake (7/20) and PT raises followed (Northland $410, Baird initiates Outperform $250); Alphabet's 7/22 "demand outpaces capacity" answers the Meta-Compute bear case. The… Compounder · GPU cloud & neoclouds catalyst · RIOT Riot Platforms, Inc. fresh MEDIUM Riot Platforms’ AI-leasing thesis depends on permanent project financing and resolution of interim borrowing before maturity. Binding funding consistent with management’s 2026-08-10 plan would establish delivery financing; a weekly close… Special situation · GPU cloud & neoclouds analysed · RKLB Rocket Lab Corporation fresh MEDIUM Rocket Lab's stabilisation case rests on operating growth absorbing acquisition dilution after its September 15 funding announcement. Iridium approval on 2026-09-24 followed by a weekly close above $64.26 confirms the narrow case only if a… Compounder · Space economy catalyst · WULF TeraWulf Inc. fresh MEDIUM TeraWulf’s AI-landlord conversion turns on CB-4 earning rent in September 2026 before a weekly close below $14.50. Wells Fargo’s September 17 coverage initiation adds attention, but rental commencement remains unverified as of September 20. Special situation · GPU cloud & neoclouds catalyst · ARM Arm Holdings plc fresh LOW Data-center royalty doubled YoY for a second quarter, but Q2 FY27 royalty growth is guided to ~13% against 22% delivered. No Arm-specific disclosure has landed since 2026-07-29, so the bid is set by third parties — BofA's 2026-08-13… Cyclical recovery · AI chips & memory catalyst · BFLY Butterfly Network, Inc. fresh LOW Butterfly Embedded chip-licensing story got marquee validation — Midjourney's up-to-$74M/5yr full-body scanner on 40 Ultrasound-on-Chip modules (2026-06-18) plus 2nd partner Aleph Neuro (2026-06-25). Fundamentals still accelerating, but… Defensive · Medtech & diagnostics catalyst · COHR Coherent Corp. fresh LOW Coherent’s AI-optics recovery requires a named PhotonLink customer and production timing at the 2026-09-21 launch. Those disclosures and a subsequent weekly close above $281.86 complete the case before a weekly close below $264 invalidates… Cyclical recovery · AI datacenter infrastructure catalyst · GLW Corning Incorporated fresh LOW Corning’s fiber-demand thesis requires Q3 2026 core sales of at least $4.9 billion and optical growth of at least 20% before a weekly close below $143. The sales threshold is management’s July guidance floor; the growth threshold is the… Cyclical recovery · AI datacenter infrastructure analysed · GLXY Galaxy Digital Inc. fresh LOW Galaxy Digital's data-center revaluation depends on Q3 Helios leasing revenue meeting its approximately $80 million forecast, with project-level adjusted EBITDA margins above 90%, before a weekly close below $24. The 2026-09-18 close of… Special situation · AI datacenter infrastructure analysed · HUT Hut 8 Corp. fresh LOW Bitcoin-miner-to-AI-datacenter-landlord re-rate is now financed fact ($4.25B IG notes 6/4, ~$16.8B contracted backlog), but the momentum leg rolled from ~$127 to ~$105 as peers WULF/IREN captured the marquee Anthropic tenant deals (7/6)… Special situation · GPU cloud & neoclouds analysed · INTC Intel Corporation fresh LOW Funded legacy-pivot leg is holding the $101.65 pre-announcement shelf by under a dollar after the 2026-08-14 close of $102.50; CEO Tan's Form 4 (105,263 sh at $95.00) is the only fresh company datapoint in a week of 13F-derived coverage.… Special situation · AI chips & memory analysed · KYMR Kymera Therapeutics, Inc. fresh LOW Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 — a maturing,… Defensive · Precision biotech & therapeutics catalyst · LRCX Lam Research Corporation fresh LOW The WFE/AI-memory capex trade that ran Lam +119% YTD into June has rolled into a group-wide correction — the worst month for chip stocks since 2008, memory momentum broken (Micron/SanDisk). The ~2026-07-29 FQ4 print is now the binary: it… Cyclical recovery · Semi foundry & equipment catalyst · MP MP Materials Corp. fresh LOW MP Materials' domestic-magnet recovery failed its $50 weekly-close test on 2026-09-18; Q4 2026 General Motors shipments remain the unresolved operating test. Compounder · Critical materials & rare earths catalyst · NVDA NVIDIA Corporation fresh LOW July de-rating unresolved and now compounded by capex scrutiny — Alphabet's first cash-flow-negative quarter since 2004 and Intel's punished $20B capex plan raise the question of whether hyperscaler spend slows. Jensen's open-weight-AI… Cyclical recovery · AI chips & memory catalyst · ONTO Onto Innovation Inc. fresh LOW June breakout fully round-tripped: ATH $386.46 (6/30) to $279.85 (7/17), now below the 50-DMA at $294.49. The tell is non-participation — TSMC raised capex to $60-64B and ASML guided up twice on 7/15-16, and ONTO closed the week at its… Cyclical recovery · Semi foundry & equipment catalyst · PURR Hyperliquid Strategies Inc fresh LOW The gamma-squeeze/index leg is over: PURR is -42% from its 6/1 high of $11.62 to $6.68 (7/17), through the $7.70 shelf, and now trades at roughly 0.78x the value of its 17.6M HYPE stack — a treasury premium that has flipped to a discount,… Retail squeeze · Crypto exchanges & financials catalyst · QCOM QUALCOMM Incorporated fresh LOW The data-center re-rating already failed: QCOM spiked to a 52-week high of $259.92 on the ~2026-06-24 Investor Day $15B-by-2029 guide, then gave back ~34% in 17 sessions to $171.78 as Hold downgrades and Apple modem-attrition math… Special situation · AI chips & memory catalyst · SHLS Shoals Technologies Group, Inc. fresh LOW Solar/BESS EBOS name re-rated as a 2nd-order AI-datacenter-power play on a record $758M Q1 backlog and the multi-GW ON.energy deal; price reclaimed the $10 pivot but consensus PT sits at spot (~$10.63 vs $10.02), so the confirmed… Theme leader · Solar & clean energy · Industrial power & grid catalyst · SYRE Spyre Therapeutics, Inc. fresh LOW Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs — SPY003 IL-23 Part A (guided mid-2026,… Defensive · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · TNGX Tango Therapeutics, Inc. fresh LOW Post-data digestion, not acceleration: the 92% ORR combo print is fully paid for and the tape has faded from $32.90 to ~$27.7, below the $30.00 June secondary. Sell-side keeps marking up (JPM Overweight $46 on 7/15, Mizuho $40 on 7/17)… Defensive · Oncology & immunology · Binary-catalyst biotech catalyst · TSM Taiwan Semiconductor Manufacturing Company Ltd. fresh LOW Q2 (7/16) beat every line and lifted FY26 growth guide above 40%, but the capex raise to $60–64B and a 2026-07-26 Samsung–Broadcom $200B foundry pact reopened the monopoly question. Theme cooled to maturing; price recovered to ~$415, still… Cyclical recovery · Semi foundry & equipment catalyst · VRT Vertiv Holdings Co fresh LOW Vertiv's grid-power expansion supports a recovery case requiring Q3 2026 revenue to meet July guidance and a weekly close above $285.78. A weekly close below $240 or Q3 revenue below $3,650 million invalidates it; the September 18 close of… Cyclical recovery · AI datacenter infrastructure catalyst · WEST Westrock Coffee Company fresh LOW Westrock Coffee’s Conway expansion supports a cash-generation revaluation, but repeat cash flow remains unproven. Confirmation requires positive third-quarter 2026 free cash flow, maintained annual guidance and a weekly close above the… Special situation · Consumer discretionary rotation catalyst · WTI W&T Offshore, Inc. fresh LOW W&T Offshore’s oil-to-cash recovery case has weakened as the 2026-09-18 adjusted close of $3.84 slipped below the dated $4.01 recovery hurdle. The thesis resolves with a daily close at or above the market’s $4.89 trailing-year high before… Compounder · Oil, energy & geopolitical catalyst ·

Dormant

685
ALOT AstroNova, Inc. fresh SUPREME AstroNova’s $29.00 cash-merger thesis played out on 2026-08-26; its 2026-09-08 Form 15 resolves the remaining filing uncertainty. Only restoration of the former public equity would reopen the closed situation. Earnings inflection · M&A & special situations analysed · AVNS Avanos Medical, Inc. fresh SUPREME Avanos Medical’s $25.00-per-share cash-acquisition thesis was settled by completion on 2026-07-27. The company’s shareholder notice confirms that exchange trading has ended, leaving a completed transaction rather than an unresolved… Earnings inflection · M&A & special situations · Medtech & diagnostics analysed · CCRN Cross Country Healthcare, Inc. fresh SUPREME Cross Country Healthcare’s $13.25 cash-merger thesis resolved when Knox Lane completed the acquisition on 2026-07-21. Exchange-confirmed trading in the original common stock would contradict the completed-outcome assessment; the July 20… Earnings inflection · M&A & special situations · Managed care & health services analysed · CNTA Centessa Pharmaceuticals plc fresh SUPREME Centessa Pharmaceuticals’ acquisition closed on 2026-06-24; the remaining story is approval-linked contingent value. Qualifying regulatory approvals settle that question, while the final CNTA close on 2026-06-23 supplies no live price test. Earnings inflection · M&A & special situations · Precision biotech & therapeutics catalyst · CRNX Crinetics Pharmaceuticals, Inc. fresh SUPREME Crinetics Pharmaceuticals’ cash-merger thesis was resolved by Vertex’s 2026-09-01 acquisition at $85.00 per eligible share. Deregistration dates remain unverified; reinstated common-stock trading would overturn the terminal-equity… Earnings inflection · M&A & special situations analysed · FBRX Forte Biosciences, Inc. fresh SUPREME Forte Biosciences’ $77-per-share cash-acquisition thesis was resolved by the 2026-08-27 merger completion. Official restoration of the former common equity would reopen the case; Nasdaq records 2026-08-26 as its last trading date. Earnings inflection · Precision biotech & therapeutics · M&A & special situations analysed · KALV KalVista Pharmaceuticals, Inc. fresh SUPREME KalVista Pharmaceuticals’ $27.00 cash-acquisition thesis was settled by Chiesi’s 2026-06-11 completion announcement. A renewed equity thesis would require documented restoration of the original common stock; the provisional September… Earnings inflection · M&A & special situations catalyst · LPRO Open Lending Corporation fresh SUPREME Open Lending Corporation’s $3.15 cash-acquisition story concluded with ANV’s confirmed completion on 2026-07-30. The public-equity narrative remains closed unless an official reversal or documented restoration of trading reopens it. Earnings inflection · Fintech & consumer credit · M&A & special situations analysed · NUVL Nuvalent, Inc. fresh SUPREME Nuvalent’s independent equity story ended with GSK’s $124-per-share acquisition on 2026-07-15. The 2026-09-14 zidesamtinib update advances GSK’s clinical portfolio; only an official restoration of the former listed equity would reopen the… Earnings inflection · Precision biotech & therapeutics · Oncology & immunology analysed · OLPX Olaplex Holdings, Inc. fresh SUPREME Olaplex Holdings’ cash-acquisition thesis was resolved by Henkel’s 2026-07-07 completion and the end of Nasdaq trading. A newly listed standalone security would reopen equity analysis; Henkel’s 2026-11-10 release addresses only the… Earnings inflection · M&A & special situations catalyst · TBRG TruBridge, Inc. fresh SUPREME TruBridge’s $26.25-per-share cash acquisition completed on 2026-07-09, ending its standalone equity catalyst. September leadership integration concerns the acquirer; only an official restoration of the original listed equity would reopen… Earnings inflection · M&A & special situations · Managed care & health services analysed · AOUT American Outdoor Brands, Inc. fresh HIGH American Outdoor Brands’ margin recovery supports an earnings-driven rerating toward Roth Capital’s $17 target dated 2026-09-04. A daily close at or above $17 would confirm that price leg; a weekly close below the $14.19 earnings-reaction… Defensive · Consumer discretionary rotation catalyst · ARX Accelerant Holdings HIGH Accelerant Holdings’ $20.25 cash acquisition by Thoma Bravo remains a completion thesis, with closing guided to the first half of 2027. Completion settles the case; a daily close below $18.25 or deal termination invalidates it. Earnings inflection · M&A & special situations catalyst · ELE Elemental Royalty Corporation HIGH Elemental Royalty Corporation’s royalty-growth case turns on completing Vizsla by 2026-09-30 with GEO guidance intact. The 2026-09-08 Mexican clearance advances that case; a weekly close below $19.00 or a missed closing window invalidates… Cyclical recovery · Critical materials & rare earths catalyst · ESPR Esperion Therapeutics, Inc. HIGH Esperion Therapeutics’ cash-merger thesis was settled by the 2026-07-13 acquisition; only conditional commercial milestones remain. The common stock ceased trading, so the historical price invalidation no longer provides a prospective test. Earnings inflection · M&A & special situations analysed · GBTG Global Business Travel Group, Inc. fresh HIGH Global Business Travel Group’s $9.50-per-share Long Lake cash acquisition remains the thesis: completion settles the case, while a daily close below $9.00 invalidates it. Shareholders approved the merger on 2026-08-03, but the verified… Earnings inflection · M&A & special situations analysed · MKTX MarketAxess Holdings, Inc. HIGH MarketAxess’s $167-per-share cash acquisition by Intercontinental Exchange remains a completion story. Completion before a daily close below $155 would validate the case; the September 25, 2026 antitrust milestone is the next dated test. Earnings inflection · M&A & special situations catalyst · MRX Marex Group plc fresh HIGH Roll-up compounder in clean momentum continuation: the sell-side is now chasing price, with KBW $80, Barclays $76 and Piper $75 targets (Jul 9-15) leapfrogging the old $60 consensus, while the Bright Point clearing bolt-on (2026-07-09)… Cyclical recovery · M&A & special situations · AI datacenter infrastructure analysed · OGN Organon & Co. fresh HIGH Organon & Co.’s $14.00-per-share cash acquisition by Sun Pharma remains a completion thesis. Payment of the agreed consideration before a daily close below $13.00 would settle the case; the 2026-07-23 shareholder approval leaves regulatory… Earnings inflection · M&A & special situations analysed · PAYO Payoneer Global Inc. fresh HIGH Payoneer Global's $7.40-per-share cash acquisition now hinges on regulatory clearance and completion after September 14 shareholder approval. Payment before a daily close below $6.75 would resolve the thesis favorably; the vote alone does… Earnings inflection · M&A & special situations analysed · RAMP LiveRamp Holdings, Inc. fresh HIGH LiveRamp’s $38.50-per-share cash acquisition by Publicis remains a regulatory-completion thesis. Publicis reaffirmed year-end completion on 2026-09-16; closing by 2026-12-31 confirms the case, while a daily close below $35, termination or… Earnings inflection · M&A & special situations analysed · SAFT Safety Insurance Group, Inc. fresh HIGH Safety Insurance Group’s $105.00 cash-merger completion case now has HSR clearance and a 2026-11-03 shareholder vote. Completion requires the remaining approvals, while a daily close below $99 invalidates the price-convergence thesis. Earnings inflection · M&A & special situations analysed · SHIP Seanergy Maritime Holdings Corp. HIGH Seanergy Maritime’s freight upside rests on Q3 daily vessel earnings exceeding its 2026-07-30 estimate of approximately $30,998 while the dividend holds at $0.35 per share. The Q3 report tests that case; a weekly close below $15.50… Compounder · Freight & logistics catalyst · SMTI Sanara MedTech Inc. HIGH Sanara MedTech's cash-and-stock acquisition by MIMEDX now has a 2026-09-30 shareholder vote; completion by year-end would settle the merger thesis. A daily close below $32.50 or failure to complete by 2026-12-31 invalidates that case. Earnings inflection · Medtech & diagnostics · M&A & special situations catalyst · TECH Bio-Techne Corp fresh HIGH Bio-Techne’s $73.00 cash acquisition by Merck KGaA remains a completion thesis, with the shareholder vote scheduled for 2026-09-23. The case resolves through payment after required approvals and is invalidated by a daily close below $70;… Earnings inflection · M&A & special situations catalyst · UTZ Utz Brands, Inc. HIGH Utz Brands’ $14.25 cash-acquisition story turns on completion in the company-guided fourth quarter of 2026. Closing fulfills the case; a daily close below $13.50 or failure to complete by 2026-12-31 invalidates it, while the September 11… Earnings inflection · M&A & special situations analysed · ABT Abbott Laboratories fresh MEDIUM Two named overhangs cleared in August and the tape handed the gain back: $112.47 on 2026-08-28 to $108.33 on 2026-09-04, RSI(14) 61.7 to 44.9, with the $103 post-Q2 gap shelf now 4.9% below. The narrative is saturated — retail-facing… Special situation · Medtech & diagnostics · Precision biotech & therapeutics analysed · ABVX Abivax SA fresh MEDIUM Abivax's recovery case requires a late-2026 obefazimod US filing and a weekly close above the July offering price of $125 by 2026-12-31, before a weekly close below $96 invalidates it. The 2026-09-21 results provide the next scheduled test… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · ABX Abacus Global Management, Inc. fresh MEDIUM The $9.00 shelf still holds — $9.61 on 2026-09-04 against $9.27 on 2026-08-14, RSI(14) 59.7 — with the $100M repurchase live since 2026-08-17 the only identifiable new bid and no company release since 2026-08-24. What remains is a… Special situation · Cybersecurity analysed · ACIW ACI Worldwide, Inc. MEDIUM Special-situation breakup narrative accelerating: Reuters (2026-07-17) reports ACI exploring a ~$1.5B sale of its Biller unit, which would surface sum-of-the-parts value and re-rate the faster-growing Payments Software segment. Q1 beat +… Special situation · M&A & special situations · Fintech & consumer credit catalyst · ADBE Adobe Inc. fresh MEDIUM Deep-value AI-disruption leg in legacy software, now with an external validator: the 2026-08-13 Silver Lake–Workday take-private report put a sponsor price on marked-down per-seat SaaS. ADBE closed 2026-08-14 at $264.02, 28.2% off the… Special situation · AI enterprise software analysed · ADI Analog Devices, Inc. fresh MEDIUM Analog Devices’ AI and industrial growth story supports a recovery thesis, with fourth-quarter delivery as the operating test. Revenue at or above the $4.3 billion guidance midpoint and a daily close above the supplied $444.13 annual high… Theme leader · Analog semiconductors · AI datacenter infrastructure catalyst · AGIO Agios Pharmaceuticals, Inc. fresh MEDIUM Agios Pharmaceuticals' mitapivat label-expansion thesis turns on FDA approval for sickle cell disease by 2026-11-01. Approval would validate the regulatory case; a weekly close below $29 would invalidate the price structure first. Earnings inflection · Binary-catalyst biotech · Rare disease & gene therapy catalyst · AKAM Akamai Technologies, Inc. fresh MEDIUM Legacy-CDN-to-AI-inference pivot got its first external validation since the failed July bounce: Q2 CIS +39% to $99M with >$2.8B YTD contract bookings (2026-08-06), then J.P. Morgan off Underweight to Neutral, PT $158 (2026-08-13). Price… Special situation · AI datacenter infrastructure · Cybersecurity analysed · ALAB Astera Labs, Inc. fresh MEDIUM Q2 (2026-08-04) answered the July margin question: GM 73.7% vs ~73% guide, and Q3 guided $540–560M vs $416.5M consensus (~40% QoQ) with Scorpio X switches in volume production a quarter early. Price has not confirmed — the 2026-08-14 close… Cyclical recovery · AI datacenter infrastructure · AI chips & memory catalyst · ALGT Allegiant Travel Company fresh MEDIUM Allegiant closed the $1.5B Sun Country acquisition (2026-05-13) to become the largest US leisure airline just as fuel flipped to a tailwind and the whole sell-side re-rated it to $142–$160; the move has more than doubled off the low, and… Special situation · Travel & leisure analysed · ALM Almonty Industries Inc. fresh MEDIUM Non-China tungsten narrative now trades on one venue: the TSX exit took effect 2026-07-31 and the ASX removal 2026-09-01, leaving Nasdaq and Frankfurt. The operating case is unchanged — Sangdong throughput since 2026-07-01, Q2 revenue… Compounder · Critical materials & rare earths · Defense & aerospace analysed · AMBA Ambarella, Inc. fresh MEDIUM Physical-AI pure-play narrative still accelerating (Rosenblatt top H2-2026 pick, PT $120; Zacks upgrade to #2 Buy 2026-07-21), but the post-Rosenblatt breakout to ~$80 round-tripped to ~$67.61 by 2026-07-24, forfeiting the $72 shelf on a… Cyclical recovery · Physical AI & robotics · AI chips & memory analysed · AMC Amc Entertainment Holdings, Inc. fresh MEDIUM Box-office recovery flipped from meme-squeeze dormancy to a fundamental earnings inflection: Q2 (2026-07-20) adj EPS $0.14 vs $(0.06) est, revenue $1.597B beat, plus a Wedbush $4 / Benchmark $3 upgrade cluster (2026-07-21). Narrative… Special situation · Freight & logistics catalyst · ANDG Andersen Group Inc. fresh MEDIUM Post-IPO roll-up re-rate that survived its binary: Q2 revenue $217.7M beat $199.3M on 2026-08-12 and FY2026 was affirmed at $980M–$1.0B, with four target raises to $49–57 on 2026-08-13. The print is behind it and no dated catalyst sits… Defensive · Semi foundry & equipment catalyst · APPS Digital Turbine, Inc. MEDIUM Digital Turbine’s mobile-advertising recovery supports a renewed re-rating case after the September price rebound. A weekly close above the $14.39 reference high would complete the price case; a weekly close below $9.50 or a cut to fiscal… Special situation · AI enterprise software · Precision biotech & therapeutics analysed · ARIS Aris Mining Corporation MEDIUM Aris Mining’s expansion case depends on Marmato producing first gold in Q4 2026 with annual production guidance intact. Company confirmation before a weekly close below $17.50 would establish the near-term commissioning leg; first gold… Compounder · Critical materials & rare earths catalyst · ARXS Arxis, Inc. MEDIUM Arxis’ defense-and-space acquisition story needs another revenue-guidance increase at the next quarterly report to confirm acceleration. The case requires organic growth to hold at the 21% reported on 2026-07-29 and ends first if a weekly… Cyclical recovery · Space economy · Defense & aerospace catalyst · ATEYY Advantest Corporation fresh MEDIUM Advantest Corporation’s AI-testing thesis requires October 28 results to sustain July’s raised forecasts and a weekly close above $216.24 before a weekly close below $200. September 10 foundry growth supports demand indirectly; subsequent… Cyclical recovery · Semi foundry & equipment · AI chips & memory catalyst · AUR Aurora Innovation, Inc. fresh MEDIUM Q2 (2026-07-29) cleared the binary without breaking the plan: >200 driverless trucks and ~$80M exit run-rate reaffirmed, FY26 revenue guided $14–16M, ~$1.2B cash after a $215M net ATM raise. Price reclaimed the broken ~$6.00 June shelf to… Defensive · Physical AI & robotics · Freight & logistics catalyst · AVTR Avantor, Inc. fresh MEDIUM Avantor’s recovery re-rating depends on Q3 delivering July’s organic growth and adjusted earnings guidance while retaining its improved full-year outlook. That confirmation must arrive before a weekly close below $14.00 breaks the price… Special situation · Medtech & diagnostics analysed · AYA Aya Gold & Silver Inc. fresh MEDIUM Aya Gold & Silver's production-growth thesis requires Q3 Zgounder output above 1.49 million silver ounces and processing above 3,889 tonnes per day. Boumadine's September 9 study strengthens the development case, but a weekly close below… Compounder · Critical materials & rare earths analysed · BBAR Banco BBVA Argentina S.A. MEDIUM Argentina country trade re-accelerated: June CPI printed 1.9% MoM on 2026-07-14 (first sub-2% of the cycle) and country risk broke to 402bp, tightest since April 2018, carrying BBAR to a fresh 52-week high of $22.47. Price now sits above… Compounder · Emerging markets catalyst · BBWI Bath & Body Works, Inc. MEDIUM Bath & Body Works’ cash-flow turnaround needs Q3 sales to decline no more than 2.5% and its approximately $650 million FY2026 free-cash-flow outlook intact. A weekly close below $18 invalidates the structural case before that operating… Special situation · Consumer discretionary rotation catalyst · BE Bloom Energy Corporation fresh MEDIUM Bloom Energy’s AI data-center power thesis now depends on earnings sustaining the September advance after index inclusion. The next quarterly report must preserve its $3.9–$4.2 billion FY2026 revenue outlook and confirm price strength… Theme leader · Industrial power & grid · AI datacenter infrastructure catalyst · BETA Beta Technologies, Inc. fresh MEDIUM Beta Technologies' recovery case rests on certification progress converting aircraft backlog into revenue. A weekly close above the September 4 reference of $22.20 would confirm the price recovery; a weekly close below $19.00 would… Compounder · EV & autonomous mobility · Freight & logistics analysed · BHE Benchmark Electronics fresh MEDIUM Beat-and-raise on 2026-07-29 (rev $756M +18% YoY, AC&C +71% YoY, FY26 lifted to ~$3B/+13%) was fully sold: price round-tripped from the $98.67 52-week high to $81.75 on 2026-08-14. The AI-cooling and lidar picks-and-shovels leg is… Cyclical recovery · AI datacenter infrastructure · Cyclical industrials catalyst · BILL BILL Holdings, Inc. MEDIUM BILL Holdings’ margin recovery needs customer stabilisation at the next quarterly report after the September 11 close erased August’s rebound. A weekly close above $52 before a weekly close below $44 would confirm the price-recovery case;… Special situation · Fintech & consumer credit catalyst · BLZE Backblaze, Inc. fresh MEDIUM Neocloud storage pick-and-shovel: the five-year ~$335M CoreWeave B2 Neo deal (2026-06-23) re-rated BLZE from the high-$7s to a 52-week high near $18, and sell-side is still chasing (Citizens to $16, 2026-07-23). Narrative accelerating but… Cyclical recovery · GPU cloud & neoclouds · AI datacenter infrastructure catalyst · BMA Banco Macro S.A. MEDIUM Banco Macro's sovereign-risk recovery gained support from August inflation of 1.7%, released September 10. The price case plays out on a weekly close above September 4's $78.57 before a weekly close below $72; Q2 credit deterioration still… Compounder · Emerging markets catalyst · BMY Bristol-Myers Squibb Co. fresh MEDIUM Post-guidance-reset re-rate printed a new 52-week high of $68.09 before the 2026-09-04 close of $66.82, but the first negative company headline of the leg — the zola-cel autoimmune CAR-T enrollment pause confirmed 2026-08-31 — arrived with… Special situation · Precision biotech & therapeutics · Oncology & immunology catalyst · BOLD Boundless Bio, Inc. fresh MEDIUM Boundless Bio’s merger thesis pairs a planned $44–48 million cash distribution with a minority Serapha interest. Completion by 2026-12-31 with that distribution intact would confirm the case; a weekly close below $2.40 would invalidate its… Earnings inflection · M&A & special situations · Rare disease & gene therapy catalyst · BTU Peabody Energy Corporation MEDIUM Peabody Energy’s Centurion recovery depends on higher production becoming shipments and positive metallurgical earnings. Third-quarter sales meeting management’s 0.5–0.7 million-ton range and positive segment adjusted EBITDA would… Special situation · Oil, energy & geopolitical · Critical materials & rare earths analysed · CBLL CeriBell, Inc. MEDIUM Ceribell’s reimbursement-backed delirium expansion needs a Q4 2026 commercial launch and a weekly close above $24.89 to confirm the next leg. A weekly close below $21.50 invalidates the price thesis; the 2026-10-01 payment start alone does… Defensive · Medtech & diagnostics catalyst · CCC CCC Intelligent Solutions Holdings Inc. MEDIUM Cheap, high-margin insurtech SaaS put in play: a Morgan Stanley-run sale process plus a fresh Elliott activist stake. Shares popped ~13% to ~$6 on the 2026-07-09 Reuters report yet still sit below a plausible PE take-out. The trade is… Earnings inflection · M&A & special situations analysed · CERT Certara, Inc. MEDIUM The self-help leg is intact and quiet: FY26 guidance was reaffirmed at the 2026-08-04 Q2 print ($367–382M revenue, $0.31–0.36 adj EPS), the ~$13M cost takeout first shows up in Q3 numbers, and the shares have held four closes between $8.13… Special situation · AI enterprise software · Precision biotech & therapeutics analysed · CGEM Cullinan Therapeutics, Inc. fresh MEDIUM CD19 T-cell-engager-in-autoimmune narrative re-rated CGEM ~3x off the $5.68 low on CLN-978 lupus/RA single-dose remissions; now drifting to ~$17.10 in a bull flag under the $19.43 high with the big data catalyst spent and no dated readout… Earnings inflection · Oncology & immunology · Precision biotech & therapeutics analysed · CLOV Clover Health Investments, Corp. fresh MEDIUM Clover Health's rating-led profitability thesis has fresh analyst coverage but still depends on the court-supported reimbursement remedy. A weekly close above the $5.41 reference high with its raised FY2026 outlook intact would confirm… Earnings inflection · Managed care & health services catalyst · CMCO Columbus McKinnon Corporation MEDIUM First full combined quarter post-Kito Crosby beat hard (adj EPS $0.61 vs $0.27 est) and drove a guidance raise on all three lines on 2026-07-30; the leg being bought is deleveraging from 4.9x toward sub-4x by FY28 on $70M of synergies. No… Special situation · Cyclical industrials · M&A & special situations catalyst · CME CME Group Inc. MEDIUM CME Group's product-launch story requires its September–October factor, hockey and compute contracts to begin trading on schedule. Missed launch dates or a weekly close below $272 would invalidate the near-term case. Special situation · Prediction markets & betting · Crypto exchanges & financials catalyst · COHU Cohu, Inc. MEDIUM Best fundamental print of the AI cycle (2026-07-30: rev $149M vs $144.08M cons.; Q3 guided $163–177M vs $146.33M) collided with a sector de-rate — the stock closed $52.88 on 2026-08-07, 28.5% under its $73.91 high and beneath the June… Cyclical recovery · AI datacenter infrastructure · Semi foundry & equipment analysed · COTY COTY INC fresh MEDIUM Balance-sheet repair, not demand recovery: FY26 net debt fell to $2,912.1M but leverage still printed 3.4x as adjusted EBITDA fell 22% to $846.9M, and the 2026-08-19 print deferred FY27 guidance to the end-CY26 Consumer Beauty review. The… Special situation · Consumer discretionary rotation analysed · CRAI CRA International, Inc. MEDIUM Beat-and-raise from 2026-08-06 — record $210.8M quarter, FY26 constant-currency guide to $805–820M — remains only partly repriced: $174.99 on 2026-08-28, 20.8% under the $221.02 high, no company headline since 2026-08-08. The leg is a toll… Cyclical recovery · Managed care & health services catalyst · CRDO Credo Technology Group Holding Ltd MEDIUM Interconnect/AEC royalty narrative still accelerating, not fading — new 52-week highs on late-June initiations (Evercore $325, Stifel $350, BofA $340) plus the early-July AI-buildout rally. But it's now mainstream and widely held, entering… Cyclical recovery · Networking & optical · AI datacenter infrastructure catalyst · CSTL Castle Biosciences, Inc. fresh MEDIUM Castle Biosciences’ recovery rests on TissueCypher sustaining its growth plan; the next quarterly results must preserve revenue and test-volume guidance. Management’s unchanged outlook at the 2026-09-15 Baird conference supports the case,… Defensive · Medtech & diagnostics · Oncology & immunology analysed · CTOS Custom Truck One Source, Inc. MEDIUM Utility T&D / grid-capex cycle with CTOS as the laggard specialty-rental picks-and-shovels name; the June breakout to $11.36 has stalled, retracing ~10% to retest the ~$10 shelf into a binary 2026-07-29 Q2 print. Theme now maturing and… Cyclical recovery · Industrial power & grid · Cyclical industrials analysed · CTRN Citi Trends, Inc. fresh MEDIUM The 2026-08-25 print resolved the binary the right way — comps +10.5%, gross margin 40.6% (+60bps), FY adjusted EBITDA guide lifted to $38–42M — and the shares still closed lower, because the raised FY sales range of $901.958M–$918.357M… Retail squeeze · Consumer discretionary rotation catalyst · CXT Crane NXT, Co. fresh MEDIUM The post-print give-back stopped rather than reversed: $50.20 on 2026-08-21 and $50.06 on 2026-09-04, RSI back to 49.5, with the $47 washout shelf untested since the 2026-08-19 $48.06 open. The sell-side anchor reset lower in the same… Special situation · M&A & special situations · Cyclical industrials analysed · DFDV DeFi Development Corp. fresh MEDIUM DeFi Development Corp.'s preferred financing creates a path to more Solana per common share. A subsequent issuer disclosure above the August 12 figure of 0.066 SOL per share would confirm that leg; a weekly close below $4.90 invalidates it. Compounder · Crypto exchanges & financials catalyst · DFIN Donnelley Financial Solutions, Inc. MEDIUM Donnelley Financial Solutions’ software transition supports margin expansion; Q3 must match Q2’s 7.8% software growth, exceed $175 million revenue and deliver at least a 26% adjusted EBITDA margin before a weekly close below $44… Special situation · AI enterprise software analysed · DGII Digi International Inc. fresh MEDIUM Hardware-to-ARR re-rating accelerating: the 2026-08-05 Q3 print put ARR at $191M (+52% YoY) with a record 29.1% adj-EBITDA margin, and FY26 revenue guidance jumped to $529–533M from $490–508M. Price closed 2026-08-14 at $85.12, 0.1% off… Special situation · Industrial power & grid catalyst · DOCN DigitalOcean Holdings, Inc. MEDIUM DigitalOcean’s AI cloud recovery needs third-quarter revenue of $304–$307 million, its August 4 guidance, and a weekly close above the former $132 August shelf. A weekly close below the July placement price of $117.54 invalidates the case. Theme leader · GPU cloud & neoclouds · AI datacenter infrastructure analysed · DOCU DocuSign, Inc. MEDIUM DocuSign’s AI agreement pivot now has higher analyst targets behind it; a weekly close at or above Piper Sandler’s September 4 target of $75 would confirm the repricing, while a weekly close below $64 would invalidate it. Special situation · AI enterprise software catalyst · DRTS Alpha Tau Medical Ltd. MEDIUM Head-and-neck re-acceleration: a 2026-06-23 first-ex-US glioblastoma treatment drove a +17.9% breakout to new 52-week highs (~$12.56 on 7/11), reclaiming the $11.99 Tolmar equity shelf. The 2026-07-21 AHNS podium with complete Alpha DaRT +… Earnings inflection · Oncology & immunology · Medtech & diagnostics catalyst · DVA DaVita Inc. MEDIUM The census-recovery re-rate stayed dead through August, but the 2026-08-21 washout close of $173.82 held: DVA closed 2026-08-28 at $180.68 with RSI(14) back to 44.9 from 10.9. The 2026-08-25 Humana value-based deal (>10,000 MA members, CKD… Special situation · Managed care & health services analysed · DXC DXC Technology Company MEDIUM DXC Technology’s AI pivot is a recovery thesis: September-quarter results must meet guidance and preserve the annual earnings outlook. A weekly close below $10.50 invalidates the price structure supporting the case. Special situation · AI enterprise software analysed · DYN Dyne Therapeutics, Inc. MEDIUM Nothing company-dated until the ~late-October Q3 print, leaving a maturing narrative to trade on small-cap biotech flow ahead of the 2027-01-21 PDUFA. Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · EDRY EuroDry Ltd. fresh MEDIUM EuroDry’s freight-led revaluation needs third-quarter charter earnings to sustain the second-quarter level. Confirmation requires reported TCE of at least $20,398 per vessel per day before a weekly close below $57.43; Panamax earnings of… Compounder · Freight & logistics · Cyclical industrials catalyst · ELF e.l.f. Beauty, Inc. fresh MEDIUM Sell-side flipped from cutting to marking up in ten days — five PT raises 2026-07-10→07-17 (JPM $94, Canaccord $97, Citi $92, RJ $87, UBS $80) on the e.l.f. Hair launch and Rhode scaling, while the stock slipped to $72.25. Narrative… Earnings inflection · Cannabis reclassification catalyst · ENTG Entegris, Inc. MEDIUM June's sentiment re-rate rolled over; the 2026-08-04 beat-and-raise re-based the story on numbers — Q2 sales $883.2M vs $835.5M consensus, Q3 guide $905–935M vs $879.8M — and drew three target raises on 08-05 (UBS $215). At $152.08 the… Cyclical recovery · AI chips & memory · Semi foundry & equipment catalyst · FET Forum Energy Technologies, Inc. MEDIUM Forum Energy Technologies’ operating-leverage re-rating needs Q3 revenue of $225–245 million and retained full-year guidance. Those results plus a weekly close above the September 11 reference high of $86.31 would confirm the case; a… Cyclical recovery · Cyclical industrials · Semi foundry & equipment catalyst · FIGR Figure Technology Solutions, Inc. fresh MEDIUM Figure Technology Solutions' Kiavi expansion needs Q3 marketplace volume to meet the $4.8–5.2 billion guidance excluding Kiavi while preserving Q2's 55% adjusted EBITDA margin. A weekly close below $30 or failure of either operating test… Cyclical recovery · Crypto exchanges & financials · Fintech & consumer credit analysed · FORM FormFactor, Inc. MEDIUM Probe-card pick-and-shovel to the HBM4 test ramp; after a parabolic run to a fresh $160.27 ATH (2026-06-30) on Russell 1000 inclusion, the 2026-07-02 chip selloff cut FORM ~24% to ~$121. HBM inflection intact (record DRAM quarter, second… Cyclical recovery · Semi foundry & equipment · AI chips & memory catalyst · FSLR First Solar, Inc. fresh MEDIUM Section 232 supplied a new leg: the 2026-08-06 proclamation sets a $0.38/W minimum import price on modules from 2026-12-04, above the ~$0.36/W FSLR struck on Q2 US bookings. Baird upgraded 2026-08-11 with a target moved to $318 from $205.… Theme leader · Solar & clean energy · Cyclical industrials analysed · FTRE Fortrea Holdings Inc. fresh MEDIUM Fortrea’s margin-repair recovery requires backlog growth and preservation of the $205 million full-year adjusted-EBITDA floor at the next quarterly report. The September 18 shelf recovery supports the case, which a weekly close below… Special situation · Oncology & immunology catalyst · GCMG GCM Grosvenor Inc. fresh MEDIUM GCM Grosvenor’s recurring-fee growth supports a revaluation, conditional on the next report sustaining FRE growth and fundraising. Confirmation requires quarterly fundraising at least matching Q2’s $2.3 billion and a weekly close above the… Compounder · Cybersecurity · Biofuels & low-carbon fuels analysed · GCT GigaCloud Technology Inc MEDIUM GigaCloud Technology's operating-leverage rerating remains the thesis; a weekly close above $53.25 would confirm price continuation, while a weekly close below $45 would invalidate it. Third-quarter results test whether the August margin… Defensive · Cyclical industrials catalyst · GERN Geron Corporation fresh MEDIUM The leg is a self-funding commercial ramp, not the myelofibrosis binary: Q2 RYTELO revenue $57.5M (+11% QoQ), quarterly cash draw down to ~$14M on $326.9M, FY guide $220–240M reiterated at the mid-to-high end. The 2026-09-02 release added… Earnings inflection · Oncology & immunology · Binary-catalyst biotech analysed · GH Guardant Health, Inc. fresh MEDIUM Guardant Health’s renewed advance prices broader Shield coverage becoming screening revenue. The next quarterly screening result must exceed Q2’s $52.9 million, reported on 2026-07-30; a weekly close below the 2026-09-04 reference close of… Compounder · Medtech & diagnostics · Oncology & immunology analysed · HIMX Himax Technologies, Inc. MEDIUM Himax Technologies' AI-sensing re-rating requires a named, shipping smart-glasses product and Q3 revenue meeting its August 6 guidance before a weekly close below $13. The September 11 reclaim of the post-earnings reference close improves… Theme leader · Analog semiconductors · AI chips & memory catalyst · HPK HighPeak Energy, Inc. MEDIUM HighPeak Energy’s second-half spending reduction supports a debt-reduction thesis that third-quarter accounts must confirm. The case resolves with lower capital spending and total debt below June’s approximately $1.19 billion before a… Compounder · Oil, energy & geopolitical catalyst · HRI Herc Holdings Inc. MEDIUM Second-order AI/power play: Herc rents the cranes and gensets that build data centers. Peer United Rentals raised FY26 guidance (2026-04-23), confirming an accelerating theme — but the stock sits +71% off its low and drifts into a binary… Theme leader · AI datacenter infrastructure · Industrial power & grid catalyst · HTZ Hertz Global Holdings, Inc MEDIUM The 2026-08-06 Q2 beat re-lit a squeeze the index deletion had just flushed: adjusted corporate EBITDA $81M cleared the top of a $50–80M guide, GAAP swung to +$64M, and the stock ran roughly 50% in two sessions amid 73.85%-of-float short… Retail squeeze · Squeeze & momentum setups catalyst · HUBS Hubspot, Inc. MEDIUM HubSpot is trading as laggard beta on the Salesforce-led software re-rate — CRM +22.6% on 2026-08-27 — carrying HUBS from $240.01 on 08-21 to $260.68 on 08-28 with no company disclosure since the 2026-08-05 guidance reset. Price now sits… Special situation · AI enterprise software catalyst · ICLR ICON plc MEDIUM ICON plc’s restatement-discount recovery depends on bookings sustaining its earnings outlook. A weekly close above the August reference of $172.23 and unchanged guidance at the next quarterly disclosure would confirm renewed recovery; a… Cyclical recovery · Oncology & immunology analysed · IDYA IDEAYA Biosciences, Inc. fresh MEDIUM IDEAYA Biosciences' darovasertib filing and expansion trials underpin a recovery thesis. Confirmation requires a weekly close above the $42.48 reference high and NDA completion by 2026-12-31 before a weekly close below $34; the October… Earnings inflection · Oncology & immunology · Precision biotech & therapeutics analysed · IMAX Imax Corp MEDIUM IMAX Corporation's record summer supports renewed premium-format repricing; a weekly close above $54.79 would confirm the case. A weekly close below $47 would invalidate it, while the next quarterly results test whether summer demand… Compounder · Oil, energy & geopolitical catalyst · IMOS ChipMOS TECHNOLOGIES INC. MEDIUM Memory-cycle re-rating in an AI costume just re-accelerated: June 2026 revenue +37.2% YoY and Q2 +28.7% YoY (both records since 2014, reported 2026-07-10) erase the May deceleration scare, and price bought back the ~17% fade to sit ~$68… Theme leader · AI chips & memory catalyst · INFQ Infleqtion, Inc. fresh MEDIUM Infleqtion’s Cisco collaboration and NVIDIA software work refresh its funded-quantum story. A daily close above $13.60 by 2026-10-07 would validate the near-term price response; a daily close below $10.90 would invalidate it. Compounder · Quantum computing catalyst · INNV InnovAge Holding Corp. fresh MEDIUM InnovAge’s September earnings beat shifts the turnaround story to fiscal 2027 growth. A weekly close above the $12.11 reference high with its 2026-09-08 outlook intact would confirm the next advance; a weekly close below $10.50 invalidates… Special situation · Managed care & health services analysed · IRWD Ironwood Pharmaceuticals, Inc. fresh MEDIUM Ironwood Pharmaceuticals’ LINZESS cash generation supports a recovery toward the market’s $5.39 high, tested by annual guidance and year-end debt reduction. A weekly close above $5.39 completes the price case; a weekly close below $3.80… Earnings inflection · Precision biotech & therapeutics · M&A & special situations analysed · IVA Inventiva S.A. fresh MEDIUM The 30-day news blackout broke: the 2026-09-02 last-patient-last-visit release in NATiV3 (1,419 patients) reaffirmed Q4 2026 topline and closed the trial-conduct timing gate, leaving database lock and unblinding as the only steps before… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · JRSH Jerash Holdings (US), Inc. fresh MEDIUM Jerash Holdings’ sourcing-migration story depends on another quarter meeting guidance. Fiscal Q2 revenue of at least $49 million and gross margin of at least 14% would confirm the case before a weekly close below $4.80 invalidates the… Defensive · Consumer discretionary rotation analysed · KEYS Keysight Technologies, Inc. fresh MEDIUM Analyst-migration re-rate's second leg (Morgan Stanley to Overweight, PT $400, 2026-07-13) has stalled — silent tape near 28x forward, empty calendar until the ~2026-08-19 Q3 FY26 print. The $290–300 breakout-shelf entry hasn't come;… Cyclical recovery · AI datacenter infrastructure · Networking & optical analysed · KMX CarMax Inc. fresh MEDIUM Turnaround re-rating went live in July: KMX broke the $50–$53 shelf to close $57.33 on 2026-07-17 (+17.2% in five sessions) after a Q1 FY27 blowout (EPS $1.31 vs ~$0.95, revenue $8.01B +6.2%), CEO Keith Barr buying 9,400 shares at $53.005… Special situation · Consumer discretionary rotation · Fintech & consumer credit catalyst · KNSA Kiniksa Pharmaceuticals International, plc MEDIUM Kiniksa Pharmaceuticals’ commercial re-rating depends on another ARCALYST revenue-guidance increase at the next quarterly report. The case fails if that report leaves the 2026-07-28 range of $980–995 million unchanged or lower, or a weekly… Defensive · Precision biotech & therapeutics analysed · KOPN Kopin Corporation fresh MEDIUM Kopin Corporation's defense orders and optical-interconnect pivot support a recovery case toward the $6.39 market high recorded as of 2026-09-18. The forecast succeeds if that high is reached by the next quarterly report, estimated for… Special situation · AI datacenter infrastructure · Defense & aerospace analysed · LGND Ligand Pharmaceuticals Incorporated fresh MEDIUM Ligand Pharmaceuticals’ royalty growth and XOMA integration support an earnings-compounding case. A weekly close above $322.61 before a close below $262, accompanied by a December 8 outlook preserving the projected 2027 XOMA contribution,… Cyclical recovery · Precision biotech & therapeutics analysed · LILA Liberty Latin America Ltd. fresh MEDIUM Liberty Latin America's break-up story needs an announced Puerto Rico and US Virgin Islands separation form and completion window by the next quarterly report. That milestone confirms the case unless a weekly close below $7.30 invalidates… Defensive · M&A & special situations · Emerging markets analysed · LNC Lincoln National Corp. MEDIUM Lincoln National Corporation’s legacy-risk transfer supports a re-rating case, with Talcott completion in Q4 2026 and a weekly close above $47 confirming it. A weekly close below $42 or failure to close the deal by 2026-12-31 invalidates… Special situation · Medtech & diagnostics · M&A & special situations analysed · MBX MBX Biosciences, Inc. fresh MEDIUM MBX Biosciences' funded once-weekly hormone-replacement program anchors the valuation story, with Q4 2026 obesity data the next clinical test. The price case requires a weekly close above the $70.70 reference high before a weekly close… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · MCS The Marcus Corporation MEDIUM Theatrical-recovery re-rating is drifting sideways with no company input: no release and no target revision since 2026-08-04, leaving consensus at $32.25 while the 2026-08-28 close of $29.02 sits 6.5% under the $31.03 52-week high.… Compounder · Consumer discretionary rotation · Travel & leisure catalyst · MEI Methode Electronics fresh MEDIUM Data-center power pivot is revenue-confirmed — record >$80M FY26 segment sales and an FY27 guide ($1.025–1.075B vs ~$952M Street) — but the post-print momentum leg has faded ~26% from the $20.38 high to ~$15. The re-rate is spent and the… Special situation · AI datacenter infrastructure · Industrial power & grid catalyst · MIRM Mirum Pharmaceuticals, Inc. fresh MEDIUM Rare-disease franchise ran to a $125 ATH on FOP data, then cooled ~9% into a confirmed 2026-07-30 Q2 print. Base compounds (Q1 sales +43% YoY, FY guide $660–680M) with FOP PDUFA 2026-09-26 and HDV Phase 3 topline 2H26 stacked ahead — but… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · MMED MiniMed Group, Inc. fresh MEDIUM MiniMed Group’s standalone-growth revaluation now has a dated separation test after Medtronic’s September 14 exchange-offer launch. The case succeeds with completion and a weekly close above the September 4 reference close of $23.29 before… Special situation · Medtech & diagnostics catalyst · MNPR Monopar Therapeutics Inc. fresh MEDIUM The rolling-NDA leg rebuilt without news: $107.72 on 2026-08-21 to $117.56 on 2026-09-04, back within 5.1% of the $123.84 high, on no company release since 2026-08-19 and with two directors selling into $109–$113 on 2026-08-25 and… Earnings inflection · Binary-catalyst biotech · Rare disease & gene therapy analysed · MYRG MYR Group, Inc. fresh MEDIUM AI/datacenter power-buildout supercycle lifting grid/electrical contractors; MYRG confirmed it with a record Q1 and a late-June breakout to fresh ATHs (~$487) above the $484.71 shelf. Theme accelerating + cluster-confirmed, but the Q2… Cyclical recovery · Industrial power & grid · AI datacenter infrastructure analysed · NEOG Neogen Corporation MEDIUM Neogen’s turnaround rests on Food Safety growth and Genomics-funded debt reduction. The confirmed 2026-10-07 investor day precedes the estimated October results test; a revenue miss, lost sale funding or a weekly close below $11.00 would… Special situation · Medtech & diagnostics · M&A & special situations catalyst · NKTR Nektar Therapeutics fresh MEDIUM M&A read-through re-accelerating: AbbVie's $10.9B Apogee buyout (June 22, 2026) reframed NKTR as the next takeout-able Treg-IL-2 atopic-dermatitis asset, driving a ~25% run off the June low to ~$70. It's sympathy optionality, not fresh… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · NOG Northern Oil and Gas, Inc. MEDIUM Northern Oil and Gas’s crude-driven recovery faces a cash-flow test as hedges limit oil-price upside. A weekly close above the $29.64 annual high completes the price case, while a weekly close below $23.00 invalidates it; third-quarter… Compounder · Oil, energy & geopolitical catalyst · NTSK Netskope, Inc. MEDIUM Netskope's September 2 revenue beat and guidance raise support an earnings-backed recovery toward J.P. Morgan's 2026-09-03 target of $18. A weekly close above $18 completes the price case; a weekly close below $13.50 invalidates it. Defensive · Cybersecurity catalyst · NWL Newell Brands Inc. fresh MEDIUM Post-print re-rating still shelved: the 2026-09-04 close of $6.11 sits 2.8% under the $6.29 52-week high with RSI(14) at 53.2, and the covering leg behind the 7/31 +15% is largely spent (10.52% of float short at the 2026-08-14 settlement,… Special situation · Consumer discretionary rotation catalyst · NXT Nextpower Inc. fresh MEDIUM Falling knife has based and turned: after a -34% unwind from the $163 high to a ~$107 June base, a fresh cluster (Truist initiate Buy $140 07-14, Guggenheim upgrade Buy 07-15) plus a 07-15 surge is re-rating the M&A-drift story. The… Theme leader · Solar & clean energy catalyst · ONC BeOne Medicines Ltd. fresh MEDIUM BeOne Medicines’ BRUKINSA growth supports a renewed-high thesis, but September price action has not confirmed it. A weekly close above the supplied $377.47 high would establish the price outcome; a weekly close below $326 would invalidate… Compounder · Oncology & immunology · Precision biotech & therapeutics analysed · OOMA Ooma, Inc. MEDIUM Ooma’s business-communications roll-up faces a September 29 test of its raised $332.0–333.5 million fiscal 2027 revenue outlook. Sustained guidance and a subsequent weekly close above the September 11 reference high of $23.38 would confirm… Special situation · GPU cloud & neoclouds · Critical materials & rare earths catalyst · OWL Blue Owl Capital Inc. MEDIUM Private-credit-stress bottom trade picked up a second strand: Blue Owl managed funds led a $2.4B GPU-equipment financing for IREN on 2026-08-28, days after Oppenheimer took its target to $17. Price closed $12.02 on 2026-08-28, 5% below the… Compounder · Biofuels & low-carbon fuels · AI datacenter infrastructure catalyst · OXM Oxford Industries, Inc. fresh MEDIUM Setup inverted since the June breakdown. OXM reclaimed its 200-day ($39.11) and 50-day ($39.94) off the $35.83 low, the CEO bought 2,500 shares at $36.90 on 2026-06-12, and ~$25M of filed IEEPA tariff-refund claims — 4% of market cap,… Special situation · Consumer discretionary rotation catalyst · P Everpure, Inc. fresh MEDIUM Everpure’s hyperscaler expansion supports a recovery thesis that needs quantified fiscal-2028 revenue at the September 23, 2026 analyst meeting and a weekly close above $110. A weekly close below $92 invalidates the case. Cyclical recovery · AI datacenter infrastructure catalyst · PARR Par Pacific Holdings, Inc. fresh MEDIUM Par Pacific's distillate-margin story now depends on Q3 operating confirmation as inventories rebuild from scarce levels. A weekly close above $86.49 would confirm price continuation; a weekly close below $76 would invalidate it. Compounder · Oil, energy & geopolitical catalyst · PD PagerDuty, Inc. fresh MEDIUM The read has flipped from value trap to ownership story. Price reclaimed the 200-DMA (~$10.30 on 2026-07-17, +13% in three weeks), Truist lifted its PT to $11 on 2026-07-09, and the 2026-07-14 addition of Alex Shootman — who sold Workfront… Special situation · AI enterprise software · M&A & special situations analysed · PEB Pebblebrook Hotel Trust fresh MEDIUM Pebblebrook Hotel Trust’s lodging recovery requires October 29 results to sustain its raised earnings outlook before the $16 breakout shelf fails. The case resolves positively if third-quarter RevPAR growth exceeds +1% and annual guidance… Earnings inflection · Travel & leisure analysed · PENG Penguin Solutions, Inc. fresh MEDIUM Q3 (July 7) broke the model wide open: revenue $478.7M vs $405.5M consensus (+48% YoY), EPS $0.84 vs $0.54, FY26 growth guide lifted 12%→22% and FY27 pre-guided ~30%. The stock then round-tripped from $89.86 to ~$60 on the $750M… Cyclical recovery · AI datacenter infrastructure · AI chips & memory catalyst · PENN PENN Entertainment, Inc. fresh MEDIUM Q2 (2026-08-06) kept the digital turnaround on schedule — interactive adj-EBITDA loss $9.5M (+$52.5M YoY), Q4-2026 profitability target and $1.963B retail EBITDAR midpoint intact — but the tape decoupled: prediction-market headlines took… Special situation · Crypto exchanges & financials analysed · PGEN Precigen, Inc. fresh MEDIUM PAPZIMEOS launch-ramp durability is the binary — the first FDA-approved RRP therapy printed $21.6M net product revenue in Q1 2026, and the now-confirmed Aug 4 Q2 print (announced Jul 21) grades whether the ramp compounds sequentially or… Earnings inflection · Precision biotech & therapeutics · Rare disease & gene therapy catalyst · PLMR Palomar Holdings, Inc. fresh MEDIUM Palomar Holdings' $270–280 million FY2026 adjusted-income guidance, issued August 4, anchors the specialty-insurance growth thesis. Confirmation requires a weekly close above $144.79 before a weekly close below $128 invalidates it. Compounder · Managed care & health services analysed · PNRG PrimeEnergy Resources Corporation fresh MEDIUM Geopolitical crude bid re-fired after the 2026-07-08 US strikes and Hormuz blockade — WTI back to ~$80 from $68.86, PNRG +8.9% MTD to $186.51 and above the 200-day. Structurally better than June: GCX in-service flipped Waha gas positive,… Retail squeeze · Oil, energy & geopolitical catalyst · PRCH Porch Group, Inc. fresh MEDIUM Reciprocal-pivot re-rate has largely printed: $9.26 (6/5) to $15.98, now consolidating at $13.68 after KBW's 7/13 valuation downgrade that still raised its target to $16.25. Narrative intact but maturing; the 2026-08-04 Q2 print is the… Special situation · Housing, homebuilders & proptech · Managed care & health services catalyst · PRGS Progress Software Corporation fresh MEDIUM Disciplined software roll-up ("Total Growth Strategy") re-rated by a fresh catalyst cluster: Q2 beat + FY guide raise (2026-06-30) and the $400M Domo buy (2026-07-22). Special-situations theme active, but a maturing low-beta compounder —… Special situation · AI enterprise software · M&A & special situations catalyst · PRM Perimeter Solutions, Inc. fresh MEDIUM Monopoly wildfire retardant (PHOS-CHEK) into a season at national Preparedness Level 5 — 3.85M acres burned YTD (NIFC, 7/18), ~157% of the 10-yr average. JPM initiated Overweight $50 on 7/9, lifting the 4-analyst average target to $45.… Defensive · Industrial power & grid catalyst · PTGX Protagonist Therapeutics, Inc. fresh MEDIUM De-risked dual-royalty story accelerating into a binary: icotrokinra (oral IL-23, J&J) already approved and paying 6–10% royalties; rusfertide (PV, Takeda) into a Q3 2026 PDUFA. Stock at a fresh ATH ($143.29, Jul 20) as the PV theme runs —… Earnings inflection · Precision biotech & therapeutics catalyst · PVLA Palvella Therapeutics, Inc. fresh MEDIUM Palvella Therapeutics’ QTORIN filing puts an accelerated FDA review in focus. Acceptance with Priority Review and a weekly close above $157.77 would complete the case before a weekly close below $137 invalidates it; the filing… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics analysed · RAPP Rapport Therapeutics, Inc. fresh MEDIUM RAPP broke to all-time highs at $42.62 (2026-07-17, +6.2%) on zero company news — the move is pure sell-side re-rating (BTIG reiterated Buy/$65 on 7/16, consensus PT $56.64, 12 desks Strong Buy) with Phase 3 FOCUS now enrolling globally.… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · RDIB Reading International Inc fresh MEDIUM Reading International’s asset-sale deleveraging thesis turns on completing the contracted $41.0 million cinema-property sale around 2026-10-30 and discharging its mortgage. A weekly close below $12 would invalidate the market case before… Retail squeeze · Housing, homebuilders & proptech catalyst · RELY Remitly Global, Inc. fresh MEDIUM Operating-leverage leg intact but stalling: since the 2026-08-05 Q2 raise to $1.978–1.988B / $410–415M, the only new information has been supply — a Form 4 dated 2026-08-26 shows CFO Mehta selling 25,000 shares at $26.15, one dated… Compounder · Fintech & consumer credit analysed · RGEN Repligen Corporation fresh MEDIUM Repligen's bioprocessing recovery and BioLife deal support a breakout thesis above the $182.03 market high. BioLife approval on 2026-10-05 and a weekly close above that high would confirm the next leg; a weekly close below $158 would… Cyclical recovery · Rare disease & gene therapy catalyst · RLYB Rallybio Corporation fresh MEDIUM Rallybio’s Avenzo merger thesis combines a cash distribution with residual oncology exposure; completion and a declared distribution would establish the outcome. A weekly close below $14 invalidates the price case, while failure to close… Earnings inflection · M&A & special situations · Oncology & immunology analysed · RMAX Re/Max Holdings, Inc. fresh MEDIUM Merger arb that finally got a date. DOJ granted HSR early termination 2026-07-13 and both special meetings are set for 2026-08-14, removing the regulatory leg. RMAX $11.10 vs ~$11.86 blended (5.150 REAX at $2.21 plus the prorated $13.80… Earnings inflection · M&A & special situations · Housing, homebuilders & proptech analysed · RNG Ringcentral, Inc. fresh MEDIUM RingCentral’s AI pivot needs paid-adoption growth and delivery against quarterly revenue guidance to substantiate its rerating. The price case is a weekly close above the $76.36 reference high before a weekly close below $64; the next… Special situation · AI enterprise software analysed · RRGB Red Robin Gourmet Burgers, Inc. fresh MEDIUM Deleveraging turnaround repricing: ~$96M / 116-unit refranchising cuts net debt ~$147M→~$51M, removing the going-concern tail that pinned RRGB near $2.46. Tape +38.7% since the ~2026-05-20 Q1 print, into the low-$7s near the $7.89 high.… Special situation · Consumer discretionary rotation catalyst · S SentinelOne, Inc. fresh MEDIUM SentinelOne's AI-security story has regained market support after September's Cybersecurity rally, despite the August earnings-guidance cut. A weekly close above the $23.84 reference high would complete the price-recovery case; a weekly… Theme leader · Cybersecurity · AI enterprise software catalyst · SCZM Santacruz Silver Mining Ltd. fresh MEDIUM Santacruz Silver's producer re-rating rests on deferred concentrate sales becoming revenue and added milling capacity reaching production. Q3 shipment disclosure and management's 2026-12-31 commercial-production milestone settle those… Compounder · Critical materials & rare earths catalyst · SE Sea Limited fresh MEDIUM Three-engine re-acceleration — Shopee GMV +30%, Monee loan book +71%, Garena's best quarter in 5 years — drove a Q1 beat (2026-05-12) and a +19% one-month recovery off the $77 low. Fundamentally accelerating, but the stock is short-term… Compounder · Emerging markets · Fintech & consumer credit analysed · SEPN Septerna, Inc. fresh MEDIUM Septerna’s funded oral-drug platform underpins a recovery thesis after the September 18 shelf reclaim. A weekly close above the $48.19 market high before a weekly close below $33 would confirm the price case; clinical validation still… Defensive · Precision biotech & therapeutics analysed · SM SM Energy Company MEDIUM SM Energy’s merger-integration story supports a further rerating. The price case is a weekly close above Wells Fargo’s $47 target of 2026-08-13 before a weekly close below Seaport’s $35 target of 2026-09-03; neither analyst valuation is… Defensive · Oil, energy & geopolitical catalyst · SMRT SmartRent, Inc. fresh MEDIUM RSI(14) cooled 87.8→74.7 while price only slipped $1.49→$1.43, so the momentum extreme unwound sideways. Still no dated catalyst until the ~November Q3 print. Special situation · Housing, homebuilders & proptech analysed · SNDX Syndax Pharmaceuticals, Inc. MEDIUM Menin-inhibitor commercial ramp accelerating: Revuforj + Niktimvo franchise cleared $100M/quarter with revenue +224% YoY, and the leg being bought is frontline AML label expansion (~10x TAM). Stock coils below 52-week-high resistance… Earnings inflection · Precision biotech & therapeutics catalyst · SPSC SPS Commerce, Inc. MEDIUM De-rating-repair leg: Q2 (2026-07-30) beat on adjusted EPS $1.27 vs $1.09 with EBITDA +19% on 6% revenue growth, while the FY26 revenue band was cut on the 2026-06-30 3P divestiture. Price reclaimed the ~$70 200-day, but the fresh Morgan… Special situation · AI enterprise software · Freight & logistics analysed · STRL Sterling Infrastructure, Inc. fresh MEDIUM Sterling Infrastructure’s data-center construction story now rests on recovering the failed $550 shelf while preserving its raised earnings guidance. A weekly close above $550 would establish the recovery case; a weekly close below $465… Cyclical recovery · AI datacenter infrastructure catalyst · SWKS Skyworks Solutions, Inc. fresh MEDIUM Skyworks Solutions' Qorvo merger story supports further repricing, with a weekly close above the September 18 high of $91.32 defining success. A weekly close below $84.40 invalidates the price thesis; completion beyond calendar 2026 would… Earnings inflection · Analog semiconductors analysed · TBLA Taboola.com Ltd. fresh MEDIUM Legacy open-web ad network repricing as a toll booth on AI answer surfaces: the 2026-06-16 DeeperDive ad-network launch (35% take rate, open to third-party LLMs/agents) plus the 2026-07-01 Wikitree win drove a breakout to 52-week highs… Special situation · Crypto exchanges & financials · AI datacenter infrastructure catalyst · TK Teekay Corporation Ltd. MEDIUM Teekay Corporation’s record tanker earnings support price continuation beyond its September 11, 2026 high of $14.38. A weekly close above $14.38 confirms that narrow case; a weekly close below $14.38 invalidates it. Compounder · Freight & logistics analysed · TOI The Oncology Institute, Inc. fresh MEDIUM Starling Oncology’s delegated-care expansion supports a profitability re-rating if Q4 2026 contracts launch and FY2026 adjusted EBITDA meets the company’s $2 million floor. A weekly close below $5.13 invalidates the market thesis. Special situation · Managed care & health services catalyst · TRVI Trevi Therapeutics, Inc. fresh MEDIUM Second breakout leg confirmed: TRVI cleared the June $18.17 all-time high and printed $20.22 on a +9.85% July 17 session (8.3M shares, $19.07 close), lifting the tape ~+45% in six weeks on Phase 3 launch mechanics and institutional… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · TTMI TTM Technologies, Inc. MEDIUM The 2026-08-05 binary resolved bullishly — Q2 revenue $1.004B beat both the $930–970M guide and $962M consensus, book-to-bill rose to 1.49, Q3 guided $1.100–1.140B vs $1.073B consensus. Yet the 2026-08-14 close of $140.0 is 36.8% below the… Cyclical recovery · AI datacenter infrastructure · Defense & aerospace catalyst · TXN Texas Instruments Incorporated MEDIUM Texas Instruments’ analog and data-center recovery needs Q3 revenue to meet its July guidance and a weekly close above $272. A weekly close below $250 or Q3 revenue below $5.65 billion would invalidate the case; the September 11 close of… Theme leader · Analog semiconductors · AI datacenter infrastructure catalyst · ULCC Frontier Group Holdings, Inc. fresh MEDIUM Fuel-relief leg replaced by an earnings-delivery leg: the 2026-07-29 Q2 print put adjusted EPS at $(0.10) against a $(0.60)–$(0.45) May guide on record $1,279M revenue, and guided 2H to breakeven-or-better. The catch is that guide assumes… Earnings inflection · Travel & leisure · Oil, energy & geopolitical catalyst · UROY Uranium Royalty Corp. MEDIUM Uranium Royalty Corp.’s Sweetwater expansion needs cash-flow confirmation. Positive operating cash flow and disclosed Sweetwater royalty revenue, alongside a weekly close above the August 21 reference of $4.38, would substantiate the case… Cyclical recovery · Nuclear & uranium catalyst · USO United States Oil Fund, LP MEDIUM The driver rotated: Rubio's 2026-08-25 shift from strikes to sanctions drained the escalation bid, but EIA's 0.095M bbl crude build vs 1.600M expected (08-26) and oil rigs -5 to 447 vs 454 est (08-28) carried USO to $129.70. The narrative… Earnings inflection · Oil, energy & geopolitical catalyst · VCYT Veracyte, Inc. fresh MEDIUM Sell-side is now chasing a move it missed: VCYT broke to a 52-wk high $60.91 (closed $59.13 on 2026-07-17, +124% YoY) as Piper initiated Overweight $66 (07-15) and Canaccord lifted a Hold PT $42→$60. Fundamentals still accelerating (Q1 rev… Cyclical recovery · Medtech & diagnostics · Oncology & immunology analysed · VET Vermilion Energy Inc. MEDIUM Vermilion Energy’s European gas revaluation needs Q3 cash flow to confirm the September price recovery. The case plays out if Q3 free cash flow exceeds C$122 million and production meets 116,000–118,000 boe/d before a weekly close below… Compounder · Oil, energy & geopolitical catalyst · VG Venture Global, Inc. MEDIUM LNG-export narrative re-accelerating on Europe's winter gas scramble plus a Middle East risk premium; VG ran +23% off the $12 mid-July shelf to $14.31 as Plaquemines ramps and CP2 advances. The 2026-08-11 pre-market Q2 print is the binary… Compounder · AI datacenter infrastructure · Oil, energy & geopolitical analysed · VIA Via Transportation, Inc. fresh MEDIUM Via Transportation's transit-software re-rating depends on meeting Q3 revenue guidance and preserving its Q4 adjusted-profitability goal. A weekly close below $24, Q3 revenue below $137.6 million, or withdrawal of the positive Q4 adjusted… Defensive · AI enterprise software analysed · VRA Vera Bradley, Inc. fresh MEDIUM Vera Bradley’s September earnings rally prices in a turnaround; a weekly close above the observed $4.26 annual high before a weekly close below $3.98 would confirm the next price leg. That outcome would establish price continuation, not a… Special situation · Consumer discretionary rotation analysed · VRNS Varonis Systems, Inc. fresh MEDIUM Varonis Systems' takeover story depends on reported Proofpoint talks producing a signed offer above the September 18 close of $47.56. A weekly close below $41 or confirmed termination of the talks invalidates the thesis. Earnings inflection · Cybersecurity · AI datacenter infrastructure analysed · WDAY Workday, Inc. fresh MEDIUM The 2026-08-27 print removed the fundamental leg of the bear case — cRPO +14.2% inside the guided 13.5–14.5% band, FY27 margin guide lifted to 31.0%, a new $4.0B buyback — while the Q3 cRPO guide of 11–12% sits under the ~13.3% consensus.… Earnings inflection · AI enterprise software catalyst · WEX WEX Inc. MEDIUM Hated fuel-card/fintech inflecting: the 2026-07-22 Q2 beat (Adj EPS $5.35 vs $5.05) and FY26 guide raise to $19.68-$20.08 discredit the EV-kills-fuel-cards and rate-cut-kills-float bear case; PTs jumped to $200-210 (Mizuho/KBW, 7/24).… Special situation · Fintech & consumer credit · Cyclical industrials catalyst · WIX Wix.com Ltd. fresh MEDIUM Base44 margin inversion is the live leg and the market is now paying up for it: after the 2026-08-04 beat ($563.1M, +15%; adj EPS $1.39 vs $1.16) and the ~60% 2H gross-margin guide, price ran from the 2026-08-07 close of $60.20 to $66.14… Special situation · AI enterprise software catalyst · WK Workiva Inc. fresh MEDIUM Workiva's earnings re-rating now rests on a higher margin target and paid AI adoption. Q3 delivery against guidance and a weekly close above the 2026-09-04 reference close of $76.55 would confirm the case; a weekly close below $70… Special situation · AI enterprise software analysed · WNC Wabash National Corp. MEDIUM Wabash National Corporation’s tariff-supported recovery depends on backlog converting into narrower losses. The case requires an affirmative final China injury decision and Q3 delivery against July 29 guidance before a weekly close below… Special situation · Cyclical industrials · Freight & logistics catalyst · WTTR Select Water Solutions, Inc. MEDIUM Select Water Solutions’ contracted water-infrastructure transition supports a recovery toward its September 11 reference high of $22.18. A weekly close above that level confirms the price case; a weekly close below $18 invalidates it,… Special situation · Oil, energy & geopolitical analysed · XGN Exagen Inc. fresh MEDIUM Post-print re-rating off the 2026-08-04 Q2 beat (revenue $19.941M vs $17.817M consensus, FY26 guide lifted to $72–75M) is now digesting rather than extending: $7.92 on 2026-08-21 to $7.58 on 2026-09-04 with RSI(14) cooling from 86.7 to… Defensive · Medtech & diagnostics analysed · YETI YETI Holdings, Inc. MEDIUM Tariff-margin-recovery turnaround now getting sell-side confirmation: Goldman upgraded to Buy/$63 on 2026-07-20 (vs Canaccord's $45 Hold a month earlier), pushing YETI through the $51.89 multi-year high. The leg still hinges on the… Special situation · Consumer discretionary rotation · Freight & logistics catalyst · ZBIO Zenas BioPharma, Inc. MEDIUM First-in-disease B-cell modulator: obexelimab BLA (IgG4-RD, 56% flare cut, HR 0.44) hit the FDA 2026-05-28, and the ~60-day filing determination — acceptance plus a possible Priority Review grant — is due within days, a fresh near-term… Earnings inflection · Binary-catalyst biotech · Oncology & immunology catalyst · ZETA Zeta Global Holdings Corp. MEDIUM Palantir Foundry re-platforming now has a management clock — phase one guided complete within 30–40 days of the 2026-07-06 Citi event, landing on the ~2026-08-04 Q2 print. Price reclaimed the $21 shelf that capped the June recovery (+14%… Theme leader · AI enterprise software catalyst · ZIP ZipRecruiter, Inc. fresh MEDIUM Q2 print on 2026-08-05 put revenue at $118.1M (+5% YoY, +10% QoQ) with Quarterly Paid Employers +12% sequentially and adjusted EBITDA margin at 12% vs 8% a year earlier, alongside a debt reduction of more than half — a trough-reversal read… Special situation · Managed care & health services · AI datacenter infrastructure catalyst · ZS Zscaler, Inc. fresh MEDIUM Zscaler’s AI-security launch has renewed its recovery story, but faster growth remains unproven. Q1 FY27 revenue above the September 3 guidance of $935–939 million and a higher annual outlook would confirm the case; a weekly close below… Compounder · Cybersecurity · AI enterprise software catalyst · ZYME Zymeworks Inc. fresh MEDIUM Zymeworks’ Ziihera approval supports royalty growth; Q3 2026 royalties must exceed Q2’s $1.8 million to confirm the next commercial step. A weekly close below $25 invalidates the market case before that confirmation. Earnings inflection · Oncology & immunology · Precision biotech & therapeutics analysed · AA Alcoa Corporation LOW Alcoa Corporation’s tariff-supported earnings story needs a recovery above the September 3, 2026 close of $51.05. Management’s September 10 argument that Canadian duty relief could help remains unconfirmed by price; a weekly close below… Compounder · Cyclical industrials catalyst · AAOI Applied Optoelectronics, Inc. LOW Applied Optoelectronics’ optical-transceiver expansion needs Q3 revenue of at least $255M and a weekly recovery above $110.21 to validate the case. A weekly close below $100 invalidates the recovery thesis. Cyclical recovery · Networking & optical analysed · AAON AAON, Inc. fresh LOW Beat-and-raise on 2026-08-10 (Q2 sales $627.0M, +101.2%; FY guide up to $2.235–2.307B) landed with gross margin 24.3% vs 26.6% and the FY margin guide cut to 25–26%. Targets were cut the next day and the entire 2026-05-07 re-rating gap has… Cyclical recovery · AI datacenter infrastructure catalyst · AAPL Apple Inc. LOW July's rotation-crown has slipped — Polymarket now gives Apple 20% odds of ending 2026 as the largest company (7/24) and semis are breaking out again (NVDA 7/23). The live narrative is the 'anti-CapEx AI trade' as Alphabet turns… Earnings inflection · Mega-cap AI platforms · Managed care & health services analysed · ABEO Abeona Therapeutics Inc. LOW The post-print drift has continued without repair: the 2026-08-28 close of $5.92 sits two cents above the $5.90 shelf the prior note named as the break, with RSI(14) at 21.8 and no Abeona press release at all between 2026-08-13 and… Earnings inflection · Rare disease & gene therapy · Precision biotech & therapeutics catalyst · ABNB Airbnb, Inc. LOW Airbnb’s post-Q2 growth re-rating failed its published $175 weekly-close test on September 11, 2026, when shares closed at $170.19. The remaining operating case turns on Q3 revenue meeting the August 6 guidance floor of $4.69 billion. Compounder · Consumer discretionary rotation · AI enterprise software analysed · ACB Aurora Cannabis Inc. fresh LOW Aurora Cannabis's takeover thesis requires improved Curaleaf terms or a competing definitive offer before a weekly close below $3.40. Curaleaf's 2026-09-14 regulatory application advances the dispute, but its 2026-09-15 letter retained… Earnings inflection · M&A & special situations analysed · ACDC ProFrac Holding Corp. fresh LOW ProFrac's frac-pricing recovery has September financing relief, but operating confirmation is missing. The case requires Q3 stimulation margin above the 9% reported on 2026-08-06 and a weekly close above the August reference of $5.37… Earnings inflection · Managed care & health services · Oil, energy & geopolitical catalyst · ACHC Acadia Healthcare Company, Inc. fresh LOW Acadia Healthcare's turnaround case requires confirmation of its 2026-07-28 earnings outlook and a weekly recovery above $30.20 before a weekly close below $27. The 2026-09-18 close of $28.33 leaves recovery unconfirmed despite the latest… Special situation · Managed care & health services catalyst · ACHR Archer Aviation Inc. LOW Archer Aviation’s acquisition-led recovery thesis failed when the 2026-09-11 weekly close of $5.58 breached its published $5.65 threshold. Completion of the Boeing transaction remains the business test, but cannot reverse that price… Compounder · Defense & aerospace · Physical AI & robotics analysed · ACLS Axcelis Technologies, Inc. fresh LOW Axcelis has stopped falling without being re-bid: $115.57 on 2026-08-28 to $115.08 on 2026-09-04, RSI(14) down to 22.0, 39.9% under the $191.6 high. What is left is a de-rated implant franchise plus an undated China SAMR ruling into the… Earnings inflection · Semi foundry & equipment · M&A & special situations catalyst · ACMR ACM Research, Inc. fresh LOW The base break published 2026-08-16 has held without extending: the 2026-09-04 close of $74.44 is two cents above the 2026-08-28 weekly close and still under the $76.29 June base low close, with RSI(14) down to 32.8 and no company-dated… Cyclical recovery · Semi foundry & equipment analysed · ACN Accenture PLC fresh LOW Accenture's recovery depends on enterprise AI work supporting growth. The case requires fiscal 2027 local-currency growth guidance starting at 3% or higher on 2026-10-01 and a daily close above $189.61 by 2026-10-14, before a daily close… Special situation · AI enterprise software catalyst · ADSK Autodesk, Inc. fresh LOW Autodesk’s AI and asset-operations expansion supports a residual recovery case after its conference failed to restore price confirmation. A weekly close above $250 before a weekly close below $205 would confirm that case; the 2026-09-18… Special situation · AI enterprise software · Housing, homebuilders & proptech analysed · ADTN ADTRAN Holdings, Inc. fresh LOW ADTRAN Holdings’ optical-led margin recovery needs Q3 revenue of at least $295.0 million and non-GAAP operating margin of at least 5.5% to establish recovery. September product headlines renew attention, but a weekly close below $7.00… Special situation · Networking & optical · Cyclical industrials catalyst · AEIS Advanced Energy Industries, Inc. LOW Datacenter-power picks-and-shovels re-rating is now fully mainstream — Morgan Stanley initiated Overweight $421 (07-22) atop Wells $465 and Susquehanna $535 — yet the stock fell 12.65% on 07-02 and is sitting on its 200-day while analyst… Cyclical recovery · AI datacenter infrastructure · Semi foundry & equipment catalyst · AEM Agnico Eagle Mines Ltd. LOW Agnico Eagle Mines’ gold-driven cash generation supports a recovery case, tested by the September 16 Fed decision. A weekly close above the market’s August 28 reference close of $206.25 establishes recovery before a weekly close below $199… Compounder · Critical materials & rare earths catalyst · AFRM Affirm Holdings, Inc. fresh LOW The +80%-off-March recovery re-rate has matured and rolled over: Morgan Stanley pulled its Overweight ('valuation call') on 2026-06-25, and price faded ~30% from the $100 high back onto the reclaimed 200-day near $70 while targets stayed… Compounder · Fintech & consumer credit analysed · AGL agilon health, inc. fresh LOW agilon health’s re-rating depends on Q3 confirming margin repair after its September partnership expansion. Medical margin of at least $105 million with the annual outlook intact would validate the operating case; a weekly close below $80… Special situation · Managed care & health services analysed · AGX Argan, Inc fresh LOW AI-data-center gas-EPC theme still accelerating (4.1+ GW gas backlog, $973.6M cash, zero debt), but AGX has round-tripped from the $805.75 ATH to $563, losing both the ~$675 breakout and ~$600 shelves. Mean reversion toward the pre-run… Cyclical recovery · AI datacenter infrastructure · Industrial power & grid analysed · AGYS Agilysys, Inc. fresh LOW Hospitality vertical-SaaS recovery has re-accelerated into its print: AGYS ran ~+18% to $108.98 (2026-07-10) off the June ~$92 base, clearing the two lowest analyst targets ($100/$110) ahead of a confirmed 2026-07-27 Q1 FY2027 binary that… Special situation · AI enterprise software analysed · AIP Arteris, Inc. fresh LOW Q2 (2026-08-06) beat and raised — revenue $24.1M +46%, TTM variable royalties $8.6M +65%, FY26 guide lifted to $95-98M — and the stock still closed $28.32 on 2026-08-14, 41.7% under the 6/30 high. The $33 weekly break fired while the… Cyclical recovery · AI chips & memory · AI datacenter infrastructure analysed · AIRO AIRO Group Holdings, Inc. LOW AIRO Group Holdings’ recovery case rests on drone backlog conversion after the September tariff narrative failed. A Nord Drone closing by 2026-09-30 and a weekly close above the broken $8.00 level would establish the near-term case; a… Earnings inflection · Defense & aerospace catalyst · AKBA Akebia Therapeutics, Inc. fresh LOW VOICE outcomes win (USRC trial stopped early, June 2026) de-risked Vafseo's dialysis-anemia case, but the tape bled to ~$1.22, only ~48% above the $0.82 low and still fading; the late-July/early-August Q2 print is the binary —… Earnings inflection · Precision biotech & therapeutics catalyst · AKTS Aktis Oncology, Inc. LOW Aktis Oncology's radiopharmaceutical story needs September conference attention to restore the August breakout. A weekly close above the 2026-08-28 close of $25.78 would confirm recovery, while a weekly close below $22 would invalidate the… Compounder · Oncology & immunology · Precision biotech & therapeutics catalyst · ALGM Allegro MicroSystems, Inc. fresh LOW The June AI data-center power-attach re-rate has flipped from being marked up to marked down: TD Cowen cut its target to $66 (2026-07-13) and Barclays downgraded to Equal-Weight at $48 (2026-07-20), the first target below the June range —… Cyclical recovery · Analog semiconductors · AI datacenter infrastructure analysed · ALHC Alignment Healthcare, Inc. fresh LOW Profitable-MA-disruptor narrative broke on 2026-07-08: a whistleblower suit from a former Chief Transformation Officer alleges the +88% adjusted-EBITDA inflection was manufactured by reclassifying opex as capex across FY2024-25. Shares… Earnings inflection · Managed care & health services catalyst · ALK Alaska Air Group, Inc. LOW Alaska Air Group’s recovery case depends on restored guidance on 2026-09-29 and a weekly close above $47 by the estimated 2026-10-22 results. A weekly close below $38 or Investor Day passing without a full-year framework invalidates the… Special situation · Travel & leisure · Cyclical industrials catalyst · ALKS Alkermes plc LOW Alkermes plc's orexin sleep-drug expansion needs supportive clinical data and a weekly close above $49.17 to confirm recovery. A weekly close below $44 invalidates that case as the estimated 2026-09-30 ALKS 7290 window approaches. Special situation · Precision biotech & therapeutics catalyst · ALLE Allegion Public Limited Company LOW Allegion’s electronic-access growth story failed its published price test when the 2026-09-11 weekly close of $153.35 breached $154. The continuation thesis is invalidated; the operating growth case remains unconfirmed after management’s… Special situation · Cybersecurity catalyst · ALMS Alumis Inc. fresh LOW The lupus leg is gone: LUMUS missed BICLA at Week 48 and every secondary in the overall 408-patient population on 2026-09-01, and the stock closed 2026-09-04 at $11.10 with RSI(14) at 18.2, 63.4% below the $30.30 high. What is left is a… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics analysed · ALNT Allient Inc. fresh LOW Record-orders story intact — Q2 2026 bookings $201.3M (+49% YoY), 1.31x book-to-bill, backlog $298.0M — but the supply picture changed after the note: the CEO's trusts sold 70,000 shares at $112.49–$115.765 on 2026-08-10 and 13D holder… Cyclical recovery · Cyclical industrials · Physical AI & robotics analysed · ALTO Alto Ingredients, Inc. LOW Ethanol-to-specialty/low-carbon pivot re-rated ~6x off $0.92, but both fuel catalysts — the June 45Z cash sale and the Russell index add — are spent, and price has round-tripped from the $6.11 July high to ~$4.64, losing the $5.10-$5.20… Special situation · Biofuels & low-carbon fuels catalyst · AMAT Applied Materials, Inc. LOW Applied Materials' recovery case is that equipment earnings can restore a weekly close above $492.32 before a weekly close below $437 invalidates it. The 2026-09-11 close of $456.49 leaves the August price structure unrepaired after the… Cyclical recovery · Semi foundry & equipment · AI datacenter infrastructure catalyst · AMBQ Ambiq Micro, Inc. fresh LOW Q2 (2026-08-11) net sales $33.9M, +89.7% YoY and a $36–37M Q3 guide above the $34.0M Street have bought nothing: the 2026-09-04 close of $57.45 sits 36.5% under the $90.48 high with RSI(14) at 31.7. A Form 4 filed 2026-09-02 shows the CEO… Defensive · AI chips & memory analysed · AMKR Amkor Technology, Inc. fresh LOW A second anchor — the $1.5B Nvidia advanced-packaging/test partnership (2026-07-23) stacked on the 2026-06-16 TSMC 10-yr Arizona deal — is re-rating Amkor from single-customer Apple OSAT toward US AI back-end anchor. But every catalyst… Cyclical recovery · Semi foundry & equipment · AI chips & memory catalyst · AMN AMN Healthcare Services fresh LOW Healthcare-staffing cyclical recovery, real but maturing and now at the highs: ~$32.9 (2026-07-24), just off a fresh 52-wk high $36.27 (~+120% off $14.87). Truist's 2026-07-22 lift to a Street-high $40 Buy is the first target leading… Special situation · Managed care & health services catalyst · AMP Ameriprise Financial, Inc. fresh LOW Ameriprise Financial’s wealth-platform recovery requires a weekly close above $553.46 and third-quarter client flows above $3.1 billion before a weekly close below $540 invalidates it. Huntington’s planned October transition supplies the… Cyclical recovery · Cybersecurity catalyst · AMPL Amplitude, Inc. fresh LOW Amplitude's AI analytics reacceleration case needs improving customer retention and recovery above the August $14.30 high. A weekly close below $12.60 invalidates the price case; the next quarterly report tests retention against the 103%… Theme leader · AI enterprise software analysed · AMRX Amneal Pharmaceuticals, Inc. LOW Amneal Pharmaceuticals’ specialty-and-biosimilar revaluation needs price confirmation alongside intact annual guidance. The case resolves with a weekly close above the $19.10 reference high before a weekly close below $16.50; Leerink’s… Special situation · Precision biotech & therapeutics analysed · AMSC American Superconductor Corporation LOW Grid/advanced-conductor supplier to data-center and utility power; backlog still ~+40% YoY (~$280M), but the tape broke after the 2026-05-28 beat-and-soft-guide and a late-June Russell removal piled on passive selling. Below the lost ~$40… Cyclical recovery · Industrial power & grid catalyst · AMZN Amazon.com, Inc. LOW Amazon's cloud-growth recovery case depends on earnings validating its infrastructure spending and price reclaiming the August record. A weekly close above $284.02 completes the price case; a weekly close below $245 invalidates it, with… Compounder · Mega-cap AI platforms · AI datacenter infrastructure analysed · ANAB AnaptysBio, Inc. fresh LOW AnaptysBio’s Jemperli rights-reversion thesis turns on a written Chancery judgment; the September 25 brief advances the case without settling it. A judgment granting reversion before a weekly close below $52 would establish the thesis… Earnings inflection · M&A & special situations · Oncology & immunology catalyst · ANRO Alto Neuroscience Inc. fresh LOW Alto Neuroscience’s funded depression-trial program supports a recovery case, but September price weakness lowers conviction. A weekly close above $36.64 would establish recovery before a weekly close below $28 invalidates it; PACE-2 must… Earnings inflection · Precision biotech & therapeutics catalyst · AOSL Alpha and Omega Semiconductor Limited fresh LOW Post-parabola digestion. The Apr–May "second-order AI power-semi" re-rate (~3x to $54.34) is fully priced, above the $30.50 consensus PT with no fresh company catalyst in 11+ weeks; the 2026-07-15 pop was a newsletter-driven volume spike,… Cyclical recovery · AI datacenter infrastructure catalyst · APH Amphenol Corporation LOW AI-interconnect content leg unchanged since the 2026-07-29 print — orders $10.7B, book-to-bill 1.23:1, Q3 guided above consensus — but the bid has not come back: $157.74 on 2026-08-28 is flat on the week while RSI(14) slid from 43.4 to… Cyclical recovery · AI datacenter infrastructure · Analog semiconductors catalyst · APLD Applied Digital Corporation LOW Applied Digital's recovery rests on contracted AI capacity becoming recurring rent. The case requires fiscal Q1 2027 rental revenue above Q4's $50.6 million and a weekly close above the $28.23 August shelf before a weekly close below $24… Special situation · GPU cloud & neoclouds catalyst · ARCT Arcturus Therapeutics Holdings Inc. LOW Arcturus Therapeutics’ regained vaccine rights underpin a revaluation thesis that requires ARCT-810 data and a stated regulatory development path by 2026-09-30. Missing that disclosure boundary or a weekly close below $12 invalidates the… Earnings inflection · Precision biotech & therapeutics catalyst · AREC American Resources Corporation LOW American Resources Corporation’s critical-minerals refining thesis breached its published $2.40 weekly price test on 2026-09-11. Recovery above that level and filed evidence of commercial value reaching the parent would be needed to… Cyclical recovery · Critical materials & rare earths catalyst · ARES Ares Management Corporation LOW Ares Management’s fee-growth story faces a price-confirmation test after the 2026-09-11 close of $131.64. A weekly close above the September 4 reference of $140.15 before a weekly close below $130 would complete the recovery case; another… Compounder · Biofuels & low-carbon fuels · Cybersecurity catalyst · ARHS Arhaus, Inc. LOW Arhaus's order-recovery thesis requires Q3 2026 delivered-sales growth above Q2's 4.0% and a weekly close above the lost $9.00 market shelf. A weekly close below $8.00 invalidates the case. Defensive · Oil, energy & geopolitical catalyst · ARTV Artiva Biotherapeutics, Inc. fresh LOW Artiva Biotherapeutics’ AlloNK thesis hinges on expanded rheumatoid arthritis data and pivotal-trial initiation by year-end 2026. Those milestones must arrive before a weekly close below $8.61 invalidates the market case. Earnings inflection · Rare disease & gene therapy catalyst · ASML ASML Holding N.V. LOW ASML's September customer agreements reopen its lithography growth story, but the price recovery remains unconfirmed. A weekly close above $1805 by 2026-10-14 and third-quarter sales meeting July guidance would establish the case; a weekly… Cyclical recovery · Semi foundry & equipment catalyst · ASTS AST SpaceMobile, Inc. LOW AST SpaceMobile’s spectrum-access recovery requires a disclosed Grain agreement and a weekly close above $62.40 by 2026-11-05. A weekly close below $55.74 would invalidate the case first. Earnings inflection · Space economy analysed · ASX ASE Technology Holding Co., Ltd. fresh LOW Advanced-packaging pricing power is real — quotes raised 20%+ (2026-07-01), 2026 capex hiked to US$8.5B, CoWoS-equivalent capacity tripling to 25k wpm — but the tape topped at $45.51 the same day and sits ~15% lower inside a 13% semi… Cyclical recovery · Semi foundry & equipment · AI datacenter infrastructure catalyst · ATEN A10 Networks Inc fresh LOW AI-security re-rate off the 2026-06-15 TrojAI deal has stalled: ATEN churning ~$35 below the $37.36 ATH, momentum cooling as Mizuho lifts its target to $34 but stays Neutral — analyst catch-up, not fresh conviction. The 2026-08-05 Q2 print… Theme leader · AI datacenter infrastructure · Networking & optical analysed · ATHM Autohome Inc. fresh LOW No company disclosure since the 2026-08-20 print; what moved is the research around it — Citi lifted its target from $17 to $22 on 2026-08-24, Goldman from $19 to $21, and consensus now reads $21.44, below the 2026-09-04 close of $22.03.… Special situation · Emerging markets · Semi foundry & equipment analysed · AU AngloGold Ashanti plc fresh LOW AngloGold Ashanti’s gold-margin rally thesis failed when its 2026-09-18 weekly close of $103.29 breached $105. A separate recovery case requires a weekly close back above $105 and production confirmation at the 2026-11-05 results. Compounder · Critical materials & rare earths catalyst · AUGO Aura Minerals Inc. fresh LOW Gold/copper producer basing $53–$76 under a broken ~$72 shelf after a ~45% fall from the $110 high. Q2 output slipped 8% QoQ — first sequential drop after a record Q1 — as gold cools to the low-$4,000s and sell-side keeps trimming (JPM to… Compounder · Critical materials & rare earths analysed · AUTL Autolus Therapeutics plc LOW Autolus Therapeutics’ AUCATZYL growth story lost price confirmation when the 2026-09-11 close breached the published $2.05 weekly threshold. A recovery case requires a weekly reclaim above $2.05 and delivery against the $140–150 million… Defensive · Oncology & immunology · Rare disease & gene therapy analysed · AVGO Broadcom Inc. LOW Broadcom’s custom AI ramp supports an earnings-recovery thesis if Q4 AI revenue meets its $21.7 billion guide at the planned 2026-12-09 report and shares reclaim $370 before a weekly close below $340. The September 11 close of $361.99… Cyclical recovery · AI chips & memory analysed · AVLN Avalyn Pharma Inc. fresh LOW Avalyn Pharma’s inhaled-antifibrotic re-rating depends on recovering the September 4 market close of $37.39 before a weekly close below $30. The September 8 modeling release left clinical efficacy unresolved ahead of MIST results guided to… Earnings inflection · Precision biotech & therapeutics analysed · AVR Anteris Technologies Global Corp. fresh LOW Post-catalyst drift: the CMS/first-patient/France de-risking sequence is spent, and Q2 (reported 2026-08-12) missed both lines — EPS $(0.30) vs $(0.21), revenue $1.009M vs $1.500M — yet the 2026-08-14 close held $9.40 with RSI 66.9.… Defensive · Medtech & diagnostics analysed · AVTX Avalo Therapeutics, Inc. fresh LOW Avalo Therapeutics' abdakibart recovery case rests on funded Phase 3 development; fuller LOTUS data and a weekly close above the September 4 reference of $19.23 would confirm it. A weekly close below $16 invalidates the case. Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · AVXL Anavex Life Sciences Corp. LOW Anavex Life Sciences’ governance rerating thesis failed its price test: the 2026-09-11 close of $2.62 breached the published $2.75 weekly threshold. The 2026-09-24 board vote still settles control, but it cannot reverse that recorded… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · AXTI AXT Inc LOW AXTI's contracted-InP leg is intact on paper with no price expression: the 2026-09-02 close of $56.95 reclaimed neither the $58 line lost 09-01 nor April's $64.25 placement shelf lost 08-28, and no AXT release or filing is dated later than… Cyclical recovery · Semi foundry & equipment catalyst · AZTA Azenta, Inc. LOW Azenta's cash-backed operating recovery needs positive organic growth at the next results and a weekly close above the August shelf at $32.04. The September 11 close of $30.85 leaves confirmation outstanding; a weekly close below $28… Special situation · Medtech & diagnostics · M&A & special situations catalyst · AZZ AZZ Inc. LOW Beat-and-raise fired 2026-07-08 — Q1 adj EPS $1.85 vs $1.69, FY27 guide lifted twice on Metal Coatings momentum — but the catalyst is now behind the stock, which sits at all-time highs (~$157), ~23x forward and above consensus, with Wells… Cyclical recovery · Industrial power & grid analysed · BABA Alibaba Group Holding Limited fresh LOW Alibaba's cloud revaluation depends on Qwen commercial terms at the September 22–24, 2026 Apsara Conference and recovery above the $118.90 market shelf. The case fails on a weekly close below $112 or if the conference ends without those… Compounder · AI enterprise software · AI datacenter infrastructure catalyst · BAK Braskem S.A. fresh LOW Braskem's restructuring recovery depends on a binding parent plan that preserves listed equity without creditor-driven dilution. The 2026-09-24 subsidiary hearing tests the first agreement; the estimated 2026-11-22 parent creditor-support… Earnings inflection · Emerging markets · M&A & special situations catalyst · BAND Bandwidth Inc. fresh LOW Late-stage small-cap CPaaS squeeze: +360% YoY into the mid-$70s, ~5% below the $79.08 high, with Citizens ($86, 2026-07-20). Riley ($85) both lifting targets in July. A confirmed Q2 print on 2026-07-29 is a binary two trading days out —… Retail squeeze · AI datacenter infrastructure · GPU cloud & neoclouds analysed · BAX Baxter International Inc. fresh LOW Baxter International's turnaround re-rating failed its published $24 weekly-close test when the shares closed at $23.80 on 2026-09-11. The operating-recovery premise remains unconfirmed by repeatable earnings improvement. Special situation · Medtech & diagnostics catalyst · BBBY Bed Bath & Beyond, Inc. LOW Lemonis "Everything Home" roll-up keeps closing deals — Container Store now wholly owned (2026-07-08), TwoPonds folded in (2026-07-01) — but the tape has bled from $5.83 to ~$4.96 and sits on the $4.26 52-week low as shares balloon past… Special situation · Managed care & health services · Crypto exchanges & financials catalyst · BBY Best Buy Company, Inc. LOW Tape flipped since early July: BBY broke to a fresh 52-week high $87.35 (~$85.41 on 2026-07-17, +27.6% YTD) on RGB-LED TV exclusivity plus an AI-PC/MacBook refresh cycle. But price sits ~8% above the $79.15 consensus target while Loop… Special situation · Networking & optical catalyst · BCAX Bicara Therapeutics Inc. LOW Bifunctional EGFR/TGF-β narrative in HPV-negative head & neck cancer stalled after the ASCO 2026 three-year-OS re-rate: $27.76 close is ~10% off the $30.99 high on roughly half prior turnover, consensus PT ~$31.46 sits only 13% above spot,… Earnings inflection · Oncology & immunology · Binary-catalyst biotech analysed · BEEM Beam Global LOW Beam Global’s battery pivot needs revenue conversion: Q3 revenue matching $8.562 million, backlog above $5.4 million and quantified battery revenue would confirm the case. A weekly close below $1.20 invalidates the market thesis. Special situation · EV & autonomous mobility catalyst · BH Biglari Holdings Inc. LOW Biglari Holdings’ re-rating case depends on sustained Steak n Shake earnings improvement and recovery of the lost price shelf. Confirmation requires third-quarter pre-tax operating earnings above Q2’s $6,274 thousand and a weekly close… Special situation · Consumer discretionary rotation catalyst · BHC Bausch Health Companies Inc LOW The post-print round trip is complete: the 2026-07-29 beat-and-raise (adj EPS $1.26 vs $1.04 consensus) carried BHC to a $7.90 high and the 2026-08-28 close of $6.32 handed all of it back. What is left is roughly $2.4B of equity on… Special situation · Precision biotech & therapeutics · Binary-catalyst biotech analysed · BHVN Biohaven Ltd. LOW Biohaven's recovery case rests on SK licence funding and removal of the opakalim enrollment hold. Completion of both and a weekly close above $14 would establish recovery; a daily close below $12.71 invalidates it, while the earlier… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics analysed · BIDU Baidu, Inc. ADS LOW The last dated event in a flow-mechanical leg lands 2026-09-07: southbound Stock Connect eligibility for the Hong Kong counters that turned dual-primary on 2026-09-01. The ADR closed $95.58 on 2026-09-03, -41.2% from the $162.52 high, with… Special situation · EV & autonomous mobility · Mega-cap AI platforms catalyst · BIOA BioAge Labs, Inc. LOW BioAge Labs' recovery hypothesis links September 8 clinical progress to a weekly reclaim of $9.00 before a weekly close below $8.49. The prior shelf thesis failed on September 11; QUELL-CV results remain the next test of biomarker efficacy. Earnings inflection · Precision biotech & therapeutics catalyst · BIRK Birkenstock Holding plc LOW Birkenstock Holding plc’s raised earnings outlook supports a fragile recovery case, resolved by a weekly reclaim above $36 before a weekly close below $31. The September 11, 2026 close of $31.13 leaves that case unconfirmed. Defensive · Consumer discretionary rotation catalyst · BJRI BJ's Restaurants, Inc. fresh LOW BJ's Restaurants' traffic-led reset needs price recovery and confirmation of its raised sales outlook. A weekly close above the $60.77 pre-results shelf plus third-quarter confirmation of fiscal 2026 comparable-sales guidance would… Special situation · Consumer discretionary rotation analysed · BKNG Booking Holdings Inc. fresh LOW Booking Holdings’ repurchase-led earnings story has failed its published $188 weekly price test: the 2026-09-18 adjusted close was $167.90. A separate recovery case requires a weekly reclaim of $188 and Q3 room-night and revenue growth… Compounder · Travel & leisure catalyst · BKSY BlackSky Technology Inc. fresh LOW Gen-3 subscription ramp landed in Q2 (2026-08-06): revenue $33.316M vs $30.68M est, +50% YoY, adjusted EBITDA $4.7M, FY26 guide affirmed at $130–150M. But EPS missed at $(0.54) vs $(0.36), cash is $36.9M against a $50–60M capex guide, and… Defensive · Space economy · Defense & aerospace catalyst · BLDP Ballard Power Systems, Inc. fresh LOW Ballard Power Systems’ GeoPura pivot needs reported growth to reverse a broken price structure. The recovery case requires next-quarter revenue above Q2’s $20.6 million, backlog of at least $156.6 million and a weekly close above the… Special situation · AI datacenter infrastructure · Industrial power & grid analysed · BLKB Blackbaud, Inc. LOW Blackbaud’s repurchase-led recovery needs sustained 3.0% organic growth and a weekly close above $47.52 by Q3 results. The $45.48 close on 2026-09-11 leaves that case unconfirmed; a weekly close below $44 invalidates it. Special situation · AI enterprise software catalyst · BLMN Bloomin' Brands, Inc. fresh LOW Bloomin' Brands' margin-repair story supports only a tentative price recovery after its August advance failed. A weekly close above the September 4 reference of $9.79 would establish recovery; a weekly close below the September 18… Special situation · Consumer discretionary rotation catalyst · BNGO Bionano Genomics, Inc. fresh LOW Bionano Genomics’ clinical-adoption and reimbursement story supports a test of the $2.13 annual high. A daily close above that level would confirm the price case; a weekly close below the September 18 reference close of $1.73 would… Defensive · Medtech & diagnostics catalyst · BRBR BellRing Brands, Inc. fresh LOW BellRing Brands’ tentative recovery case rests on October pricing supporting a weekly return above the lost $10 threshold before full-year results. The prior base has failed; a subsequent weekly close below the September 18 reference close… Defensive · Consumer discretionary rotation catalyst · BRKR Bruker Corporation fresh LOW Post-ASMS instrument re-rate broke back toward the $64.54 high and added a second leg: semiconductor-metrology strength (orders +20% YoY) pulled Leerink to $70 and top targets to $65–70. But at ~$62 the name sits ~13% over its 50-DMA and… Special situation · AI chips & memory catalyst · BROS Dutch Bros Inc. LOW Drive-thru coffee comps re-accelerating (Q1 +8.3%, FY guide raised) and the sell-side is now catching up — Stephens initiated Overweight $80, Morgan Stanley to $88 in mid-July. But June's run to ~$72 cooled to the mid-$60s, and the… Defensive · Consumer discretionary rotation catalyst · BSIN Big Sky Industrial Inc. LOW Big Sky Industrial's helium-and-carbon pivot must produce first helium revenue in Q1 2027 and secure carbon monitoring approvals. The timetable disclosed on 2026-08-11 defines the case; a weekly close below $1.30 or a disclosed delay… Special situation · Biofuels & low-carbon fuels analysed · BTBT Bit Digital, Inc. fresh LOW Both legs of the wrapper are now rolling over: WhiteFiber (WYFI, ~70.5% owned) de-rated from $38.50 to $27.57 as the June neocloud mania cooled, and BTBT slid to ~$1.50, a step above its $1.25 low. SOTP discount still ~49% (~$745.6M WYFI… Special situation · GPU cloud & neoclouds · AI datacenter infrastructure catalyst · BTDR Bitdeer Technologies Group fresh LOW Spring miner-to-AI re-rate has fully unwound: BTDR lost the $15 shelf to $12.56 (2026-07-09) as AI-cloud ARR plateaued at ~$69M for a 2nd month. A signed-but-not-effective Tydal colocation lease (2026-06-29) and a $36M Nevada plant are the… Special situation · Bitcoin miners · AI datacenter infrastructure analysed · BTE Baytex Energy Corp. fresh LOW July's Hormuz flare re-armed the oil-geopolitical premium, but it has since drained — WTI slipped to the low $70s and the 2026-07-17 sanctions wind-down passed with no barrel shortage, a contained-conflict bid rather than a supply shock.… Compounder · Oil, energy & geopolitical catalyst · BTGO BitGo Holdings, Inc. LOW Broken IPO that cleared its 2026-07-21 lockup without a supply flood but is grinding on the $4.665 all-time low with no bounce; Goldman cut its target to $7.75, and the undated $100M Galaxy verdict plus the ~2026-08-26 Q2 print are the… Earnings inflection · Crypto exchanges & financials analysed · BVS Bioventus Inc. LOW Bioventus's acquisition-review thesis requires a definitive acquisition agreement above the 2026-09-11 close of $12.98 before a weekly close below $12.50. The August 5 proposal disclosure supports the case, but the review has no deadline… Earnings inflection · Medtech & diagnostics analysed · BWIN The Baldwin Insurance Group, Inc. LOW Take-private premium is bleeding while sell-side chases it higher: price slipped to $27.25 (2026-07-17) from $28.41 (2026-07-02) even as KBW went to $31 and JPM to $30. Nothing is signed, and the 2026-07-30 Q2 print (guide $485–490M,… Earnings inflection · Managed care & health services analysed · CABA Cabaletta Bio, Inc. fresh LOW Autoimmune CD19 CAR-T reset story, now funded — $225.1M cash at 2026-06-30, runway into mid-2027 — but registrational RESET-Myositis data are guided to mid-2027 and the BLA to 2H27, so no clinical datapoint resolves inside 30 days.… Earnings inflection · Precision biotech & therapeutics · Rare disease & gene therapy analysed · CACI CACI INTERNATIONAL CLA fresh LOW CACI International's defense-technology re-rating requires a weekly recovery above $646 and reaffirmed fiscal 2027 guidance at the next results. A weekly close below $600 would invalidate the recovery case. Special situation · Defense & aerospace catalyst · CADL Candel Therapeutics, Inc. fresh LOW Candel Therapeutics’ recovery case requires a weekly reclaim of $11.80 and its planned Q4 2026 prostate-cancer filing before a daily close below $10.85. The September 18 close already invalidated the previous momentum thesis. Earnings inflection · Oncology & immunology catalyst · CAI Caris Life Sciences, Inc. fresh LOW Caris Life Sciences’ molecular-profiling growth supports another revenue-guidance increase at the next quarterly report. Guidance above the 2026-08-05 upper bound of $1.040 billion would confirm the case; a weekly close below $22 would… Theme leader · Medtech & diagnostics analysed · CAKE Cheesecake Factory Incorporated (The) fresh LOW Casual-dining re-rate got a genuine second leg: Citi's 2026-07-10 raise to a street-high $90 (Buy) on a rewards/app traffic-inflection thesis gapped shares 7% to all-time highs (~$86, 52wk high $86.66 on 2026-07-18). For the first time the… Special situation · Consumer discretionary rotation analysed · CAL Caleres Inc fresh LOW Q2 was pulled forward one day to 2026-09-09 (announced 2026-09-01), compressing the read into a single session: FY2026 consensus of $1.62 adjusted EPS sits at the top of the company's own $1.40–$1.65 guide, Famous Footwear is guided down… Earnings inflection · Freight & logistics · Consumer discretionary rotation analysed · CARG CarGurus, Inc. LOW CarGurus’ margin-improvement and repurchase story failed its published $35 weekly price test at the September 11, 2026 close of $34.42. Third-quarter results can distinguish operating weakness from price deterioration, but cannot undo that… Special situation · Managed care & health services · Consumer discretionary rotation catalyst · CBRL Cracker Barrel Old Country Store, Inc LOW Cracker Barrel's turnaround thesis failed its $50 weekly-close test at the $49.48 close on 2026-09-11. The confirmed 2026-09-23 results will test July's strengthened operating outlook, but cannot reverse the recorded price invalidation. Special situation · Consumer discretionary rotation catalyst · CCJ Cameco Corporation LOW Nuclear-uranium theme maturing and CCJ's structure has broken twice into improving news: mkt cap $44.79B (06-29) → ~$39.9B (07-25), ~$88, ~35% off the $135.24 high, absorbing a $17.5B federal AP1000 program and NJ's $24B plan. Barclays cut… Theme leader · Nuclear & uranium analysed · CCS Century Communities, Inc. LOW Century Communities’ entry-level housing recovery thesis failed its $65 weekly price test at the 2026-09-11 close of $60.54. A renewed case requires a weekly close above $65 and company results sustaining year-over-year order growth and… Compounder · Housing, homebuilders & proptech · Cyclical industrials catalyst · CCXI Churchill Capital Corp XI fresh LOW De-SPAC humanoid pure-play still bleeding premium: $17.07 (2026-08-14) → $14.57 (2026-08-21) → $13.40 (2026-09-04), RSI(14) down to 25.9. The only company-dated item since the 2026-07-14 confidential S-4 is an 2026-08-27… Earnings inflection · M&A & special situations · Physical AI & robotics catalyst · CDNL Cardinal Infrastructure Group Inc. fresh LOW Post-blowoff digestion is deepening: the ~4x data-center site-work roll-up has bled from a $96 high back to its $63 average analyst target, now below the $73 secondary price and the 50-DMA. Q1 organic +64% and an $854M backlog keep… Cyclical recovery · Cyclical industrials · AI datacenter infrastructure catalyst · CDW CDW Corporation fresh LOW Second-order AI-server reseller whose ~37% recovery off the $97 low has stalled: a mid-July push to $144 round-tripped to $133 by 2026-07-17, right in the fairway of the ~$145 consensus target. The re-rate (JPM, MS $170, Citi $145) is… Theme leader · AI datacenter infrastructure · AI enterprise software analysed · CECO CECO Environmental Corp. fresh LOW 2nd-order AI-power name — Q1 orders +97% YoY and a first-ever >$1B backlog (2026-04-28) feed the datacenter/electrification capex wave, and the closed Thermon merger doubled EBITDA. But price rolled over ~25% off the $101.24 ATH to $75.63,… Theme leader · AI datacenter infrastructure · Industrial power & grid analysed · CEG Constellation Energy Corporation LOW Constellation Energy's nuclear-contract recovery requires additional signed capacity and a weekly close above $290.04. The September 11 close of $284.75 preserves the reclaimed band, but a weekly close below $281 would end the thesis. Theme leader · Nuclear & uranium catalyst · CERS Cerus Corporation fresh LOW Two lower weekly closes now sit under the broken $2.70 shelf — $2.65 on 2026-08-28, then $2.59 on 2026-09-04 — with RSI(14) at 24.3 and an empty news tape behind the decline. The operating record is unchanged (FY26 product guide $229–231M,… Special situation · Precision biotech & therapeutics analysed · CEVA CEVA, Inc. fresh LOW Edge-AI IP momentum leg has broken: June's reclaim to within ~3% of the $51.60 high failed, and the mid-July AI-capex scare (Moonshot model) drove shares back through the ~$44 base to the mid-$30s. Sell-side still carries $48–$55 targets,… Cyclical recovery · AI chips & memory · Physical AI & robotics catalyst · CGC Canopy Growth Corporation fresh LOW The rescheduling binary CGC trades on came and went: the DEA hearing closed 2026-07-15 with no verdict, briefs due 2026-08-17 and the ALJ recommendation undated into H2 2026, likely litigated into 2027. Shares closed $0.89 on 2026-07-24,… Earnings inflection · Cannabis reclassification catalyst · CHYM Chime Financial, Inc. fresh LOW Busted-IPO fintech: operations accelerating (Q1 rev +25% to $647M, first GAAP profit, FY guide raised to $2.66–2.69B) but the stock trades ~19% below its $27 IPO and bases near post-IPO lows — a compressed multiple, not an accelerating… Earnings inflection · Fintech & consumer credit analysed · CIEN Ciena Corporation LOW The 1.6T WaveLogic demand cycle is intact at the order book, but the trade has broken: $627.00 (06-02) to ~$370 (07-18) is a ~41% de-rating, and the $455–$467 shelf that framed the prior read is gone. Multiple compression from 54x forward,… Cyclical recovery · Networking & optical · AI datacenter infrastructure catalyst · CLDX Celldex Therapeutics, Inc. LOW Celldex Therapeutics’ barzolvolimab case requires both Phase 3 CSU trials to meet their primary efficacy endpoints by 2026-10-31 before a weekly close below $35. The 2026-09-11 close of $36.90 leaves the structural case unresolved ahead of… Earnings inflection · Binary-catalyst biotech · Oncology & immunology catalyst · CLFD Clearfield, Inc. fresh LOW The May earnings-miss squeeze has fully round-tripped to a dead tape in the mid-$30s, below the ~$36 gap base, with the retail-sentiment narrative spent. The sole live driver is the 2026-08-05 fiscal-Q3 print — guided to a sharp sequential… Retail squeeze · Networking & optical catalyst · CLPT ClearPoint Neuro, Inc. fresh LOW Picks-and-shovels delivery play on CNS gene therapy: ClearPoint's SmartFlow cannula and MRI navigation are the standard route to the brain for uniQure's AMT-130 Huntington's BLA (soft Q3-2026 window). The June re-rate held near $18.72… Cyclical recovery · Medtech & diagnostics · Rare disease & gene therapy catalyst · CLS Celestica, Inc. fresh LOW AI-datacenter EMS picks-and-shovels story still fundamentally climbing after the 2026-04-27 Q1 crush (rev +53% to $4.05B, FY26 guide raised to $19B), but the tape broke ~21% off its $474 June high and heads into a binary 2026-07-27 Q2… Cyclical recovery · AI datacenter infrastructure catalyst · CLW Clearwater Paper Corporation LOW Clearwater Paper's paperboard recovery depends on September extending August's pricing increase and third-quarter earnings meeting guidance. The case requires another SBS assessment increase and $20–30 million of third-quarter adjusted… Special situation · Cyclical industrials · Semi foundry & equipment catalyst · CMG Chipotle Mexican Grill, Inc. LOW Chipotle Mexican Grill's expansion-led recovery needs positive third-quarter traffic and a return above $38.52 by 2026-10-28. The 2026-09-11 close of $36.20 weakens that case; a weekly close below $35 or negative third-quarter transaction… Compounder · Consumer discretionary rotation analysed · CNMD CONMED Corporation fresh LOW CONMED Corporation's sale-premium thesis failed its published $46 weekly-close test on 2026-09-18. A disclosed transaction would establish a new deal case; September operating commentary has not resolved the July sale report. Earnings inflection · Medtech & diagnostics · M&A & special situations analysed · COCO The Vita Coco Company, Inc. LOW The Vita Coco Company's growth-to-margin thesis failed its $60 weekly price test at the 2026-09-11 close of $52.01. A recovery above that shelf and quantified freight-cost guidance would reopen the case; the 2026-09-16 conference is the… Compounder · Consumer discretionary rotation catalyst · CODI Compass Diversified LOW Compass Diversified’s asset-sale and debt-reduction story needs operating confirmation and recovery toward B. Riley’s $15 target before a weekly close below $11 breaks the thesis. The 2026-09-11 adjusted close of $11.01 leaves the existing… Special situation · M&A & special situations catalyst · COMP Compass, Inc. LOW Now stretched into a binary ~2026-07-29 Q2 print ($4.0–4.2B guide) with an open NY AG antitrust probe. Special situation · Housing, homebuilders & proptech catalyst · CORT Corcept Therapeutics Incorporated LOW Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry… Earnings inflection · Oncology & immunology · Binary-catalyst biotech catalyst · CPIX Cumberland Pharmaceuticals Inc. LOW Cumberland Pharmaceuticals’ post-Apotex recovery depends on ifetroban results restoring clinical credibility. The case requires disclosed endpoint results followed by a weekly close above the September 11 high of $8.97 before a weekly… Special situation · M&A & special situations · Precision biotech & therapeutics analysed · CRCT Cricut, Inc. LOW Cricut’s platform transition now has Maker 5 behind it; the next quarterly report must show growth in both segments before a daily close below $5.16 breaks the case. The 2026-09-03 launch satisfies the earlier announcement condition but… Special situation · AI enterprise software analysed · CRL Charles River Laboratories International, Inc. fresh LOW Charles River Laboratories’ demand-recovery continuation thesis was invalidated by the 2026-09-18 weekly close of $278.06 below $280. The 2026-09-24 Investor Day tests the operating framework but cannot undo that breach. Special situation · Precision biotech & therapeutics catalyst · CROX Crocs, Inc. fresh LOW Legacy-brand turnaround with the raised guide intact and the tape still unwinding: after the 2026-07-30 beat-and-raise (FY2026 adj EPS $13.70–$14.00), closes went $131.72 (08-14) → $122.11 (08-21) → $117.53 (09-04), RSI(14) 26.9, -16.8%… Special situation · Consumer discretionary rotation catalyst · CRS Carpenter Technology Corp fresh LOW Aero-defense superalloy pricing cycle intact (three contracts at >30% hikes; Q4 op-income guide $205-210M, +37% YoY), but the July flush to $532 has been bought back to ~$603 straight into the 2026-07-30 Q4 print — now four sessions out… Cyclical recovery · Defense & aerospace · Managed care & health services catalyst · CRTO Criteo S.A. LOW Criteo's recovery case rests on ChatGPT advertising translating into financial stabilization. Q3 contribution excluding traffic acquisition costs reaching $241 million without another annual outlook cut would validate it; a daily close… Earnings inflection · M&A & special situations · AI datacenter infrastructure catalyst · CRVS Corvus Pharmaceuticals, Inc. LOW Corvus Pharmaceuticals’ soquelitinib recovery case requires a weekly close above the August 28 close of $14.16 before a weekly close below $12.50. Angel’s eczema results, guided on August 6 to late 2026, remain the next clinical test;… Earnings inflection · Oncology & immunology · Binary-catalyst biotech analysed · CSCO Cisco Systems, Inc. LOW Legacy-networker AI re-rate intact and now at its binary: the $118–120 shelf held through July, price closed $121.43 on 2026-08-07 with RSI(14) at 78.4, and five sell-side target raises landed 07-22 → 08-06 (Citi $112→$139) ahead of the Q4… Special situation · Networking & optical · AI datacenter infrastructure catalyst · CSIQ Canadian Solar Inc. LOW Canadian Solar’s recovery thesis rests on domestic-module contract repricing after management’s 2026-08-27 policy discussion. Disclosed price increases and a weekly close above the former $14.00 shelf would establish the case; a weekly… Special situation · Solar & clean energy · Cyclical industrials catalyst · CTSH Cognizant Technology Solutions Corporation LOW Cognizant's enterprise-AI pivot needs third-quarter revenue confirmation and a recovery above the August 28 close of $64.04. Revenue below the July 29 guidance floor of $5.600 billion or a weekly close below $58 would invalidate the case. Special situation · AI enterprise software catalyst · CVLG Covenant Logistics Group, Inc. LOW The margin-inflection leg broke at its own catalyst: Q2 (2026-07-29) adjusted OR 95.9% vs 94.6% PY — second straight quarter of YoY deterioration — revenue $332.9M missed $340.4M, and Stephens cut its 23-day-old target to $54 on 07-31.… Defensive · Freight & logistics catalyst · DDD 3D Systems Corporation LOW June's $50M raise at $3.05 (16.4M sh) is already underwater: shares last $2.775 (2026-07-02), below the offering floor, with ~$50M shelf undrawn and soft Q2 guidance (rev $93–95M, adj. EBITDA still negative) into the 2026-08-10 print. A… Special situation · Defense & aerospace · Cyclical industrials analysed · DDOG Datadog, Inc. fresh LOW June's sell-side upgrade wave has exhausted and the first cut printed — Bernstein to Market Perform (PT $226, 2026-07-06) as the stock rolled over. AI-observability narrative intact but maturing; the $278.71 parabola round-tripped and the… Theme leader · AI enterprise software analysed · DFTX Definium Therapeutics, Inc. LOW Definium Therapeutics’ recovery thesis turns on September’s Panorama anxiety trial confirming DT120 efficacy and restoring the pre-readout price structure. Success requires a positive primary endpoint and a weekly close above $46.14 before… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · DIOD Diodes Incorporated LOW The AI-server/auto power-content re-rate that carried DIOD to a ~$126 all-time high (June 18) has round-tripped: a double-top, an analyst downgrade, more insider selling and a sector-wide semi selloff pushed it to ~$96 by July 10, through… Theme leader · Analog semiconductors · AI datacenter infrastructure catalyst · DJT Trump Media & Technology Group Corp. LOW Fusion pivot is the leg: the 2025-12-18 all-stock TAE Technologies merger (>$6B, ~50/50 fully diluted) is what's actually being bought, while the crypto-treasury leg was terminated 2026-08-07. The S-4 was still unfiled as of 2026-08-05,… Special situation · Oil, energy & geopolitical analysed · DLTR Dollar Tree Inc. fresh LOW Dollar Tree’s multi-price earnings-growth thesis failed its published $124 weekly-close test at the 2026-09-18 close of $111.96. Renewed support requires a weekly close above $124 and third-quarter comparable-store sales within the 3%–4%… Special situation · Consumer discretionary rotation catalyst · DNTH Dianthus Therapeutics, Inc. LOW Dianthus Therapeutics’ claseprubart re-rating depends on supportive December clinical evidence and a dated pivotal readout. The price case requires a weekly close above $115.96 by 2026-12-31 before a weekly close below $100 invalidates it. Earnings inflection · Binary-catalyst biotech · Oncology & immunology catalyst · DNUT Krispy Kreme, Inc. fresh LOW Krispy Kreme’s refranchising story requires cash generation and lower leverage, but its August recovery thesis was invalidated by the $3.02 weekly close on 2026-09-18 below the published $3.25 threshold. September promotions continued… Retail squeeze · Fintech & consumer credit · Squeeze & momentum setups catalyst · DRD DRDGOLD Ltd. fresh LOW DRDGOLD’s gold-margin and processing-expansion thesis lost its published price support when the 2026-09-18 close breached $27.50. The continuation case is invalidated; a renewed expansion case requires completed commissioning and reported… Compounder · Critical materials & rare earths catalyst · DSGN Design Therapeutics, Inc. fresh LOW Design Therapeutics’ frataxin-biomarker thesis depends on its Q4 2026 update establishing a regulatory path for DT-216P2. Supportive FDA feedback and a defined registrational design would substantiate the case; a weekly close below $13.50… Earnings inflection · Precision biotech & therapeutics · Rare disease & gene therapy analysed · DTIL Precision BioSciences, Inc. LOW Precision BioSciences’ hepatitis B gene-editing thesis needs replicated liver-biopsy results by year-end 2026. The case succeeds if additional patients show cccDNA reduction without treatment-limiting safety findings before a weekly close… Earnings inflection · Rare disease & gene therapy · Precision biotech & therapeutics analysed · DUOT Duos Technologies Group, Inc. LOW The pivot is now structural: the rail subsidiary was sold 2026-08-05 (related party — interim CFO owns 50% of the buyer), leaving an edge-colocation operator carrying a 2026-07-16 five-year 10 MW hyperscaler contract worth >$111M. The tape… Special situation · AI datacenter infrastructure · GPU cloud & neoclouds analysed · DXCM DexCom, Inc. LOW CGM leader's recovery has aged from catalyst-pop to an analyst-revision grind — Mizuho $90 (7/15), Truist $87 (7/16) into a ~7% two-day pop to $76.65 — but price is high-$70s still under the 200-EMA and the confirmed July 30 Q2 print is… Defensive · Medtech & diagnostics analysed · DXYZ Destiny Tech100 Inc. LOW Destiny Tech100's Anthropic listing story supports a low-conviction recovery case after the reported timetable slipped. A daily close above the August 28, 2026 close of $34.74 before a daily close below $29.50 would satisfy its price test. Retail squeeze · Prediction markets & betting analysed · EDIT Editas Medicine, Inc. fresh LOW Editas Medicine's EDIT-401 recovery thesis failed its published price test when the 2026-09-11 weekly close reached $2.70, below $2.75. The company's Q1 2027 data-update guidance leaves human lipid lowering unresolved; the market failure… Special situation · Rare disease & gene therapy analysed · EFOR Everforth, Inc. LOW Everforth's AI-services re-rating needs Q3 2026 revenue above Q2's $1,007.0 million and consulting book-to-bill of at least 1.2 to 1. A weekly close below $28.50 breaks the price thesis before that operating confirmation. Special situation · AI enterprise software · Defense & aerospace catalyst · ELVN Enliven Therapeutics, Inc. LOW Enliven Therapeutics’ re-rating case depends on starting the pivotal ELVN-001 trial within its guided second half of 2026. Disclosed initiation and a weekly close above the $61.15 high recorded on 2026-09-11 would confirm the case before a… Earnings inflection · Oncology & immunology · Binary-catalyst biotech catalyst · ELVR Elevra Lithium Limited LOW The August leg failed at the print: the ADR closed $59.09 on 2026-08-28 versus $67.76 on 2026-08-21, even as the FY26 report guided FY27 production to 198,000–210,000 dmt against FY26's 197,967 dmt and GFEX carbonate settled CNY 158,700/t… Compounder · Cyclical industrials catalyst · ENOV Enovis Corporation LOW Post-Colfax orthopedic pure-play turnaround: LimaCorporate integration plus FCF-conversion recovery (43% in 2024 toward a 70–80% target) is the self-help story, but price has rolled over from $34 toward $27 while three brokers cut targets.… Special situation · Medtech & diagnostics · Physical AI & robotics analysed · ENPH Enphase Energy, Inc. LOW IQ SST AI-data-center pivot (announced 2026-04-28) that drove a spring squeeze has stalled — stock de-rated ~16% in a month to ~$45 (2026-07-09), sell-side uniformly neutral with PTs on top of price (Susquehanna $45, 2026-07-10), and SST… Special situation · Solar & clean energy · Industrial power & grid analysed · ENVA Enova International, Inc. LOW Enova International’s credit-growth recovery requires a weekly close above $235.43 and Q3 confirmation of its raised growth outlook and credit resilience. A weekly close below $223 invalidates the case before that confirmation. Compounder · Fintech & consumer credit catalyst · EOLS Evolus, Inc. LOW Evolus’s margin-led re-rating failed its published $8.00 weekly price test at the $7.84 close on 2026-09-11. The business case remains subject to delivery of management’s 2026 revenue guidance of $330–337 million and adjusted gross margin… Defensive · Precision biotech & therapeutics · Medtech & diagnostics catalyst · EPAM EPAM SYSTEMS, INC. fresh LOW Compounder narrative broken on 2026-08-06: FY26 organic constant-currency growth cut to 2.0%–3.0%, Q3 guided to ~1.7% YoY. Price has stalled rather than extended lower ($99.90 close 2026-08-11 vs $97.43 on 2026-08-07), but the AI-native… Special situation · AI datacenter infrastructure catalyst · EPC Edgewell Personal Care Company fresh LOW Edgewell Personal Care's takeover-and-recovery thesis needs renewed deal evidence or confirmed growth to restore the market's $29.50 high. A weekly close above $29.50 would complete the price case; a weekly close below $25 would invalidate… Earnings inflection · M&A & special situations analysed · EQNR Equinor ASA fresh LOW European winter gas-security theme re-accelerating; Equinor, the swing Norwegian pipeline supplier, held ~$40 through a Q2 double-miss on a $1.125B buyback bid. Defensive · Oil, energy & geopolitical analysed · ERAS Erasca, Inc. LOW FDA Fast Track for ERAS-0015 in metastatic pancreatic (2026-08-24) landed on 16.4x average volume for a -0.17% close; J.P. Morgan then marked to a street-high $33 on 2026-08-27 while the 2026-08-28 close was $18.03 against a $23.5… Earnings inflection · Oncology & immunology · Binary-catalyst biotech catalyst · ERO Ero Copper Corp. fresh LOW Ero Copper's copper-growth re-rating now depends on operating delivery after its September 14 strategy update. A weekly close at or above the prior $40.40 high before a weekly close below $33.80 would establish that the recovery case… Cyclical recovery · Critical materials & rare earths analysed · EVC Entravision Communication LOW Smadex AI-DSP re-rate broke to a new 52-week high of $13.48 with no dated company news since 2026-07-12 — an anticipatory leg into the 2026-08-10 Q2 print, the binary on whether Q1's +204% ATS growth and ~22% EBIT margin held.… Special situation · AI enterprise software catalyst · EVER EverQuote, Inc. LOW EverQuote’s insurance-advertising growth thesis needs price confirmation: a daily close above $27.87 before a weekly close below $23.82 would satisfy the price test. Third-quarter revenue below $198 million or adjusted EBITDA below $28… Defensive · Managed care & health services catalyst · EVH Evolent Health, Inc fresh LOW The late-June retail bounce has fully unwound — EVH traded ~$5.76 on 2026-07-07, back under the $6.59–6.86 consensus target band and well under Truist's flat $7. Nothing carries the name now except the confirmed 2026-08-06 Q2 print, which… Earnings inflection · Managed care & health services · Oncology & immunology analysed · EXFY Expensify, Inc. LOW Legacy expense-SaaS pivot re-rated on the 2026-08-06 Q2 print: revenue $33.9M beat $33.688M, paid-member decline halved to -2% YoY, FY26 FCF guide doubled to $12M-$14M, ~7% of shares retired, and New Expensify ARR from net-new customers… Special situation · AI enterprise software · Cybersecurity analysed · EXK Endeavour Silver Corp. LOW Endeavour Silver’s Terronera ramp supports a silver operating-leverage thesis that requires Q3 cost confirmation. The case needs Q3 2026 all-in sustaining cost at or below $30 per silver ounce with annual $27–28 guidance retained before a… Compounder · Critical materials & rare earths analysed · EXLS ExlService Holdings, Inc. fresh LOW ExlService Holdings’ AI-services re-rating needs renewed revenue confirmation. A daily close above the August reference close of $37.53 and organic growth guidance of at least 13% would validate the recovery case; a daily close below $34… Theme leader · AI enterprise software · Managed care & health services analysed · EXTR Extreme Networks, Inc. LOW Legacy campus-networking name re-rating ~+140% off Feb lows on the Platform ONE / Agent ONE AI-NetOps story plus SaaS ARR +29% YoY; theme still accelerating but spot ($33.71, 07-10) has run through consensus PT $29.06 into the June bull… Special situation · Networking & optical · AI enterprise software catalyst · FAC Factorial Energy Inc. LOW Freshly de-SPAC'd solid-state battery name has fully unwound its debut mania — down ~78% from the $25.33 ATH to ~$5.67, breaking clean through the former $9.26 floor into a fresh 52-week low at $4.24. Cantor's $18 target now sits ~217%… Defensive · Solar & clean energy · Freight & logistics analysed · FBIN Fortune Brands Innovations, Inc. fresh LOW Activist-plus-new-CEO turnaround has stopped accelerating and started digesting: after the +30% run off Garden's $40.6 buy, price has chopped $50–54 for three weeks while sell-side targets climbed past spot (Goldman $61 on 7/10, Barclays… Special situation · Housing, homebuilders & proptech · Cyclical industrials catalyst · FCEL FuelCell Energy, Inc. LOW Street targets re-rated up to the price rather than the reverse: average PT $22.83 across 8 analysts vs the 2026-08-07 close of $20.43, after B. Riley $13→$32 (6/29) and UBS $22→$27 (7/14). The AI-power bid still works (7/30 Microsoft… Retail squeeze · AI datacenter infrastructure · Industrial power & grid analysed · FIG Figma, Inc. fresh LOW Design incumbent re-rated as an AI winner (BofA Buy, $30 PT, 7/7) rather than an AI casualty, yet the stock churns below its 100/200-day moving averages with heavy short interest into its first public earnings print on 8/5 — that print,… Earnings inflection · AI enterprise software analysed · FLEX Flex Ltd. LOW AI-manufacturing re-acceleration: the 2026-07-09 Cerebras CS-3 production expansion is the first company-specific bid since the S&P-inclusion +6% pop round-tripped to ~$147, refreshing the data-center power/EMS narrative into the ~07-29 Q1… Special situation · AI datacenter infrastructure · Industrial power & grid analysed · FLY Firefly Aerospace Inc. LOW Narrative and price have fully decoupled: FLY stacked a $144M CLPS award, a Moon BASE seat and a $13M Mars subcontract into a -47% drawdown, falling 9.6% on 7/16 on the awards headline itself. At $19.27 vs a $45 IPO price and 31% below the… Defensive · Space economy · Defense & aerospace catalyst · FLYW Flywire Corporation Voting fresh LOW Flywire's execution re-rating requires Q3 growth confirmation and a recovery above the $19.54 market high. Growth above 16% excluding foreign-exchange effects and ancillary services, retention of full-year guidance, and a weekly close… Defensive · Fintech & consumer credit · AI enterprise software analysed · FN Fabrinet fresh LOW Optical cluster re-accelerated in July (AAOI +390% YTD, LITE +138%, COHR +107%) while Fabrinet sits ~$478, +0.7% YTD and ~36% under its $748.89 high. Revenue compounds at +30% but the tape has decoupled from its own theme — a… Cyclical recovery · Networking & optical · AI datacenter infrastructure analysed · FOSL Fossil Group, Inc. LOW Fossil Group's margin-turnaround rerating failed its published $5.00 weekly-close test with the 2026-09-11 close of $4.73. The operating recovery remains unconfirmed pending evidence for management's 2026-08-12 forecast of Q4 sales growth… Special situation · Consumer discretionary rotation · Small-cap value rotation catalyst · FOUR Shift4 Payments, Inc. LOW Payments roll-up at ~$50, a hair above its $46.26 52-week low set on a 2026 guide-down. The Global Blue tax-free-shopping integration ("Shift4 One," launched 2026-07-14) is the transformation leg, but the 2026-07-30 Q2 print is the binary… Earnings inflection · Fintech & consumer credit · Travel & leisure analysed · FPS Forgent Power Solutions, Inc. fresh LOW Second secondary in five weeks — ~43.6M shares at $49 on July 2, now including company primary dilution — confirms the recurring-supply pattern and dragged the stock from its $65.56 June-4 ATH back to the offering line. The… Theme leader · Industrial power & grid · AI datacenter infrastructure analysed · FRD Friedman Industries Inc. LOW Tariff-driven HRC steel prices at multi-year highs powered record FY2026 (EPS $2.76, sales +46%); FRD hit an all-time-high close $37.42 on 2026-06-18 and was flagged overbought the same day. The narrative is maturing and priced near the… Defensive · Cyclical industrials · Critical materials & rare earths catalyst · FSLY Fastly, Inc. LOW Fastly’s security-led recovery now has a Comcast deployment story; the 2026-09-22 Investor Day tests whether it gains financial support. The recovery case requires a weekly close above $27.69 with annual revenue guidance intact before a… Special situation · Cybersecurity · AI chips & memory catalyst · FWRD Forward Air Corporation LOW Busted-merger workout losing its bid: the +48% June bounce to $14.87 (on a speculative Amazon-bolt-on thesis) has faded ~13% to ~$13, whole-company sale is now reported "unlikely," and the 2026-07-10 chairman exit forfeited… Earnings inflection · Cyclical industrials · Freight & logistics analysed · G Genpact Limited fresh LOW Agentic-operations pivot keeps compounding in the segment data — ATS +24.1% to $363M, FY guide lifted to at least 25% on 2026-08-06 — while the 73% legacy book grew 1.9% and caps consolidated growth near 7%. The 10-Q filed 2026-08-07… Special situation · AI enterprise software catalyst · GCO Genesco Inc. fresh LOW The operating turnaround is real but priced, and its one asymmetric leg — the activist proxy fight — lost its teeth: ISS (2026-07-07) backed all nine board directors and urged holders to withhold from the two Radoff/Jumana nominees, so the… Earnings inflection · Consumer discretionary rotation analysed · GDRX GoodRx Holdings, Inc. fresh LOW GoodRx's Pharma Direct and subscription pivot must restore total revenue growth. The next quarterly release confirms the case if growth returns and the $790–805 million annual outlook holds before a weekly close below $3.00 invalidates the… Special situation · Managed care & health services analysed · GEN Gen Digital Inc. fresh LOW Gen Digital’s security-funded financial-services pivot supports a recovery thesis, tested by Q2 revenue against August’s guidance. The price case succeeds with a weekly close above the September 18 adjusted high of $31.41 before a weekly… Special situation · Cybersecurity · Fintech & consumer credit analysed · GENI Genius Sports Limited fresh LOW Sports-data toll-booth under the prediction-market boom, but the boom arrived and the toll didn't: Kalshi/Polymarket cleared $50B+ of World Cup volume (Coindesk, 2026-07-14) while GENI slid $6.43 → $6.30 and printed $5.98 intraday July 17.… Cyclical recovery · Prediction markets & betting analysed · GFI Gold Fields Ltd ADR fresh LOW Margin-to-cash story intact from H1 (2026-08-25: $2.225bn adjusted FCF, dividend +132%, realised $4,678/oz), but the macro leg inverted on 2026-09-04 when 162k August payrolls against ~53k expected pushed September hike odds to roughly 65%… Compounder · Critical materials & rare earths catalyst · GFS GlobalFoundries Inc. fresh LOW Photonics/CHIPS delivery kept accelerating — comms/data-center revenue +62% YoY in Q2 (2026-08-05), $300M Commerce LoI 2026-07-29 — while the multiple collapsed 39.2% from the $89.83 52wk high to $54.58 on 2026-08-14. What's on offer is a… Cyclical recovery · Semi foundry & equipment · Networking & optical catalyst · GGAL Grupo Financiero Galicia S.A. fresh LOW Argentina disinflation is still working — June CPI printed 1.9% MoM on Jul 14, an improvement on May's 2.1% — but the ADR faded the good print, dropping ~7% on the week to ~$50 and losing both the $51.07 50-day and the $52.86 200-day.… Compounder · Emerging markets catalyst · GLUE Monte Rosa Therapeutics, Inc. fresh LOW ZEUS (ziltivekimab, MACE HR 0.99) failed on 2026-07-31 and took GLUE −27.16% to $16.52, its worst session on record, because the hsCRP-to-outcomes link under MRT-8102's ASCVD story is exactly what ZEUS could not demonstrate. Platform,… Earnings inflection · Precision biotech & therapeutics · Oncology & immunology analysed · GOLF Acushnet Holdings Corp. fresh LOW Premium-golf consumable franchise (Titleist Pro V1) that ran to a $119.65 all-time high on a defensive-quality rotation, then bled ~11% of the mania premium back to the ~$104–105 June breakout shelf ($104.66 on 2026-07-24). The 2026-08-06… Compounder · Medtech & diagnostics catalyst · GOOG Alphabet Inc. LOW Alphabet’s Cloud backlog-conversion story needs sustained growth and margins without another capital-spending increase. The next quarterly report tests that case against the July results; a weekly close below $328 invalidates the… Compounder · Mega-cap AI platforms analysed · GRND Grindr Inc. fresh LOW Grindr’s premium-subscription pivot underpins a recovery thesis, but EDGE monetization remains unmeasured. A daily close above $17.94 by 2026-09-30 would complete the recovery case; a weekly close below $14.50 or expiry without that… Special situation · Fintech & consumer credit · AI datacenter infrastructure analysed · GRPN Groupon, Inc. fresh LOW Groupon’s squeeze-revival case requires a weekly close above $22 and third-quarter billings growth of at least 4% before a weekly close below $18. The September 18, 2026 close of $19.08 leaves the price condition unmet, while the September… Retail squeeze · Squeeze & momentum setups catalyst · GSHD Goosehead Insurance, Inc. fresh LOW Goosehead Insurance’s recovery case requires renewed core-revenue growth and a weekly reclaim of $64 after the September 18 structural failure. Q3 core growth above 10% would confirm the operating leg; a weekly close below $54.28 would… Earnings inflection · Managed care & health services analysed · GSM Ferroglobe PLC LOW US trade-remedy leg: the 2026-08-03 USITC affirmative vote forces AD/CVD orders on Australian and Norwegian silicon metal, on top of Angola/Laos orders live since 2026-03-17. Q2 (2026-08-04) delivered the sequential recovery — $13.1M adj… Cyclical recovery · AI chips & memory · Industrial power & grid catalyst · GTM ZoomInfo Technologies Inc LOW Legacy B2B data business trying to re-price as the data layer under AI go-to-market agents. The 2026-08-05 post-print gap is intact but unextended — $3.97 on 2026-08-21, RSI(14) cooled 76.9→58.9 — and the 2026-08-11 Microsoft Copilot MCP… Special situation · AI enterprise software catalyst · GTN Gray Media, Inc. LOW Gray Media's political-advertising and consolidation story needs Q3 guidance delivery and a weekly recovery above $5.00. A weekly close below $4.50 invalidates the remaining repricing thesis; Q3 revenue below management's $935 million… Special situation · Fintech & consumer credit · Precision biotech & therapeutics analysed · GTX Garrett Motion Inc. LOW Turbo cash-cow re-rated (~8–9x → ~18x) on a datacenter/industrial oil-free cooling narrative; the parabolic Feb→June leg (~$20→$36) is spent, shares faded ~11% to the 50-day near $32.30, and the ~late-July Q2 print is the first chance to… Special situation · AI datacenter infrastructure · Cyclical industrials catalyst · GWRE Guidewire Software, Inc. fresh LOW Guidewire Software’s cloud-and-AI re-rating thesis failed its price test when the 2026-09-18 weekly close of $144.29 breached $155. Pohjola’s September 15 PricingCenter selection supports customer expansion, but a replacement recovery case… Theme leader · AI enterprise software catalyst · HCC Warrior Met Coal, Inc. LOW Warrior Met Coal’s Blue Creek ramp supports a cash-generation thesis, but price confirmation requires a weekly close above $110.18 before a weekly close below $95. Third-quarter results must sustain the sales outlook without further… Defensive · Critical materials & rare earths catalyst · HELE Helen of Troy Limited fresh LOW Helen of Troy's debt-reduction recovery failed its published price test at the 2026-09-18 close of $26.84. The expected 2026-10-08 results would test whether lower leverage and retained cash guidance support a renewed case, conditional on… Special situation · Consumer discretionary rotation catalyst · HELP Cybin Inc. fresh LOW Post-dilution CNS microcap re-firing with the psychedelic cohort (ATAI, CMPS all moving 2026-07-16) after a June social-velocity blowoff and a 10.3M-share secondary at $4.85. Both covering shops cut targets in July while holding Buy. No… Retail squeeze · Precision biotech & therapeutics · Binary-catalyst biotech analysed · HIMS Hims & Hers Health, Inc. LOW GLP-1 reaccel gets marked to market on 2026-08-10: guide $680-700M (+25-28%) vs Q1's +4%, street at $698.9M. Since the last note the FTC/CA/UT sued (2026-07-29, N.D. Cal.), BofA cut $37 to $30, and Amazon ($50/mo Medicare GLP-1,… Retail squeeze · Managed care & health services · Precision biotech & therapeutics analysed · HL Hecla Mining Company LOW Hecla Mining Company's silver-margin story now hinges on recovering the 2026-09-03 close of $21.21. A weekly close above $21.21 completes the recovery case; a weekly close below $19 invalidates it. Compounder · Critical materials & rare earths analysed · HMY Harmony Gold Mining Company Limited fresh LOW Harmony Gold’s cash-return thesis failed when the 2026-09-18 weekly close of $19.92 breached its published $20 threshold. The declared October dividend remains a catalyst, but it cannot reverse that recorded invalidation. Compounder · Critical materials & rare earths catalyst · HOV Hovnanian Enterprises, Inc. Class A LOW The housing-bill leg is spent — the Act auto-enacted 2026-07-11 and nothing dated has replaced it — yet HOV has re-rated to $137.78 (2026-08-07), 11.8% off the $156.16 high, on no company news. The confirmed 2026-08-20 Q3 print (quarter… Earnings inflection · Housing, homebuilders & proptech catalyst · HPP Hudson Pacific Properties, Inc. LOW Hudson Pacific Properties’ recovery case rests on leasing gains overcoming the cash restrictions disclosed on 2026-09-11. A weekly close above the August reference level of $14.50 would confirm the price recovery; a weekly close below $12… Earnings inflection · Housing, homebuilders & proptech analysed · HRB H&R Block, Inc. fresh LOW H&R Block’s cash-return re-rating needs a recovery to its 2026-09-04 close of $49.06 with fiscal 2027 guidance intact before a weekly close below $44. The 2026-09-18 close of $44.25 leaves that recovery case under pressure. Special situation · Biofuels & low-carbon fuels catalyst · HROW Harrow, Inc. fresh LOW Show-me on an H2 ramp with nothing company-dated to resolve it before the ~November Q3 print: the reaffirmed $350–365M FY2026 guide needs the back half to roughly double H1's $114.9M against $292.4M loans payable net, and sell-side FY… Earnings inflection · Precision biotech & therapeutics analysed · HTLD Heartland Express, Inc. fresh LOW The margin-recovery leg printed on 2026-07-30 (operating ratio 91.0% vs 105.9%) and drew no lasting bid: price slid from $12.84 on 2026-08-21 to $12.44 on 2026-09-04, RSI 43.9, at the bottom of the August $12–$13 band, while freight… Special situation · Freight & logistics · Cyclical industrials catalyst · HURN Huron Consulting Group Inc. LOW AI-disruption discount still unwinding, but the bid has stopped widening: the 2026-08-28 close of $159.84 is below the 2026-08-21 close of $161.64, no analyst has moved a target since 2026-07-29, and Huron has published nothing since the… Theme leader · AI datacenter infrastructure · Managed care & health services analysed · IART Integra LifeSciences Holdings Corporation LOW Med-device turnaround re-rating is now fully banked into Hold-grade targets: BMO initiated Market Perform $19 (Jul 9) and Citi raised to Neutral $19 (Jul 8), both landing on the tape (~$18.76). The distressed-to-fair leg is done; only… Special situation · Medtech & diagnostics catalyst · IBKR Interactive Brokers Group, Inc. fresh LOW Interactive Brokers' account-growth story supports a recovery case, but trading activity must rebound after August's sequential decline. A weekly close above the market's $98.10 high completes the price case; a weekly close below the… Cyclical recovery · AI datacenter infrastructure analysed · ICHR Ichor Holdings LOW Memory-capex WFE subsystem re-rating broke on the 2026-08-03 Q2 print: revenue $294.8M missed $300.2M consensus, the $78 June shelf failed, and the 2026-08-07 close was $68.32 against a $112.28 high. Q3 guidance still beats ($315–345M vs… Cyclical recovery · Semi foundry & equipment catalyst · IESC IES Holdings, Inc. LOW IES Holdings' data-center backlog supports a conditional price recovery after August's failed breakout. A weekly close above the $396.98 adjusted annual high completes the recovery case; a weekly close below $345 invalidates it. Cyclical recovery · AI datacenter infrastructure · Industrial power & grid analysed · IHRT iHeartMedia, Inc. LOW M&A leg is dead — no SiriusXM headline since the 2026-05-29 NYT "stalled" report and the April spike fully round-tripped ($6.33 high → $3.86 on 2026-08-07, -39%). What is left is a binary: Q2 print 2026-08-10 after the close is the first… Earnings inflection · M&A & special situations · Cyclical industrials catalyst · IKT Inhibikase Therapeutics, Inc. fresh LOW Inhibikase Therapeutics’ Phase 3 execution could restore its pulmonary arterial hypertension re-rating. A weekly close above the September 18, 2026 reference high of $2.52 would establish the price case; a weekly close below the July… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics analysed · ILMN Illumina, Inc. LOW Illumina’s NovaSeq X recovery has a September 21 index catalyst, but price confirmation remains absent. A weekly close above the $227.69 reference high and delivery against July’s third-quarter revenue outlook would validate the case; a… Special situation · Medtech & diagnostics · Oncology & immunology catalyst · IMRX Immuneering Corporation fresh LOW Busted-catalyst pancreatic biotech: atebimetinib's 17.3-mo single-arm 1L OS is real, but the Phase 3 binary is mid-2028 and the tape keeps fading post-ASCO ($5.11→$4.32 in two weeks) even as targets climb to $18–$30. Cheap… Earnings inflection · Oncology & immunology · Binary-catalyst biotech catalyst · IMVT Immunovant, Inc. fresh LOW Immunovant’s recovery case depends on IMVT-1402 clinical progress restoring the market’s $44.96 reference high by December 31, 2026. A weekly close below $35 invalidates the case; the September 18 three-month decline and undated clinical… Earnings inflection · Oncology & immunology · Binary-catalyst biotech analysed · INDI indie Semiconductor, Inc. LOW Automotive ADAS-silicon design-win story keeps improving on paper ($7.4B backlog, $25M radar order, ams OSRAM sensor buy) while the tape stays broken below the ~$4.00 50-day MA; TD Cowen's 2026-07-13 lift to a $4.50 Hold is a thaw, not a… Cyclical recovery · Analog semiconductors · EV & autonomous mobility catalyst · INHD Inno Holdings Inc. fresh LOW Inno Holdings' remaining cash-backed recovery case requires a weekly close at or above the September 4 market close of $4.53 before a weekly close below $3.05. The September 18, 2026 close already breached the earlier $4.00 condition,… Retail squeeze · Squeeze & momentum setups catalyst · INOD Innodata Inc. fresh LOW AI training-data pure-play with a still-accelerating fundamental story (Q1 rev +54%, 40%+ FY26 guide reaffirmed 06-17) but a fully broken chart: ~-51% from the June $125.14 ATH to ~$61, with the CEO filing a fresh 200k-share sale on 07-16… Cyclical recovery · AI datacenter infrastructure catalyst · INTA Intapp, Inc. LOW Intapp’s AI integrations support an existing-client expansion thesis; the next quarterly report tests whether bookings convert into revenue. Confirmation requires revenue above the $160.3 million quarterly guide and cloud ARR growth of at… Theme leader · AI enterprise software · AI datacenter infrastructure catalyst · IONQ IonQ, Inc. LOW IonQ's combined-company guidance restores a measurable revenue story; a weekly close above $44 would establish price repair. A weekly close below $36 first would invalidate that recovery case. Earnings inflection · Quantum computing catalyst · IPAR Interparfums, Inc. fresh LOW Interparfums’ Cavalli renewal reinforces its long-license growth story, but earnings confirmation remains pending. The case plays out with a weekly close above the September 18 recorded high of $127.63 while annual guidance stays intact,… Compounder · Consumer discretionary rotation catalyst · IPX IperionX Limited fresh LOW US critical-minerals sovereignty name whose funding overhang cleared the ugly way: a 2026-07-08 US$50M ADS raise priced at $21.98, ~22% below the ~$28 pre-deal level, resetting the stock to $22.94 near its $21.66 52-week low. Pre-revenue,… Compounder · Critical materials & rare earths · Defense & aerospace catalyst · IQ iQIYI, Inc. fresh LOW Long-form streaming growth is broken in the reported numbers (Q1 2026 revenue -13% YoY, operating income to a RMB228.4m loss), so what is left is the micro-drama/overseas pivot — newly branded as Undercurrent Theater in early August 2026 —… Special situation · Squeeze & momentum setups · Emerging markets analysed · IT Gartner, Inc. LOW Gartner’s recovery depends on subscription growth improving after the August earnings rebound weakened. Confirmation requires faster contract-value growth, maintained revenue guidance and a weekly close above the August 28 reference close… Special situation · AI enterprise software catalyst · JACK Jack In The Box Inc. fresh LOW June's move was a float mechanic — Russell Microcap inclusion (effective 2026-06-30) into a 40%-short float drove $8.92 to $18.13, and it is unwinding ($14.98 on 2026-07-17, -7.76%). SSS is genuinely inflecting (-6.7% → -3.8%), but price… Retail squeeze · Squeeze & momentum setups catalyst · JBIO Jade Biosciences, Inc. fresh LOW Jade Biosciences' JADE101 dosing story supports a conditional recovery case, but patient efficacy remains unresolved. A weekly close above the lost July $21 shelf would establish price repair; a weekly close below the June offering… Earnings inflection · Precision biotech & therapeutics · Oncology & immunology catalyst · JBLU JetBlue Airways Corporation fresh LOW Fuel-reversion bull leg broke: Brent re-spiked to ~$86 (Jul 17) on renewed Mideast conflict, reversing the sub-$73 tailwind the whole trade needed. Raymond James (Jul 6) cut to Underperform flagging a Chapter 11 that wipes equity; $9.3B… Earnings inflection · Travel & leisure · Oil, energy & geopolitical catalyst · JELD JELD-WEN Holding, Inc. fresh LOW JELD-WEN's post-2026-08-03 re-rating has stalled: the 2026-09-04 close of $2.30 is back below the 2026-08-28 close of $2.53, RSI(14) has cooled from 71.2 to 61.0, and no company disclosure has landed since the 2026-08-05 analyst updates.… Earnings inflection · Housing, homebuilders & proptech catalyst · JOBY Joby Aviation, Inc. fresh LOW eVTOL cert story still advancing (FAA TIA testing, 2026 Dubai target) but the trade rolled over: ~$8 testing support, down ~33% since June 1, recovery base gone, CFO sold ~half his stake June 8, consolidation coverage marks sentiment… Earnings inflection · EV & autonomous mobility · Defense & aerospace catalyst · JWEL Jowell Global Ltd. fresh LOW Low-float China e-commerce microcap that repriced +106% intraday on 2026-08-10 with no filing behind it; the leg being bought is float scarcity (2.38M shares out, $7.3M market cap) plus a 0.04x sales optic. Nothing on the calendar resolves… Retail squeeze · Biofuels & low-carbon fuels · Semi foundry & equipment analysed · KALU Kaiser Aluminum Corporation fresh LOW Section 232 aluminum supply-shock (50% duty through 2027) plus a Q1 earnings inflection already repriced KALU ~+175% YoY to a $195 high; the move is maturing toward saturated with price at/above every published target. The estimated… Special situation · Cyclical industrials · Defense & aerospace analysed · KC Kingsoft Cloud Holdings Limited LOW China AI-compute capacity story is intact on fundamentals — AI gross billing +90% YoY and past half of public-cloud revenue in Q1 (reported 2026-05-27) — but the price leg broke: -32.3% from the $18.21 high with RSI(14) back at 70.0. The… Cyclical recovery · AI datacenter infrastructure · Emerging markets analysed · KEEL Keel Infrastructure Corp. fresh LOW Former Bitfarms miner→AI/HPC-datacenter pivot has rolled over: June's push to ~$6.14 into Citizens' $10 initiation retraced to a ~$4.975 ref by 07-06, losing the $5.00 convert shelf and drifting toward the $4.00–4.20 base. Still zero… Special situation · AI datacenter infrastructure · Bitcoin miners analysed · KGS Kodiak Gas Services, Inc. fresh LOW Legacy-pivot repricing has stalled into a four-week range: the 2026-09-04 close of $62.59 sits between the 2026-08-10 low of $59.72 and the 2026-08-14 close of $65.35, with no company press release since 2026-08-06 and no dated catalyst… Special situation · Industrial power & grid · AI datacenter infrastructure analysed · KLAC KLA Corporation fresh LOW KLA Corporation’s inspection-demand recovery case requires September revenue of at least $4.0 billion and a weekly close above $210 by its earnings report. A weekly close below $175 breaks the case; the September 18, 2026 close was $176.99. Cyclical recovery · Semi foundry & equipment · AI chips & memory catalyst · KLC KinderCare Learning Companies, Inc. fresh LOW Distressed post-IPO childcare name has retraced ~180% off its $1.75 spring low to $4.93 as growth shifts to B2B/employer care and before-after-school (Champions +17% YoY), while the core ECE business still shrinks (−3% enrollment). The ~13… Special situation · Consumer discretionary rotation · Managed care & health services analysed · KMTS Kestra Medical Technologies, Ltd. LOW WCD share-capture story intact on fundamentals — FY26 revenue $95.1M (+59%), fiscal Q4 gross margin 54.8% — but the bid has thinned: the close was $25.64 on 2026-08-28, 9.6% under the $28.35 52-week high, with RSI(14) at 13.5 against 67.8… Defensive · Medtech & diagnostics catalyst · KNX Knight-Swift Transportation Holdings Inc. fresh LOW Beat-and-raise is filed (Q2 adj EPS $0.63; Q3 guided $0.71–$0.77) but the equity is flat since 2026-08-21 at $71.99 while the driver stalled rather than reaccelerated — all-mode tender rejections 13.57% on 2026-08-25 versus a July 4 peak… Compounder · Freight & logistics · Cyclical industrials catalyst · KOD Kodiak Sciences Inc fresh LOW Kodiak Sciences' repricing case rests on September DAYBREAK success and a weekly recovery above the former $36 shelf. Both investigational arms must meet their primary endpoints, while a weekly close below $32 invalidates the setup. Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · KODK Eastman Kodak Company fresh LOW Eastman Kodak's materials pivot needs Q3 to repeat Q2's $105 million segment revenue and 26% consolidated gross margin before a weekly close below $9.20 breaks the recovery thesis. The September momentum improvement does not resolve… Special situation · Cyclical industrials · Critical materials & rare earths catalyst · KOS Kosmos Energy Ltd. fresh LOW Jubilee ramping toward ~90,000 bopd gross (J76 online, J77/J50 imminent) with GTA LNG volumes climbing. Highest-beta E&P expression bounced ~15% off the $2.00 June low; re-accelerating but still a ~$2.30, 'CCC'-rated, most-levered… Compounder · Oil, energy & geopolitical catalyst · KRO Kronos Worldwide, Inc. fresh LOW Kronos Worldwide’s titanium-dioxide recovery needs higher third-quarter selling prices and continued segment profitability to validate August’s earnings rebound. The September 11 close of $8.14 has lost the earlier $8.20 shelf; a weekly… Defensive · Cyclical industrials analysed · KRT Karat Packaging Inc. LOW Karat Packaging’s tariff-refund re-rating needs recurring sales and margin delivery to resume. Third-quarter results meeting the August 6 guidance and a weekly close above $49.80 would validate continuation; a weekly close below $40 would… Defensive · Cyclical industrials · Small-cap value rotation analysed · KSS Kohls Corporation fresh LOW Squeeze leg has stalled: Morgan Stanley's 2026-07-06 Underweight/$15 reinit broke the one-way upgrade cluster and knocked the stock -5.9% on 07-08. Price ~$17.18 still holds above the 50- and 200-day, but with the sell-side now two-sided… Retail squeeze · Squeeze & momentum setups catalyst · KVYO Klaviyo, Inc. fresh LOW Klaviyo’s AI-agent expansion still needs attributable revenue, while the September 18 close invalidated its August recovery. A weekly recovery above $17.71 and agent revenue disclosure would be required to establish a new case. Theme leader · AI enterprise software analysed · LAC Lithium Americas Corp. fresh LOW Lithium Americas’ Thacker Pass recovery thesis failed when the 2026-09-18 weekly close of $2.86 breached the published $3.00 shelf. A reclaim and the next construction update would support reassessment; JPMorgan’s September 9 endorsement… Compounder · Critical materials & rare earths analysed · LAD Lithia Motors, Inc. LOW Lithia Motors’ finance-led re-rating requires dealership revenue to recover alongside lending income. The next quarterly results test that combination; a weekly close below $340 invalidates the price thesis. Special situation · Consumer discretionary rotation · Fintech & consumer credit catalyst · LAR Lithium Argentina AG fresh LOW Commodity transmission is now broken in both directions: the GFEX front carbonate quote came off to ~CNY 152,000/t on 2026-09-04 from CNY 156,140/t on 2026-08-22 while the shares went $6.83 to $6.79. The saturated lithium-recovery story… Compounder · Critical materials & rare earths catalyst · LBRX LB Pharmaceuticals Inc LOW LB Pharmaceuticals’ funded schizophrenia trial supports a recovery thesis, tested by a weekly close above $49.48 before a weekly close below $42.80. NOVA-2 results guided for the first half of 2027 settle the separate clinical question. Earnings inflection · Precision biotech & therapeutics catalyst · LEGN Legend Biotech Corporation fresh LOW In-vivo CAR-T re-rate has matured into digestion: EHA (6/13) confirmed LB2501's 100% ORR and clean durability, but the 6/17 $226M raise at $29.35 capped the leg and JPM's 7/13 Neutral $35 reinstatement caps the Street. No fresh catalyst… Compounder · Precision biotech & therapeutics · Oncology & immunology catalyst · LGIH LGI Homes, Inc. fresh LOW LGI Homes has a low-conviction recovery case toward its former $54 threshold after August closings grew 9.9% year over year. A weekly close above $54 completes this separate stabilization hypothesis; a daily close below the September 18… Compounder · Housing, homebuilders & proptech catalyst · LGN Legence Corp. fresh LOW AI-datacenter MEP/HVAC pick-and-shovel story still improving on fundamentals (record $5.38B backlog, FY guide raised to $4.1–4.3B), but the tape has decoupled: ~33% off the $102 May close high, LGN sliced the $76 breakout shelf and rolled… Cyclical recovery · AI datacenter infrastructure catalyst · LILAK Liberty Latin America Ltd. fresh LOW Post-catalyst drift: the $500M preferred special dividend and the June Malone/Nair insider cluster already drove a ~70% run off $4.76 to ~$8.30, and the tape has stalled at $7.33. Citi cut to Neutral 2026-07-10 with a $8 target already… Defensive · M&A & special situations · Emerging markets analysed · LIND Lindblad Expeditions Holdings Inc. LOW Lindblad Expeditions’ occupancy-and-pricing rerating thesis failed when the 2026-09-11 weekly close of $25.67 breached its published $26.56 threshold. The August operating results support the underlying execution story, but they do not… Defensive · Travel & leisure analysed · LITE Lumentum Holdings Inc. LOW Two initiations in two sessions — Evercore ISI $1,100 on 08-31, Deutsche Bank $1,200 on 09-01 — and the tape closed 2026-09-02 at $870.58, still under the $885 weekly-close level and below the 08-31 close of $914.76. The $40 fiscal-2028… Cyclical recovery · Networking & optical catalyst · LOVE The Lovesac Company fresh LOW The 2026-08-27 notice made the binary real: Q2 FY27 lands before the open on 2026-09-10 against a company bar of $157–166M net sales and −$4M to +$2M adjusted EBITDA. Price closed $16.69 on 2026-09-04, under the 50-day at $16.95 and above… Earnings inflection · Consumer discretionary rotation catalyst · LQDA Liquidia Corporation fresh LOW Liquidia Corporation’s recovery case rests on YUTREPIA sales growth and a reclaim of the published $70 shelf. A weekly close above $70 plus next-quarter product sales above Q2 2026’s $170.4 million would confirm the case; a weekly close… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech analysed · LRMR Larimar Therapeutics, Inc. fresh LOW Single-asset FA regulatory binary sitting on the line that defines it: the week ending 2026-09-04 closed $3.83, 0.8% above the twice-tested $3.80 shelf, after five weeks with no company press release since the 2026-08-04 Q2 update. The… Earnings inflection · Rare disease & gene therapy · Binary-catalyst biotech catalyst · LTH Life Time Group Holdings, Inc. LOW Life Time Group Holdings’ premium-club re-rating needs recovery above the August placement price and retention of July’s raised growth outlook. A weekly close above $43.16 and unchanged guidance at the next results would satisfy the case;… Compounder · Oil, energy & geopolitical analysed · LUNR Intuitive Machines, Inc. LOW The June 30 NASA Moon BASE award ($148.3M Nova-C) bought exactly one green session before the stock broke: seven straight down days into 2026-07-13 for -24.5%, -36.5% on the month, $13.80 on 2026-07-18 versus a $38.55 May high. A live… Retail squeeze · Space economy catalyst · LZ LegalZoom.com, Inc. fresh LOW AI-reset narrative — a busted online legal-forms IPO repositioning as an AI-enabled SMB subscription platform (Anthropic partner, AI "digital mailroom") — drove a +29% 30-day rip into July. But it's stretched into the 2026-08-05 Q2 print,… Special situation · AI enterprise software · Managed care & health services catalyst · M Macy's Inc. fresh LOW Morgan Stanley broke the all-Hold wall on 2026-07-06, resuming at Overweight with a $30 target and a $3 EPS-power call vs ~$2 consensus — the first real upgrade catalyst since the Q1 beat. But price faded the note ($23.99 → $22.64 by… Special situation · Consumer discretionary rotation catalyst · MAMA Mama's Creations, Inc. fresh LOW The 2026-09-03 binary resolved for the fundamentals and against the tape: Q2 FY2027 revenue $54.58M (+55%) and EPS $0.06 both beat, gross margin recovered to 24.0% from 23.6%, and the shares still closed 2026-09-04 at $15.16, below the… Defensive · Cyclical industrials · Small-cap value rotation analysed · MANH Manhattan Associates, Inc. LOW Cloud-conversion re-rating has printed a new 52-week high: the 2026-08-28 close of $223.28 is 0.2% under the $223.76 high, RSI(14) 79.7, with price 4.2% above the $213.90 aggregate analyst target. The only new input since the 2026-07-28… Special situation · AI enterprise software · Freight & logistics analysed · MASS 908 Devices Inc. LOW 908 Devices’ handheld-detection recovery depends on the $6 million ProtectIR order announced on 2026-08-11 validating its revenue outlook. A weekly close above the $11.10 high reported on 2026-09-11 would confirm price recovery; a weekly… Special situation · Defense & aerospace · Cyclical industrials catalyst · MATV Mativ Holdings, Inc. LOW Mativ Holdings’ margin-and-debt repair thesis requires the next quarterly report to sustain a 14.1% adjusted EBITDA margin and reduce net debt below $908.2 million before a weekly close below $11.50 invalidates the price structure. Special situation · Cyclical industrials catalyst · MAX MediaAlpha, Inc. fresh LOW MediaAlpha’s insurance-advertising growth has not sustained its price structure: the $10.49 close on 2026-09-18 invalidated the published $12 weekly threshold. Final Q3 revenue below $355 million would also contradict management’s… Theme leader · Managed care & health services · AI datacenter infrastructure catalyst · MAZE Maze Therapeutics, Inc. fresh LOW APOL1 kidney proof-of-concept intact and funded into 2029, but the only news since the last note was a conference calendar: the 2026-09-02 release scheduled fireside chats on Sept 9, 10 and 15 and repeated the late-2026/early-2027 HORIZON… Earnings inflection · Precision biotech & therapeutics analysed · MCHP Microchip Technology Incorporated fresh LOW AI-data-center re-rating leg is unwinding — round-tripped from the $105.91 May ATH to the ~$84 50-day EMA under an unrebutted J Capital short thesis and a 2026-07-13 TD Cowen PT cut to $90; only the cyclical MCU/industrial recovery (~93%… Special situation · Analog semiconductors · AI datacenter infrastructure catalyst · MDB MongoDB, Inc. fresh LOW Atlas re-acceleration (+29.4% YoY, record $117M seq add; Q1 FY27, 2026-05-28) is intact, but the +18.5% post-print breakout fully round-tripped from $444.72 to a $294.10 close as the AI-software theme sold on margin-timing fear. Sell-side… Cyclical recovery · AI enterprise software catalyst · MEDP Medpace Holdings, Inc. fresh LOW Bookings-inflection leg (Q2 awards $795.7M, +28.2% YoY, 1.13x book-to-bill, FY26 guide raised 2026-07-22) unchanged on fundamentals, but the tape has given back part of the August recovery — $600.65 on 08-28 to $591.29 on 09-04 — while the… Cyclical recovery · Precision biotech & therapeutics · Oncology & immunology analysed · MESO Mesoblast Limited fresh LOW Mesoblast’s Ryoncil-funded pipeline thesis faces a sales-growth test at the next quarterly report and weakening price support. A weekly close above the 2026-07-15 high of $18.07 would complete the recovery case; a weekly close below $15… Earnings inflection · Binary-catalyst biotech analysed · MGM MGM RESORTS INTERNATIONAL fresh LOW Take-private process went live: WSJ reported substantive Diller talks 2026-07-10, MGM seated a special committee mid-July, and the board reportedly views $48.30 as too low — so the trade is now a bump handicap, not a growth story. At… Earnings inflection · M&A & special situations catalyst · MGNX MacroGenics, Inc. fresh LOW MacroGenics' MGC026 revaluation thesis turns on the 2026-10-23 cancer-data presentation. Cohort-level response and durability evidence followed by a weekly close above $4.86 would confirm the case; a weekly close below $3.90 invalidates it. Earnings inflection · Oncology & immunology · Binary-catalyst biotech analysed · MKSI MKS Inc. LOW Operating leg accelerating into a de-rating tape: Q2 (2026-08-05) beat at $1.248B revenue / $3.30 adj EPS, Q3 guide $1.310–1.390B tops the $1.243B Street, leverage down to 3.0x — and the stock still fell 4.49% on the print and sits 31.4%… Cyclical recovery · Semi foundry & equipment · AI datacenter infrastructure catalyst · MLKN MillerKnoll, Inc. fresh LOW MillerKnoll's recovery re-rating failed its published $22 weekly-close test on 2026-09-18. The 2026-09-22 results would support a replacement case only with recovering organic orders and backlog above the $679 million reported on… Special situation · Housing, homebuilders & proptech · Cyclical industrials catalyst · MMYT MakeMyTrip Limited fresh LOW MakeMyTrip's mid-year recovery bounce has stalled: after reclaiming the 200-day near $55, MMYT rolled back to ~$49, below both the 50- and 200-day, straight into an August 3 Q1 FY2027 print where consensus models EPS down ~76% YoY on ~137x… Earnings inflection · Travel & leisure catalyst · MNKD MannKind Corporation fresh LOW MannKind Corporation's Furoscix expansion tests its pivot beyond inhaled insulin. Q3 2026 Furoscix sales above Q2 2026's $22.2 million, with Tyvaso DPI royalties at least $32.4 million, would confirm the commercial leg before a weekly… Special situation · Precision biotech & therapeutics analysed · MNTN MNTN, Inc. LOW MNTN, Inc.’s profitability re-rating depends on Q3 revenue exceeding the $86 million low end of August 4 guidance, positive net income and unchanged full-year guidance before a weekly close below $11.50 breaks the recovery case. The… Defensive · AI enterprise software analysed · MOD Modine Manufacturing Co LOW Modine Manufacturing's data-center cooling recovery requires better margins and a weekly reclaim of $210. The next quarterly report must improve on the 20.2% segment gross margin reported on 2026-07-29; a weekly close below $153… Cyclical recovery · AI datacenter infrastructure catalyst · MOH Molina Healthcare, Inc. fresh LOW Molina Healthcare’s Medicaid recovery case needs a weekly close above $205 and October results preserving its July earnings floor. The 2026-09-18 close of $200.79 leaves price confirmation absent; a weekly close below $188 invalidates the… Special situation · Managed care & health services analysed · MOV Movado Group, Inc. fresh LOW Movado Group’s margin recovery remains unconfirmed by price; the re-rating case requires a weekly close above the $34.96 pre-results reference before a weekly close below $33 invalidates it. Special situation · Consumer discretionary rotation catalyst · MPWR Monolithic Power Systems, Inc. fresh LOW Monolithic Power Systems’ AI power-management recovery case needs Q3 revenue above its $1,140 million guidance floor and a weekly reclaim of the $1,313.32 June pivot. A weekly close below $1,200 ends the price-recovery case. Cyclical recovery · AI datacenter infrastructure analysed · MRAM Everspin Technologies, Inc. fresh LOW Sympathy bid off the Micron-led memory supercycle and Russell 2000 inclusion floored the post-parabola markdown in the low-$20s, but the ~2026-07-28 Q2 print is now the binary: Everspin must show a non-casino datacenter/AI design win or… Retail squeeze · AI chips & memory · Squeeze & momentum setups analysed · MRNA Moderna, Inc. fresh LOW Moderna’s cancer-treatment re-rating depends on full INTerpath-001 efficacy data and recovery above the market’s $174.38 event close. A weekly close below $130 invalidates the case; September investor appearances provide dated… Compounder · Binary-catalyst biotech analysed · MRVI Maravai LifeSciences Holdings, Inc. fresh LOW Maravai LifeSciences’ Moderna-linked supplier thesis failed its published $7.24 weekly-close test on 2026-09-18 at $6.97. Company-reported vaccine orders and a recovery above that threshold are needed to establish a new case. Cyclical recovery · Precision biotech & therapeutics · Medtech & diagnostics analysed · MSFT Microsoft Corporation LOW AI-capex derating still in control and now colliding with a hostile print tape: Alphabet lost ~$294B on 2026-07-24 punished purely for AI spend, Tesla/Intel/Google all sold post-earnings, and MSFT reports Q4 FY26 on 2026-07-29 AMC below… Compounder · Mega-cap AI platforms · AI datacenter infrastructure analysed · MTH Meritage Homes Corporation fresh LOW Housing-rebound-on-rate-cuts trade that carried MTH to a $85.38 52-week high has reversed: it lost the $75 June breakout shelf to $74.17 (-4.2% on 7/17) as mortgages held at 6.49% and Zelman capitulated to Neutral (7/7). Fundamentals still… Compounder · Housing, homebuilders & proptech catalyst · MTRN Materion Corporation LOW Beryllium critical-materials scarcity narrative still building, but the parabola cracked: a new ATH of $298.76 in early July gave way to a 5.6% reversal on 2026-07-07 to $247.20, now ~$258 and still ~9% above KeyBanc's $237 top target. The… Compounder · Critical materials & rare earths · Defense & aerospace analysed · MTSI MACOM Technology Solutions Holdings, Inc. fresh LOW AI optical-interconnect arms-dealer with fundamentals still accelerating (FY26 DC growth guide >60%, Q3 guide $331-339M) but a July-broken chart: ~36% off the $418.90 high to ~$267 on the semi selloff, Russell Value index removal, and… Cyclical recovery · Networking & optical · AI datacenter infrastructure catalyst · MTUM LOW The AI-memory leg MTUM rotated into at the May reconstitution has rolled over: SOX -20%+ from its June peak, memory names in a bear market, and the fund closed $302.09 on 2026-07-17, below the $310 shelf that defined the… Compounder · AI chips & memory · AI datacenter infrastructure catalyst · MYE Myers Industries, Inc. fresh LOW Legacy plastics maker re-rated ~2.4x on a "Focused Transformation" — MTS distribution arm in discontinued ops, capital concentrated behind Signature/MegaDeck composite matting (Infrastructure orders +130% YoY, Q1 adj EPS $0.44 vs $0.28).… Special situation · Cyclical industrials catalyst · NABL N-able, Inc. fresh LOW N-able's recovery case rests on repurchase support and recurring-revenue stabilization. The next quarterly report must show ARR above Q2's $544.5 million and revenue within the $134.5–135.5 million Q3 guidance before a weekly close below… Special situation · Cybersecurity analysed · NAT Nordic American Tanker fresh LOW Nordic American Tankers' freight-rate rally needs exceptional contracts to lift reported fleet earnings. Confirmation requires the next fleet-wide daily TCE to exceed Q2 2026's $63,000 per ship before a weekly close below the September 18… Compounder · Freight & logistics catalyst · NBR Nabors Industries Ltd. fresh LOW Leveraged ~2x oil-beta proxy on the Hormuz war premium, +90% YTD near $100 but now rolling over: Susquehanna cut its target to $85 (2026-07-08) as the sell-side stops chasing, and the ~2026-07-23 Q2 print — the first to lap the premium —… Compounder · Oil, energy & geopolitical catalyst · NCLH Norwegian Cruise Line Holdings Ltd. fresh LOW Norwegian Cruise Line Holdings’ remaining case is activist-led recovery toward the $16 shelf lost on 2026-09-04. A weekly close above $16 would establish initial repair, while a weekly close below $14 would invalidate the case. Defensive · Travel & leisure · Consumer discretionary rotation catalyst · NEO NeoGenomics, Inc. fresh LOW Oncology-dx turnaround accelerating — NGS +26%, PTEN IHC CDx (first FDA IHC companion dx in prostate, paired to AZ's TRUQAP) launched Jul 9, and TD Cowen $14→$19 / BofA $11→$16 on Jul 13 lifted consensus to ~$15.67, back above spot. But Q2… Special situation · Precision biotech & therapeutics · Medtech & diagnostics catalyst · NESR National Energy Services Reunited Corp fresh LOW National Energy Services Reunited's oilfield expansion supports a recovery case: a weekly close above $36.31 before one below $32 would settle the price leg. The next quarterly release tests whether second-quarter revenue of $520.8 million… Cyclical recovery · Oil, energy & geopolitical catalyst · NEXA Nexa Resources S.A. fresh LOW Cyclical zinc-recovery confirmed and fully priced: Q1 EBITDA +126% YoY and Aripuanã's record 13kt ramp drove a run to the $16.89 high, but the equity now chops $12–13 while LME zinc printed a fresh 2026 high near US$3,622 — a bearish… Special situation · M&A & special situations analysed · NGNE Neurogene Inc. fresh LOW Neurogene's financed Rett gene-therapy thesis turns on Embolden meeting its clinical endpoint in the second half of 2027 before a weekly close below $30 breaks the market structure. Earnings inflection · Rare disease & gene therapy analysed · NKE Nike, Inc. LOW NIKE's turnaround thesis requires the 2026-10-01 report to confirm gross-margin expansion and preserve its fiscal 2027 revenue outlook. A weekly close below $36 invalidates the recovery case; BMO's September Underperform initiation and the… Special situation · Consumer discretionary rotation catalyst · NNE Nano Nuclear Energy Inc. LOW Nuclear-microreactor narrative has stopped converting news into demand: a Truist Hold/$22 initiation (7/14) and a Virginia consortium announcement (7/17) landed inside four sessions and NNE still printed a fresh 52-week low at $15.78… Compounder · Nuclear & uranium analysed · NOK Nokia Corporation fresh LOW AI-networking legacy re-rate extending on a harder catalyst leg — first commercial AI-RAN platform with Nvidia (07-15) plus Taiwan Mobile, Orange Belgium and NestAI defense wins. Theme accelerating, but the 2026-07-23 pre-open Q2 print is… Special situation · Networking & optical · AI datacenter infrastructure analysed · NP Neptune Insurance Holdings Inc. fresh LOW The 2026-07-21 beat-and-raise has round-tripped: the 2026-08-14 weekly close of $31.71 is under the $32 post-print shelf, BMO cut to Market Perform on 2026-07-30, and the CFO sold 100,000 shares into $30.74–$32.12 on Aug 12–13. Operations… Defensive · Managed care & health services analysed · NRIX Nurix Therapeutics, Inc. fresh LOW Nurix Therapeutics' Roche-backed bexobrutideg story needs renewed clinical evidence after September's conference window. A weekly close above the $27.79 reference high would confirm the price leg; a weekly close below $24 would invalidate… Earnings inflection · Oncology & immunology · Binary-catalyst biotech analysed · NSIT Insight Enterprises, Inc. fresh LOW Genuine VAR margin-mix turnaround (Q1 GM +240bps, cloud GP +35%) but a derivative AI tag: hardware GP guided flat, sales +1%. Range-bound $102–123 since the early-June rejection; ~$110 already sits above the ~$103 street target with a… Special situation · AI datacenter infrastructure · AI enterprise software catalyst · NUTX Nutex Health Inc. fresh LOW Re-rating leg has stalled: NUTX closed $162.98 on 2026-07-17 after five straight down days, ~20% off the $204.00 high, giving back the June breakout that B. Riley's 2026-06-26 Buy/$290 initiation topped out. A $55.0M true-up of 18,950… Retail squeeze · Managed care & health services catalyst · NVCR NovoCure Limited fresh LOW NovoCure Limited’s commercial-inflection thesis requires another revenue-guidance increase and positive adjusted EBITDA at the next quarterly report. A weekly close below $15.40 invalidates the July repricing; unchanged guidance would fail… Earnings inflection · Oncology & immunology · Medtech & diagnostics analysed · NVEC NVE Corporation LOW NVE Corporation’s recovery case depends on repeating June’s product-sales jump and reclaiming the lost $105 shelf. The next quarterly report must show product sales at or above $10,734,735 alongside a weekly close above $105 before a… Earnings inflection · Analog semiconductors analysed · NWPX NWPX Infrastructure, Inc. fresh LOW Legacy steel-pipe maker re-rated into a water-infrastructure + precast roll-up on a record $373M WTS backlog, an ~83% Q1 beat, and the Permalok RBJ field win. Narrative intact but the setup is extended — last near $148, ~35% above the… Special situation · AI datacenter infrastructure · Cyclical industrials catalyst · NXPI NXP Semiconductors N.V. fresh LOW NXP Semiconductors' recovery case requires demand confirmation at October 27 earnings and a subsequent weekly close above UBS's published $270 target. A weekly close below $220 would invalidate the price structure first. Theme leader · Analog semiconductors · AI chips & memory catalyst · ODFL Old Dominion Freight Line, Inc. fresh LOW Freight-cycle recovery in the top-margin LTL name is drawing a broadening upgrade cluster now printing above spot (Stifel $256 Jul 21, Truist $250 Jul 15, RJ $241 Jul 13), but growth is still rate and mix with tons/day negative. The… Defensive · Freight & logistics · Cyclical industrials analysed · ODTX Odyssey Therapeutics, Inc. fresh LOW Odyssey Therapeutics' OD-001 re-rating depends on October expansion data sustaining its reported ulcerative-colitis efficacy. Confirmation requires comparable results retaining 27% remission and 61% response at UEG Week on October 17–20,… Earnings inflection · Precision biotech & therapeutics catalyst · OEC Orion S.A. LOW Deep-cyclical carbon black where the 2024–25 tire-restock leg already failed (-32.5% from the $10.72 52-week high). What is left is a trough-and-deleverage read: Q2 2026 adj. EBITDA $58.2M (+26% sequential, -15% YoY), FY26 guide reaffirmed… Defensive · Cyclical industrials · Biofuels & low-carbon fuels catalyst · OFIX Orthofix Medical Inc. LOW Orthofix Medical’s reimbursement-led recovery thesis failed when the 2026-09-11 weekly close of $8.93 breached $9.30. The next quarterly results must establish whether the operating recovery survives through confirmation of the revenue and… Special situation · Medtech & diagnostics analysed · OII Oceaneering International Inc. fresh LOW Oceaneering International’s offshore earnings recovery needs third-quarter confirmation and a weekly close above $54.11 to validate renewed re-rating. A weekly close below $46 would invalidate the case; the September 8 sales range alone… Special situation · Oil, energy & geopolitical · Physical AI & robotics catalyst · OKLO Oklo Inc. LOW Three straight cohort-driven sessions carried OKLO from the 2026-07-29 close of $36.84 to $43.33 on 2026-08-04, with no Oklo release behind any of them. The 2026-08-07 Q2 call is the binary. Earnings inflection · Nuclear & uranium catalyst · OMDA Omada Health, Inc. fresh LOW Omada Health’s GLP-1 companion-care re-rating thesis failed when the September 18 weekly close of $20.43 breached its published $22 threshold. September 10’s long-term financial targets do not reverse that invalidation; a weekly close… Compounder · Managed care & health services analysed · ON ON Semiconductor Corporation fresh LOW The AI-power re-rate is unwinding, not consolidating: ON closed $87.37 on 7/17, below the 6/26 Synaptics deal-gap floor, with targets cut twice in three weeks (TD Cowen to $95 on 7/13, Mizuho to $125 on 7/1). Merger-arb supply plus a fixed… Theme leader · Industrial power & grid analysed · ONDS Ondas Inc. fresh LOW Ondas Inc.’s acquisition-led defense expansion needs Q3 revenue of $140–$155 million and a narrower adjusted EBITDA loss to validate it. A weekly close below $7.00 breaks the recovery case before that operating confirmation. Retail squeeze · Defense & aerospace catalyst · OPEN Opendoor Technologies Inc LOW Early-July retail squeeze is broken: OPEN lost the $4.88 insider shelf and $4.50 base, fell ~12% to $3.88 on 2026-07-24 on a technical breakdown plus fresh housing weakness, into an Aug 4 Q2 print. A rolled-over meme trading into an… Retail squeeze · Housing, homebuilders & proptech · Squeeze & momentum setups analysed · OPI Office Properties Income Trust Common shares of beneficial interest fresh LOW Office Properties Income Trust's recovery depends on refinancing completion and property sales validating post-reorganization equity. Expected financing settlement on 2026-09-24 supplies a dated test; the price case requires a weekly close… Defensive · M&A & special situations catalyst · ORBS Eightco Holdings Inc. fresh LOW Eightco Holdings' recovery case rests on token assets and repurchases disclosed on 2026-09-17. Higher reported holdings and restored Nasdaq compliance would confirm it; a weekly close below $1.00 would invalidate it. Theme leader · Crypto exchanges & financials · AI datacenter infrastructure analysed · ORIC Oric Pharmaceuticals, Inc. fresh LOW mCRPC PRC2 story de-risked as rinzimetostat enters registrational Phase 3 (Himalayas-1, 2026-07-14) with Bayer supplying NUBEQA and a J&J-backed enozertinib lung program behind it. But pivotal data is 2028+, so the only near-term mover is… Earnings inflection · Oncology & immunology · Binary-catalyst biotech catalyst · OTEX Open Text Corporation LOW Open Text Corporation’s cash-return stabilization case depends on first-quarter revenue meeting its $1.220–1.250 billion plan with annual guidance intact. The 2026-09-11 close of $23.06 leaves the structure above its published shelf, but a… Special situation · AI enterprise software catalyst · OTLY Oatly Group AB LOW Oatly’s guidance-led recovery failed its published $13.00 weekly price test at the $12.71 close on 2026-09-11. The next quarterly report must establish whether the operating recovery survives through confirmation of July’s revenue-growth… Special situation · Managed care & health services · Consumer discretionary rotation analysed · OUST Ouster, Inc. fresh LOW Squeeze leg broke: +43% in four sessions to a $63.79 high, then management priced 3.62M shares at $55.22 (~8% discount) and closed ~$191.9M net on 2026-07-06. Price round-tripped to $37.04, under the 20- and 50-day and under the $49… Retail squeeze · Physical AI & robotics catalyst · PATH UiPath, Inc. fresh LOW UiPath's agent-orchestration recovery case requires quantified commercial evidence at its 2026-09-22 Investor Day and a subsequent weekly close above $15. A weekly close below the September 11 reference close of $13.75 invalidates this new… Special situation · AI enterprise software catalyst · PAY Paymentus Holdings, Inc. LOW Beaten-down bill-pay compounder: Q1 2026 revenue +30.2% YoY yet shares carved a $20.11 June 52-week low on margin-mix fear. Now ~40% off that low into a binary ~Aug-4 Q2 print — the read is a recovering base, not a chase. Cyclical recovery · Crypto exchanges & financials analysed · PAYC Paycom Software, Inc. fresh LOW Paycom Software's operating-leverage re-rating is testing its post-Q2 price shelf after the 2026-09-11 close of $218.91. A weekly close above the $240.52 reference high would establish renewed price strength; a weekly close below $214… Special situation · Physical AI & robotics analysed · PBI Pitney Bowes Inc. fresh LOW PBI broke the $17.62 shelf to a fresh 52-week high $18.62 (Jul 16) — the buyback/cost-cut re-rate is now extending, not consolidating. But revenue still shrinks ~3% YoY, consensus PT $16.43 sits below spot, and Q2 prints after close Jul… Special situation · M&A & special situations · Cyclical industrials catalyst · PBR PETROLEO BRASILEIRO S.A.-PETROBRAS ADS (REP 1 COMMON SHARE) LOW Petrobras’s oil-linked momentum thesis requires a daily close above the September 11 reference high of $21.38 before a daily close below $21.20. Reported production growth supports the operating story, but expanding market participation… Compounder · Oil, energy & geopolitical catalyst · PCOR Procore Technologies, Inc. fresh LOW Procore Technologies' jobsite-AI re-rating failed its $55.26 weekly price test at the September 18, 2026 close of $51.27, despite DroneDeploy's completion. A rebuilt case requires a weekly recovery above $55.26 and financial confirmation… Theme leader · AI enterprise software · Housing, homebuilders & proptech catalyst · PCT PureCycle Technologies, Inc. fresh LOW Post-dilution repair story: the June 10–15 raise (~$145M equity + $287.5M 4.75% converts, ~$11.08 conv) roughly halved the stock to ~$8 while the commercial ramp (Q1 record 8.4M-lb output, +161% revenue) held. The 2026-07-15 Mitsui/RM… Retail squeeze · Critical materials & rare earths · Squeeze & momentum setups catalyst · PDFS PDF Solutions, Inc. fresh LOW Yield-analytics software re-rated on a real margin step — operating margin ~18%→25%, Platform revenue +36% YoY (Q1 reported 2026-05-07) — but the ~+280% run peaked at $69.05 on 2026-07-02 and flushed 11.5% intraday; the name is now… Cyclical recovery · Semi foundry & equipment · AI enterprise software catalyst · PESI Perma-Fix Environmental Services, Inc. fresh LOW Perma-Fix Environmental Services’ Hanford story needs Q3 revenue above $12.885 million and treatment revenue above $8.3 million to confirm waste-receipt conversion. A weekly close below $15 would invalidate the continuation thesis before… Earnings inflection · Nuclear & uranium analysed · PI Impinj, Inc. fresh LOW Post-correction RAIN RFID recovery has extended to $138.37 (2026-07-17), holding the reclaimed $128 April gap-fill and pressing the $144.57 post-earnings high — but the entire near-term read is the 2026-07-29 Q2 print (guide $103–106M, EPS… Earnings inflection · Freight & logistics analysed · PII Polaris Inc. fresh LOW Polaris’s earnings-recovery thesis failed its $62 weekly-close test at the 2026-09-18 close of $54.07. The next quarterly report tests whether operational earnings guidance survives, but cannot undo the price invalidation. Special situation · Cyclical industrials · Consumer discretionary rotation analysed · PK Park Hotels & Resorts Inc. fresh LOW Park Hotels & Resorts’ earnings recovery needs a reclaim of the $15.32 August shelf and sustained guidance at the 2026-11-04 results. A weekly close below $14.60 or full-year adjusted FFO guidance below $1.90 per share invalidates the case. Defensive · Travel & leisure catalyst · PKOH Park-Ohio Holdings Corp. fresh LOW Park-Ohio's infrastructure equipment story needs backlog growth beyond June's $252 million and retention of August's earnings guidance. The third-quarter report settles that case unless a weekly close below $45 invalidates the price… Theme leader · Industrial power & grid · Cyclical industrials analysed · PL Planet Labs PBC LOW Planet Labs’ satellite-data growth supports a tentative recovery case after the September 3 earnings beat failed to preserve its July range. A weekly close above $19.16 before a weekly close below $16.45 would establish the defined… Earnings inflection · Space economy analysed · PLAY Dave & Buster's Entertainment, Inc. fresh LOW Dave & Buster's recovery case requires positive comparable sales and a weekly reclaim of the September 4 close of $8.72 before a weekly close below $6.73 invalidates it. The September 18, 2026 close already breached the prior thesis's… Earnings inflection · Consumer discretionary rotation analysed · PLTK Playtika Holding Corp. fresh LOW Playtika Holding Corp.'s remaining recovery case depends on completed refinancing and preserved revenue guidance. Confirmation requires execution of the authorized bond financing and retention of the $2.75 billion full-year revenue floor… Earnings inflection · M&A & special situations analysed · PLTR Palantir Technologies Inc. LOW Palantir Technologies' government and commercial AI expansion supports a recovery case, confirmed by a daily close above $180.18 before a weekly close below $165. September partnership headlines broaden distribution, but the September 11… Compounder · AI enterprise software analysed · PLUG Plug Power, Inc. fresh LOW The +475% hydrogen-comeback squeeze has broken: the $3.12 Q1 gap and the 50-day both failed, price is ~$2.17 (-20% in 30d), and Susquehanna cut its target $3.75 → $2.50 on 2026-07-10. The June 30 NY Gateway close resolved as a restructure… Retail squeeze · Solar & clean energy analysed · POWI Power Integrations, Inc. fresh LOW The 800VDC AI-power re-rate has cracked. POWI lost the $74–78 May breakout shelf in a -20% week to $70.45 (2026-07-17) and now sits below the $76.20 average target for the first time since spring. The GaN cohort broke with it — NVTS is… Theme leader · Industrial power & grid · AI datacenter infrastructure catalyst · POWL Powell Industries, Inc. LOW Record orders $934M and a 3.0x book-to-bill lifted backlog to $2.4B (+69% YoY) at the 2026-08-03 print, yet shares fell 13.4% the next pre-market on a second straight EPS/revenue miss and closed 2026-08-14 at $213.48, -33.7% off the high.… Cyclical recovery · Industrial power & grid · AI datacenter infrastructure catalyst · PPTA Perpetua Resources Corp. fresh LOW Perpetua Resources’ domestic-antimony financing thesis requires definitive loan documentation and a final construction decision by 2026-12-31. The case fails first if a weekly close below $21 breaches the retained market boundary. Compounder · Cyclical industrials · Critical materials & rare earths analysed · PRGO PERRIGO COMPANY PLC fresh LOW Perrigo’s turnaround rests on asset sales reducing debt while core earnings guidance survives. A completed strategic transaction and subsequent results would confirm the case; a weekly close below $13.00 would invalidate its… Special situation · Consumer discretionary rotation analysed · PRLD Prelude Therapeutics Incorporated fresh LOW Prelude Therapeutics remains an Incyte option-exercise story: the $100 million fee would resolve the case positively if exercise precedes a weekly close below $4.75. September trial clearance adds pipeline progress, but the… Earnings inflection · Oncology & immunology · Precision biotech & therapeutics analysed · PSQL Pasqal Holding SA fresh LOW Pasqal's funded quantum-commercialisation story faces its first scheduled public-results test on 2026-09-24. A subsequent weekly close above the $10.00 merger reference would confirm the recovery case; a weekly close below $7.00 would… Defensive · Quantum computing catalyst · PTRN Pattern Group Inc. Series A fresh LOW Pattern Group's ecommerce growth story needs Q3 delivery and a price recovery after the September conference window elapsed. A weekly close above the August reference of $23.16 would confirm recovery before a weekly close below $19… Cyclical recovery · Managed care & health services · Consumer discretionary rotation catalyst · PVH PVH Corp. fresh LOW PVH Corp.’s legacy-brand reset needs earnings delivery and a recovery of the $75 shelf. The case is confirmed if Q3 results preserve the $11.80–$12.10 fiscal 2026 adjusted EPS outlook and the shares close a week above $75 before a weekly… Special situation · Consumer discretionary rotation analysed · QBTS D-Wave Quantum Inc. LOW D-Wave Quantum’s definitive federal award supports a recovery story, but Q3 recognition of its booked $20 million system sale must establish commercial conversion. The case fails on a weekly close below $16.18 or deferral of that sale… Retail squeeze · Quantum computing catalyst · QDEL QuidelOrtho Corporation fresh LOW QuidelOrtho’s recovery case requires a signed point-of-care divestiture and a weekly reclaim of $13.75 before a weekly close below $10.62. The earlier deal-rumor thesis had already breached its published price condition by September 18,… Earnings inflection · Medtech & diagnostics analysed · QLYS Qualys, Inc. fresh LOW Qualys’ post-earnings recovery case requires a weekly close above the market’s August reference of $187.05 before a weekly close below $170 breaks it. The 2026-08-04 guidance increase supports the operating story, but Q3 revenue at or… Special situation · Cybersecurity · AI enterprise software catalyst · QNST QuinStreet, Inc. fresh LOW QuinStreet's carrier-advertising recovery must translate into September-quarter guidance delivery and a price recovery before a weekly close below $17. Northland's 2026-09-17 target increase renews analyst support, but the 2026-09-18 close… Cyclical recovery · Managed care & health services catalyst · QTWO Q2 Holdings Inc LOW Q2 Holdings’ margin-led recovery needs price confirmation after the September 11 close fell below its prior consolidation. A weekly close above $66 would confirm the price case before a weekly close below $58 invalidates it; the next… Cyclical recovery · AI enterprise software analysed · QUBT Quantum Computing Inc. LOW Quantum Computing Inc.’s commercialization story supports a tentative recovery case: a weekly close above the July 2026 shelf of $8.22 would resolve it before a weekly close below $7.30 invalidates it. The September 11 close of $7.99… Retail squeeze · Quantum computing catalyst · QUIK QuickLogic Corporation fresh LOW The eFPGA/defense royalty squeeze has fully unwound: QUIK is ~$13, roughly 47% below the $24.33 June high, and the $18 shelf broke exactly as the Russell inclusion passed. July's post-quantum IP announcement drew no bid — good news into no… Retail squeeze · AI chips & memory · Defense & aerospace analysed · QURE uniQure N.V. fresh LOW FDA's 2026-06-17 reversal put AMT-130 on an accelerated-approval path with a Q3 2026 BLA — the narrative is genuinely repaired, but the move is spent: $40.25 (7/17) sits below the $45.50 June offering price with the CEO selling into it on… Earnings inflection · Precision biotech & therapeutics · Rare disease & gene therapy catalyst · RARE Ultragenyx Pharmaceutical Inc. fresh LOW The +50% June reset rally round-tripped from ~$33.46 to $28.62 (2026-07-21), parking price back on the breakout shelf ahead of two binary FDA decisions: DTX401 (GSD Ia) PDUFA Aug 23 and UX111 (Sanfilippo A) PDUFA Sep 19. The July 30 Q2… Earnings inflection · Rare disease & gene therapy · Binary-catalyst biotech analysed · RBLX Roblox Corporation fresh LOW Broken growth compounder: the age-verification rollout throttled DAUs and forced FY26 bookings guidance down to +8-12%; stock is -66% from its $150 high and below the 200-day. The 2026-07-30 Q2 print is the binary — it needs a DAU… Earnings inflection · AI enterprise software · Critical materials & rare earths analysed · RCKT Rocket Pharmaceuticals, Inc. fresh LOW Rocket Pharmaceuticals’ Danon recovery case requires clinical progress at the 2026-10-06 webinar and a weekly recovery above $3.86 before a weekly close below $3.20. The September 15 FDA-alignment announcement narrows regulatory… Earnings inflection · Rare disease & gene therapy · Binary-catalyst biotech catalyst · RDW Redwire Corporation LOW Post-SpaceX-IPO deflation broke RDW to a 2026-07-18 low near $8.51 (~67% off the 5/28 record). A relief bounce on Huntsville/Indiana facility news and $41.5M of H1 Stalker drone orders keeps running into a ~$850M dilution ceiling: the… Retail squeeze · Space economy · Defense & aerospace analysed · REAL The RealReal, Inc. fresh LOW The RealReal’s luxury-resale growth supports a recovery hypothesis, but price confirmation is absent. A weekly close above $10.00 and third-quarter delivery against August 6 guidance would establish the case; a weekly close below $8.02… Special situation · Consumer discretionary rotation analysed · REAX The Real Brokerage, Inc. fresh LOW The binary resolved — the RE/MAX combination closed 2026-08-24 — and the deal move unwound with it: RSI(14) went from 88.0 on 2026-08-21 to 38.0 at the 2026-09-04 close of $18.67, under the mechanically restated $19.50 July shelf. What… Special situation · Housing, homebuilders & proptech catalyst · RFAI RF Acquisition Corp II fresh LOW RF Acquisition Corp II's remaining story is a redemption-driven squeeze. A daily close at or above the 2026-08-21 closing high of $58 satisfies the prospective recovery case; a daily close below $35 or merger completion ends the pre-close… Retail squeeze · Squeeze & momentum setups analysed · RGTI Rigetti Computing, Inc. LOW Quantum pure-play basket is in outright hype-cycle deflation: RGTI ~$14.19 (2026-07-17), -27% MoM, and the $14 shelf that held the May CHIPS-stake gap and the June executive-order pop has broken. Inverse quantum ETFs printing +108% and the… Retail squeeze · Quantum computing analysed · RH fresh LOW Squeeze leg now ratified by the sell side — TD Cowen $220 (2026-08-08) and Wells Fargo $225 (2026-08-11) against B of A's reinstated Underperform $156 (2026-08-03) — and it resolves into the 2026-09-10 Q2 print with ~56.7% of float still… Retail squeeze · Consumer discretionary rotation catalyst · RIVN Rivian Automotive, Inc. LOW Rivian Automotive’s recovery depends on its R2 second shift starting by September 30 and October deliveries exceeding Q2’s 12,194 vehicles while annual guidance remains 65,000–70,000. A weekly close below $12.90 invalidates the recovery… Earnings inflection · EV & autonomous mobility catalyst · RLAY Relay Therapeutics, Inc. fresh LOW Relay Therapeutics' zovegalisib recovery case requires quantified Phase 3 enrollment progress by year-end 2026 and a weekly close above $20.75. A weekly close below $17.50 invalidates the case; the September 18 close of $18.84 has not… Earnings inflection · Oncology & immunology analysed · RLMD Relmada Therapeutics, Inc. fresh LOW Relmada Therapeutics’ NDV-01 re-rating thesis was invalidated by the $4.12 weekly close on 2026-09-18, below its published $4.25 shelf. A recovery above the March financing level and an announced IND submission would provide evidence for a… Earnings inflection · Oncology & immunology · Binary-catalyst biotech analysed · RMBS Rambus Inc. fresh LOW Memory theme is ripping — Micron +68% YTD with HBM sold out through 2027 — but Rambus has decoupled, down ~42% from its 2026-06-03 high of $174.10 to $101.44 while the cycle proxy sits near records. Interface content is a DIMM-unit story,… Cyclical recovery · AI chips & memory · AI datacenter infrastructure catalyst · RPAY Repay Holdings Corporation fresh LOW The Visa-headline pop has round-tripped — $4.01 on 2026-08-21 back to $3.88 on 2026-09-04 — while the deal file stayed silent: the only company items since are an 2026-08-26 NxtEdge AP partnership and a 2026-09-03 IR hire, leaving… Earnings inflection · M&A & special situations · Fintech & consumer credit analysed · RZLT Rezolute, Inc. fresh LOW The August screener bid fully round-tripped: $5.09 on 2026-08-21 to $4.58 on 2026-09-04, back under the $4.60/$4.61 summer shelf, with no clinical news since 2026-06-17. The registrational upLIFT topline is still guided only to "2H-2026"… Earnings inflection · Binary-catalyst biotech · Rare disease & gene therapy analysed · SABR Sabre Corporation fresh LOW June's +20% deleveraging bounce has fully round-tripped: $1.99 (6/26) back to $1.73 (7/17), now under the 50-day near $1.79 after failing exactly at the $1.99 consensus PT. Balance sheet is fixed, narrative is not accelerating, and a… Special situation · Travel & leisure catalyst · SAH Sonic Automotive, Inc. LOW GPU-normalization narrative broke at the 2026-07-30 print: revenue and adjusted EPS beat consensus, but adjusted EPS fell 17% YoY, franchised segment income −23%, and EchoPark FY26 GPU guidance was cut ~$300 at the midpoint. Shares… Special situation · Consumer discretionary rotation catalyst · SAIL SailPoint, Inc. fresh LOW Agentic-identity story intact and the post-earnings flush is basing: SAIL clawed from a $13.33 low (6/22) back to $15.68 (7/17), a higher low off the $10.30 bottom. Growth decelerated (ARR +26% vs +30%) and guidance was only affirmed, so… Theme leader · Cybersecurity · AI enterprise software catalyst · SANA Sana Biotechnology, Inc. LOW Type-1-diabetes functional-cure narrative: UP421's no-immunosuppression islet transplant is still producing insulin at 14 months (n=1), de-risking SC451's IND guided "as early as 2026." Rare-disease cell therapy is accelerating, but the… Earnings inflection · Binary-catalyst biotech catalyst · SANM Sanmina Corporation fresh LOW The prior break level gave way: the 2026-08-21 weekly close at $188.89 retraced the entire June re-rate. FQ3 on 2026-07-27 beat and raised — $3.46B revenue, +69.7% YoY, FY26 EPS guide lifted to $11.90–12.20 — and the tape answered with a… Special situation · AI datacenter infrastructure · Cyclical industrials catalyst · SAP SAP SE LOW SAP SE’s cloud-and-AI recovery thesis requires a weekly close at or above its 2026-08-28 reference close of $221.54 before a weekly close below $200 invalidates it. The 2026-09-11 close of $206.36 has lost the August shelf, while the… Theme leader · AI enterprise software analysed · SATL Satellogic Inc. LOW The mania leg broke in July — the $6.33 shelf and the $4.97 range low both went — and the 2026-08-05 Q2 print handed the name a different story: revenue $15.9M (+259% YoY) vs $9.6M consensus, plus the first positive operating income and… Retail squeeze · Space economy analysed · SBSW Sibanye-Stillwater fresh LOW Sibanye-Stillwater's lower debt supports a metals-led recovery toward RBC's September 16 target of $15, conditional on no weekly close below $11.50. The September 18 palladium quote of $1,283 per ounce weakens the strike-premium argument. Compounder · Critical materials & rare earths catalyst · SEER Seer, Inc. fresh LOW The take-private ladder has stalled into a stand-off: the $2.55 Radoff-JEC bid lapsed unanswered on 2026-08-10, and the group's 2026-08-13 release demanding the board disclose an evaluation timeline has drawn no company reply through the… Earnings inflection · M&A & special situations · Medtech & diagnostics catalyst · SFIX Stitch Fix, Inc. LOW Stitch Fix’s turnaround needs renewed customer growth at the 2026-09-23 results and a weekly reclaim of $3.50. A weekly close below $2.95 ends the revival case, while revenue below the June guidance floor would contradict its operating… Special situation · Consumer discretionary rotation catalyst · SHOO Steven Madden, Ltd. fresh LOW Tariff-recovery leg has stalled into a $39.71–$47.11 range with insiders selling every rally and zero buys; the whole story now hinges on the confirmed 2026-07-30 Q2 print. Consensus targets sit at or below spot ($43.75, 07-16), adjusted… Special situation · Freight & logistics catalyst · SIDU Sidus Space, Inc. LOW Sidus Space’s cash-and-launch recovery thesis failed when the 2026-09-11 close of $2.00 breached its $2.15 weekly threshold. Successful orbital operation and subsequent revenue growth remain the unresolved commercial tests. Retail squeeze · Space economy analysed · SITM SiTime Corporation fresh LOW MEMS-timing picks-and-shovels story is fundamentally intact — Q1 datacenter revenue +158% YoY to 67% of sales, Renesas timing deal closed July 1 — but the momentum leg has broken: ~$550 on July 18 is ~39% off the May 11 all-time-high close… Cyclical recovery · AI datacenter infrastructure · M&A & special situations analysed · SKM SK Telecom Co., Ltd. fresh LOW SK Telecom’s equity-funded AI data-center expansion supports a recovery case, but the September 18 close shows weakening price confirmation. A weekly close above the August reference of $40.29 would establish recovery; a weekly close below… Special situation · AI datacenter infrastructure · Emerging markets analysed · SKWD Skyward Specialty Insurance Group, Inc. LOW Skyward Specialty Insurance Group’s niche underwriting and Apollo fee income underpin an earnings-resilience thesis in softer insurance markets. Confirmation requires Q3 maintenance of the $4.80–$5.00 annual operating EPS guide and a… Defensive · Managed care & health services analysed · SLDB Solid Biosciences Inc. LOW Solid Biosciences’ SGT-003 thesis depends on functional Duchenne data supporting an accelerated-approval pathway. Favorable disclosed FDA feedback would validate the case; an adverse regulatory outcome or a weekly close below $8.00 would… Earnings inflection · Rare disease & gene therapy · Binary-catalyst biotech catalyst · SLN Silence Therapeutics Plc LOW Silence Therapeutics’ post-readout continuation thesis was invalidated by the 2026-09-11 weekly close of $13.02 below $13.50. Divesiran’s August clinical result remains relevant, but a renewed case requires price recovery and a disclosed… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech analysed · SLS SELLAS Life Sciences Group, Inc. fresh LOW Borrowed sector re-rate has cooled: SLS closed $13.86 on 2026-09-04, 10.3% under the 2026-08-21 high of $15.46, RSI back to 54.1, while REGAL's last published count is still 78 of 80 from 2026-05-11 and BMF Capital's 2026-08-31 short… Retail squeeze · Oncology & immunology · Binary-catalyst biotech catalyst · SMR NuScale Power Corporation LOW NuScale Power’s remaining case is a binding TVA power contract by end-2026 before a daily close below $7.96. The August-range recovery already failed when the shares closed at $8.61 on 2026-09-11, below the published $8.64 boundary. Earnings inflection · Nuclear & uranium catalyst · SMWB Similarweb Ltd. fresh LOW Similarweb’s AI data-licensing pivot needs Q3 revenue conversion to validate its repricing. Confirmation requires revenue within the $80.5–82.5 million guidance issued on 2026-08-12 and an AI-related revenue share above Q2’s 13%, before a… Special situation · AI enterprise software analysed · SNDR Schneider National, Inc. LOW Schneider National's contract-rate recovery needs the next report to sustain its improved Truckload margin and raised earnings outlook. The case is confirmed if margin matches the second quarter's 8.2% and the $0.90–$1.10 annual adjusted… Defensive · Freight & logistics · Cyclical industrials catalyst · SNEX StoneX Group Inc. fresh LOW StoneX Group's recovery case rests on revenue stabilization and a return above its September 4 reference close. Fiscal Q4 net operating revenue of at least $719.7 million and a weekly close above $69.46 would confirm it; a weekly close… Special situation · AI datacenter infrastructure catalyst · SPIR Spire Global, Inc. LOW Spire Global’s government weather-data recovery thesis failed its $13 weekly-close condition at the $11.42 close on 2026-09-11. The September 18 delivery milestone tests execution, but cannot reverse that recorded failure. Defensive · Space economy catalyst · SPRB Spruce Biosciences, Inc. fresh LOW Spruce Biosciences’ Q4 2026 filing story depends on submitting its tralesinidase alfa application before a weekly close below $50. Management reiterated the window on 2026-09-15; submission by 2026-12-31 settles this filing case, while a… Earnings inflection · Precision biotech & therapeutics analysed · SPRY ARS Pharmaceuticals, Inc. LOW Single-product epinephrine name whose one catalyst — a July no-prior-auth formulary add for neffy — came and went unpaid; the stock has since broken its old $6.66 52-week low to fresh lows near $6. The neffy ramp is real but the access… Earnings inflection · Precision biotech & therapeutics catalyst · SRAD Sportradar Group AG LOW Scope expanded, revenue did not: the 2026-08-27 Polymarket deal widened to 20+ leagues and ~300,000 matches a year, and the 2026-08-26 Euroleague renewal runs to 2031, yet the 2026-08-28 close of $12.94 sits below the $13.82 of two weeks… Cyclical recovery · Prediction markets & betting catalyst · STAA STAAR Surgical Company fresh LOW The re-rating leg failed and has not been re-bid: after the 2026-08-21 weekly close at $23.14 broke the $23.50 shelf, ten sessions produced only $23.47 on 2026-09-04 and a 2026-09-02 CTO appointment the tape ignored. What is left is a… Earnings inflection · Medtech & diagnostics analysed · STM STMicroelectronics N.V. fresh LOW The June AI-data-center re-rating has failed its retest: $62.06 on 2026-07-17 is -22% from the 2026-06-22 high of $79.82 and back under the early-June breakout base, with a $1.5B convertible overhang and a 7% selloff that ignored a BofA… Earnings inflection · Analog semiconductors · AI datacenter infrastructure catalyst · STRO Sutro Biopharma, Inc. fresh LOW Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June… Earnings inflection · Binary-catalyst biotech · Oncology & immunology catalyst · STTK Shattuck Labs, Inc. fresh LOW Shattuck Labs' receptor-blocking antibody story has advanced to an open Crohn's trial, according to management on September 8. The near-term recovery case requires a weekly close above September 4's $6.79 reference close before a weekly… Compounder · Precision biotech & therapeutics · Oncology & immunology analysed · STUB StubHub Holdings, Inc. LOW June's busted-IPO recovery leg has fully reversed. D.C.'s RESALE Act (10% resale-markup cap, effective 2027-01-01) plus a Texas AG probe into undelivered World Cup tickets broke the experience-economy narrative; at ~$8.60 STUB trades below… Special situation · Travel & leisure analysed · SUPV Grupo Supervielle S.A. LOW Grupo Supervielle’s recovery thesis needs disinflation to reach credit growth and earnings. The next quarterly report tests for sequential loan growth and a nonperforming-loan ratio below 5.5%, while a weekly close below $7.50 invalidates… Compounder · Emerging markets catalyst · SVV Savers Value Village, Inc. LOW Busted-IPO thrift retailer's June recovery has stalled and rolled back toward its ~$9 base as the June 27 Russell-deletion passive-bid loss bites; the July 30 Q2 print is now an imminent, FX-exposed binary rather than a five-weeks-away… Defensive · Consumer discretionary rotation analysed · SWVL Swvl Holdings Corp Class A fresh LOW Swvl Holdings' financing-led re-rating still needs operating confirmation after its September 8 bank-facility expansion. A weekly close above the reported $7.94 52-week high would complete the continuation case; a weekly close below the… Retail squeeze · AI enterprise software analysed · SXC Suncoke Energy Inc fresh LOW Coal-policy sympathy trade is fully dead: SXC has gone nowhere for three weeks, $8.39 on 2026-06-27 to $8.37 on 2026-07-17, pinned to the $8 shelf with no narrative velocity. The only live variable is the Q2 print, pulled forward to… Special situation · Cyclical industrials · Freight & logistics analysed · SYNA Synaptics Incorporated fresh LOW Synaptics' fixed-ratio onsemi merger remains the central thesis; completion on announced terms before a weekly close below $90 would validate it. The September 15 annual proxy does not establish a merger-vote date. Earnings inflection · M&A & special situations · Analog semiconductors catalyst · TAL TAL Education Group fresh LOW Legacy-pivot re-rating still intact on fundamentals — Q1 FY2027 revenue +31.9% to $758.4M with selling and marketing down 5% — but the post-print impulse has largely round-tripped: $12.16 on 2026-08-11 to $11.32 on 2026-08-21, RSI 37.2,… Special situation · Semi foundry & equipment · Consumer discretionary rotation analysed · TASK TaskUs, Inc. LOW Mix-shift re-rating: AI Services hit $66.1M (+25.8%) in Q2 CY2026 on 2026-08-05 — seventh straight quarter above 25% — and is guided above 30% YoY in Q4 on AV/robotics work, against a 25%-of-revenue Trust & Safety book the market assumes… Special situation · Physical AI & robotics analysed · TBI Trueblue, Inc. LOW Deep-cyclical industrial staffer re-rated +140% off the $3.18 low on a staffing-demand recovery and a data-center/energy labor boom lifting PeopleReady +19% YoY. Still loss-making (Q1 net -$19.8M), margins compressed, and the… Special situation · Cyclical industrials catalyst · TDOC Teladoc Health, Inc. fresh LOW Teladoc Health’s cash-flow support case depends on BetterHelp stabilising before a weekly close below $6.00. The next quarterly report must meet the Q3 revenue floor of $569 million, hold average paying users at least at Q2’s 0.346 million… Special situation · Managed care & health services analysed · TDUP ThredUp Inc. LOW ThredUp's remaining case is a price recovery as buyer growth survives the August guidance reset. A weekly close above the $3.07 reference close of 2026-08-14 would satisfy that case; a weekly close below $2.50 invalidates it. Defensive · Consumer discretionary rotation catalyst · TEN Tsakos Energy Navigation Ltd. fresh LOW Tsakos Energy Navigation’s tanker earnings and fleet renewal support a continuation thesis. A weekly close above $52.81 before a weekly close below $52.09 would confirm the next price leg. Compounder · Freight & logistics catalyst · TENB Tenable Holdings, Inc. fresh LOW The S&P SmallCap 600 bid expired on schedule — after the ~12% move on 2026-08-27 and the $37.67 close on 2026-08-28, the 2026-09-04 close of $34.25 has handed most of the index gap back, and the 2026-09-03 OpenAI CyberAgents announcement… Special situation · Cybersecurity · AI enterprise software analysed · TENX Tenax Therapeutics, Inc. LOW Tenax Therapeutics’ recovery case depends on FDA acceptance of an enriched LEVEL-2 design after the failed trial’s subgroup signal. An agreed protocol would substantiate the case; a weekly close below $1.70 would invalidate its market… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics analysed · TER Teradyne, Inc. fresh LOW Parabolic AI-test leg broke hard: $483.84 closing ATH (2026-06-30) to $322.36 (2026-07-17), −33% in twelve sessions on a memory-glut scare, with the whole $446–$550 analyst band now stranded above spot. Company guided Q2 revenue DOWN… Cyclical recovery · Semi foundry & equipment · AI chips & memory catalyst · TGTX TG Therapeutics, Inc. LOW The catalyst leg is spent; what is left is whether the $46–48 shelf holds through a two-month news vacuum into year-end subcutaneous Phase 3 topline. Compounder · Oncology & immunology · Precision biotech & therapeutics catalyst · TH Target Hospitality Corp. fresh LOW The AI-datacenter-landlord re-rate has stalled: TH peaked at $20.85 and has given back ~21% to $16.36 (2026-07-17) as TDR Capital affiliates distribute shares in-kind to partners, losing the $17 secondary clearing shelf while Oppenheimer… Special situation · AI datacenter infrastructure · Cyclical industrials catalyst · THC Tenet Healthcare Corporation New LOW Tenet Healthcare’s hospital-margin re-rating needs a weekly close above the August 21 high of $280.77 before a weekly close below $262 breaks the extension. The next results test whether the 18.0% hospital margin and annual earnings… Special situation · Managed care & health services catalyst · TIC TIC Solutions, Inc fresh LOW Post-merger re-rate: engineering/geospatial backlog hit a record $1.18B (+20% YoY) on 2026-08-06 while legacy inspection fell ~5.5% combined, and UBS's 2026-08-11 upgrade (Buy, PT $12.50 from $11.00) prices an inflection that Q2's +2.5%… Special situation · M&A & special situations analysed · TLN Talen Energy Corporation LOW Contracted-floor re-rating has stopped paying: the 2026-08-05 Q2 raised FY26 Adj EBITDA guidance to $2,025–2,225M and PJM's 2028/29 auction cleared >10 GW at the $325/MW-day cap, yet the stock closed $347.71 on 2026-08-07, 22% below the… Theme leader · Industrial power & grid · AI datacenter infrastructure analysed · TLRY Tilray Brands, Inc. fresh LOW Reform binary spent without resolving: the DEA hearing closed 2026-07-15 with only a 2026-08-17 briefing deadline and no ALJ timeline, so Schedule III is now an open-ended administrative process. TLRY printed a fresh 52-week low of $4.20… Earnings inflection · Cannabis reclassification · Consumer discretionary rotation catalyst · TMC TMC the metals company Inc. fresh LOW The deep-sea-mining reshoring leg is broken: TMC has cut through the $3.93 prior 52-week low to a fresh $3.57 low near $3.74, roughly -67% from the $11.35 high, with no bid and no near-term catalyst. The decisive NOAA license decision is… Earnings inflection · Bitcoin miners · Critical materials & rare earths catalyst · TNDM Tandem Diabetes Care, Inc. LOW Beaten-down insulin-pump turnaround; the whole re-rate hinges on the tubeless Mobi ("Toby") 510(k) — planned for a Q2 filing but still unconfirmed after the quarter closed 2026-06-30 — plus margins scaling toward a ~60% Q4 exit. Shares… Special situation · Medtech & diagnostics catalyst · TNXP Tonix Pharmaceuticals Holding Corp. fresh LOW Tonix Pharmaceuticals’ Tonmya launch thesis requires Q3 sales and prescriptions to exceed Q2’s approximately $11.0 million and 12,592 prescriptions before a weekly close below $10.50. The 2026-09-18 close of $10.87 leaves weak price… Defensive · Precision biotech & therapeutics analysed · TORO Toro Corp. fresh LOW Panagiotidis shipping shell (NOT lawnmower TTC) ran 1.93→8.50 on a sub-NAV/special-dividend story that is now fully paid out and closed. Six weeks of dead tape since the 2026-06-05 payout ($3.8M cash + 5,707,246 NEW shares); on a true… Retail squeeze · Freight & logistics · M&A & special situations analysed · TRIP TripAdvisor, Inc. LOW Tripadvisor's residual-value case rests on TheFork proceeds and Experiences growth supporting a weekly recovery above $10. A weekly close below $9 invalidates the price case; failure to close TheFork by December 31, 2026 defeats the… Special situation · Travel & leisure · M&A & special situations analysed · TSAT Telesat Corporation Class A Common Shares and Class B Variable Voting Shares LOW Legacy GEO operator re-rating on a funded LEO pivot: 2026-08-04 C$2.3B, 15-year Canadian Arctic Mil-Ka contract expands Lightspeed 156→225 satellites and lifts the 2032 revenue target to US$4.9B from US$3.2B. Price closed at the 52-week… Special situation · Space economy · Defense & aerospace analysed · TSHA Taysha Gene Therapies, Inc. fresh LOW De-risking is behind the stock and the calendar in front of it is empty: after the clean 2026-06-22 data and the $6.00 June raise, no company-dated event lands before the ~November Q3 update, and the tape has drifted to a $5.60 close on… Earnings inflection · Rare disease & gene therapy · Precision biotech & therapeutics analysed · TSLA Tesla, Inc. LOW Tesla’s autonomy thesis requires Cybercab deployment to become a measurable business, confirmed by operating fleet and ride-pricing disclosures plus a daily close above $376.37. A daily close below $357 invalidates that case; the estimated… Compounder · EV & autonomous mobility · Physical AI & robotics catalyst · UCTT Ultra Clean Holdings, Inc. fresh LOW WFE upcycle intact fundamentally but the tape broke: -35% from the $142.59 all-time close (2026-06-30) back under the ~$95 breakout shelf on sector-wide selling with no company news. Failed breakout, no support to $80.55, binary Q2 print… Cyclical recovery · Semi foundry & equipment analysed · UFPT UFP Technologies, Inc. fresh LOW UFP Technologies' medical-outsourcing recovery case requires a weekly reclaim of $300 before a weekly close below $273. The prior case failed at the 2026-09-18 close, while CI Medical's acquisition release provides no financial… Cyclical recovery · Medtech & diagnostics analysed · UHAL U-Haul Holding Company LOW U-Haul Holding Company's storage-led re-rating failed when the 2026-09-11 close of $64.05 breached its published $68 weekly threshold. A recovery case requires a weekly close above the former $68.25 July shelf and improving storage… Special situation · Housing, homebuilders & proptech catalyst · UI Ubiquiti Inc. fresh LOW Broken parabola gone flat: six weeks of $530–$570 chop after the May 8 print (GM 47.0%, rev +18.7%, but EPS $3.88 vs ~$4.42 whisper) with zero scheduled catalyst until the Q4 FY26 report on 2026-08-21. Fundamentals intact, tape dead,… Earnings inflection · Networking & optical analysed · UNH Unitedhealth Group Incorporated fresh LOW UnitedHealth Group's margin repair has yet to earn a market re-rating; the 2026-10-13 results test its $19.50–$20.00 full-year adjusted earnings-per-share outlook. A weekly close below $375 invalidates the price case. Special situation · Managed care & health services catalyst · UNIT Uniti Group Inc. fresh LOW Hyperscaler dark-fiber demand turned the post-Windstream deleveraging grind into a growth story (~$1.5B disclosed funnel, $68.7M of Q1 IRU revenue from one hyperscaler), but the June re-rate to ~$11 has stalled in a three-week range above… Special situation · AI datacenter infrastructure · M&A & special situations catalyst · URGN UroGen Pharma Ltd. LOW UroGen Pharma’s ZUSDURI launch-growth thesis requires third-quarter revenue above the second quarter’s $50.4 million before a weekly close below $40 invalidates the structure. The confirmed 2026-09-15 conference adds management exposure,… Compounder · Precision biotech & therapeutics · Oncology & immunology catalyst · UUUU Energy Fuels Inc. LOW Two sell-side target raises in consecutive sessions — HC Wainwright's $29.25 on 2026-09-01 and Cantor Fitzgerald's $33 reiteration on 2026-09-02 — moved the shares less than 1%, to a $14.29 close 48.4% under the 52-week high. With rare… Compounder · Nuclear & uranium · Critical materials & rare earths catalyst · VAC Marriott Vacations Worldwide Corporation fresh LOW Marriott Vacations Worldwide’s earnings-led re-rating failed its $106 weekly price test at the 2026-09-11 close of $103.59. The next quarterly results must establish whether the operating recovery still supports the $805–830 million… Special situation · Travel & leisure · Fintech & consumer credit analysed · VECO Veeco Instruments Inc. LOW Merger-arb tracking stock for Axcelis: fixed 0.3575 ACLS/VECO, both votes cleared 2026-02-06, only China SAMR remains before the 2026-09-30 outside date. ACLS's slide to ~$134 de-pegged VECO to a premium over the exchange ratio (~$48) —… Earnings inflection · M&A & special situations · Semi foundry & equipment catalyst · VEEV Veeva Systems Inc. fresh LOW Veeva Systems’ recovery rests on Vault CRM adoption overcoming Salesforce competition, supported by 16% subscription growth reported on 2026-08-26. A daily close above the September 18 reference high of $306.22 would complete the recovery… Theme leader · AI enterprise software · Medtech & diagnostics catalyst · VERI Veritone, Inc. fresh LOW Veritone’s rebound prices a negotiated resolution of its $45.6 million November debt maturity. The case plays out if repayment, refinancing or extension completes before 2026-11-15 and before a weekly close below $0.50; September’s… Earnings inflection · AI enterprise software catalyst · VERU Veru Inc. fresh LOW The Novo squeeze is fully round-tripped and the funding answer arrived on 2026-07-02: a $21.8M at-the-market program via Oppenheimer/Canaccord. At $2.42 (07-15) that is ~9M shares against ~16M outstanding — the company will now sell stock… Retail squeeze · Precision biotech & therapeutics analysed · VIAV Viavi Solutions Inc. LOW Networking-optical test theme still accelerating and the laggard test-and-measurement sleeve is finally re-rating: Susquehanna lifted its target to $66 (2026-07-01) and the small-cap-over-hyperscaler rotation flagged 2026-06-29 favors… Cyclical recovery · Networking & optical · AI datacenter infrastructure catalyst · VICR Vicor Corporation LOW Operating numbers still inflecting (Q2 guide ~$142M, book-to-bill >2.0, backlog $300.6M) but the chart has broken: $237.62 on 2026-07-17 is ~38% off the $382.65 July high, with $271 and $300 both lost and relentless CEO 10b5-1 supply. The… Cyclical recovery · AI datacenter infrastructure analysed · VIOT Viomi Technology Co., Ltd fresh LOW Viomi Technology’s recovery now depends on appliance sales and profit after Nasdaq compliance was restored on 2026-09-18. The case requires second-half revenue above RMB740.0 million and positive net income before a weekly close below… Defensive · Oil, energy & geopolitical · Semi foundry & equipment analysed · VIR Vir Biotechnology, Inc. fresh LOW Q2 (2026-08-05) printed $238.9M revenue and $0.47 diluted EPS on Astellas upfront recognition — an accounting swing, and the tape read it as one: $9.24 on 2026-08-14, still under the $10.36 Astellas equity strike, with Morgan Stanley and… Earnings inflection · Binary-catalyst biotech · Oncology & immunology analysed · VKTX Viking Therapeutics, Inc. LOW Viking Therapeutics' maintenance-dosing story needs September data showing retained weight loss with less frequent treatment and a weekly close above $34. The case fails on a weekly close below $30 or a missed September 30 readout window. Earnings inflection · Precision biotech & therapeutics catalyst · VMI Valmont Industries, Inc. LOW Valmont Industries’ utility-growth story supports a recovery case that requires a weekly close above $520 with its July earnings guidance maintained or raised. A weekly close below $470 first invalidates the case; the September 11, 2026… Theme leader · Industrial power & grid analysed · VOR Vor Biopharma Inc. LOW Vor Biopharma’s telitacicept pivot depends on positive global Phase 3 results within its first-half 2027 guidance window. The recovery thesis fails if a weekly close below $20 occurs first, while a failed endpoint or delayed results… Special situation · Oncology & immunology catalyst · VOYG Voyager Technologies, Inc. LOW Voyager Technologies’ order-book re-rating needs price recovery and September NASA procurement progress. The case requires a weekly close above the August $38.40 reference before a weekly close below $32, unchanged $275–305 million 2026… Compounder · Space economy catalyst · VPG Vishay Precision Group, Inc. fresh LOW The AI-precision re-rate broke at the print: Q2 (2026-08-05) missed on revenue ($83.936M vs $84.646M) and adjusted EPS ($0.04 vs $0.19), Q3 guide midpoint sits below consensus, and the stock gapped -26.95% to $73.78 and has since made… Theme leader · Analog semiconductors · AI datacenter infrastructure catalyst · VSH Vishay Intertechnology, Inc. LOW Cycle-turn re-rate has fully round-tripped: down ~46% from $69.47 to the high-$30s, now under the $50 June placement and below every covering analyst's target. Q1's 1.34 book-to-bill and $1.6B backlog were real but sit at ~35x forward into… Earnings inflection · Industrial power & grid catalyst · VSTS Vestis Corporation fresh LOW Vestis Corporation's turnaround depends on cost reductions delivering fiscal 2026 earnings and cash-flow guidance. The full-year report tests the $310–315 million adjusted EBITDA and $160–170 million free-cash-flow ranges issued on… Special situation · GPU cloud & neoclouds catalyst · VSXY Victorias Secret & Co. LOW Turnaround re-accelerated with no new number: the July mid-$70s range broke, a $99.97 52-week high printed, then 11% came back into the 2026-09-03 Q2 report. Consensus target $91.40 sits ~3% over the $89.02 close on 2026-08-14, so the… Special situation · Consumer discretionary rotation catalyst · WHD Cactus, Inc. fresh LOW International wellhead order narrative from the 2026-07-29 Q2 beat is intact, but the re-rating leg is largely spent: Citigroup cut to Neutral on 2026-08-20 while raising its target to $75, and the shares closed $69.43 on 2026-08-21, 5.8%… Cyclical recovery · Oil, energy & geopolitical analysed · WING Wingstop Inc. LOW Two analyst target cuts in ten days (Wells Fargo to $170, DA Davidson to $200) into the 2026-07-29 Q2 print signal de-risking ahead of the H2 comp-turn binary; a ~50% relief bounce off the $116.35 low is unproven, and the print — not… Earnings inflection · Consumer discretionary rotation · Precision biotech & therapeutics catalyst · WLFC Willis Lease Finance Corporation LOW Engine-leasing supercycle still printing records (Q1 rev +23%, EPS $4.03 vs $3.02 est), but the theme is maturing and the stock has faded ~18% off its 2026-07-06 ATH into the now-completed 3-for-1 split. The event stack has collapsed to… Cyclical recovery · Cybersecurity analysed · WRLD World Acceptance Corporation LOW World Acceptance Corporation’s credit-recovery and repurchase thesis needs Q2 revenue above $139.2 million with delinquency no higher than June’s readings. Those results would confirm the operating case if they arrive before a weekly close… Special situation · Fintech & consumer credit catalyst · WSC WillScot Holdings Corporation LOW Cyclical modular-space leasing recovery with a small data-center kicker and an activist/M&A floor, but range-bound and digesting: shares drifted to ~$26 under the $31.88 high after the 2026-06-27 Russell growth-index removal. The confirmed… Theme leader · Space economy · Housing, homebuilders & proptech catalyst · WSM Williams-Sonoma, Inc. LOW Williams-Sonoma's August 26 growth-guidance increase supports a recovery toward Evercore ISI's September 9 target of $240. A weekly close above $240 would demonstrate that recovery; a weekly close below $225 would invalidate it. Defensive · Consumer discretionary rotation · Cybersecurity catalyst · XENE Xenon Pharmaceuticals Inc. LOW Xenon Pharmaceuticals' recovery thesis requires an on-time azetukalner application and a weekly reclaim of the failed $62 shelf. Management guided submission to Q3 2026 on 2026-08-06; a weekly close below $55 or a disclosed filing delay… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · XHG XChange TEC.INC LOW XChange TEC's AI-insurance acquisition story needs a definitive First Cycle agreement and price recovery to validate it. The case requires a daily close above the $4.62 high reported as of 2026-09-11 before a daily close below that date's… Retail squeeze · M&A & special situations · AI datacenter infrastructure analysed · XOS Xos, Inc. fresh LOW First-ever U.S. Air Force award (prototype OTA for the Xos Hub mobile BESS, announced 2026-08-17, terms not disclosed) took the stock ~100% on 2026-08-18 and put a defense-pivot narrative on a going-concern EV maker that just missed Q2… Retail squeeze · Defense & aerospace · EV & autonomous mobility catalyst · XRAY DENTSPLY SIRONA Inc. LOW Dentsply Sirona's turnaround re-rating failed its published $11 weekly-close test with the $10.46 close on 2026-09-11. A renewed recovery case requires a weekly close above $11, stabilising sales and maintained annual guidance. Special situation · Consumer discretionary rotation catalyst · XRX Xerox Holdings Corporation LOW Distressed-deleveraging special situation that round-tripped its June activist pop into a binary 2026-07-30 Q2 print. At ~$2.60 it sits below the $2.75 Hold consensus and inside the $2.25–$2.50 target band; anchor buyer STARTEEPO (8.8M sh,… Special situation · M&A & special situations · Cyclical industrials catalyst · XTLB XTL Biopharmaceuticals Ltd. LOW XTL Biopharmaceuticals' psychedelic recovery case requires a disclosed Psyga trial start or binding ibogaine partnership and a weekly close above the June 30, 2026 financing reference of $2.70. A weekly close below $2.20 invalidates it;… Special situation · Precision biotech & therapeutics · M&A & special situations analysed · YAAS Youxin Technology Ltd LOW Youxin Technology’s residual recovery case requires a weekly reclaim of $2.00 and a definitive RiverBit agreement before a weekly close below $1.00. The previous $2.00 floor thesis failed at the 2026-09-11 close of $1.39. Retail squeeze · Crypto exchanges & financials · AI enterprise software analysed · YEXT Yext, Inc. fresh LOW Yext’s margin-and-share-count recovery needs AI products to restart recurring-revenue growth. The case requires next-quarter ARR above $440.8 million before a daily close below $5.90; Envision on 2026-09-30 tests commercial evidence but… Special situation · AI enterprise software catalyst · YSS York Space Systems Inc. LOW York Space Systems’ procurement-delay recovery case failed when its 2026-09-11 weekly close breached $8.86. Funded orders, backlog growth and recovery of that shelf are required to establish a new case. Earnings inflection · Space economy analysed · ZBRA Zebra Technologies Corporation fresh LOW Zebra Technologies’ automation re-rating needs Q3 earnings confirmation after the September 18 close weakened to $346.63. The recovery case resolves with a weekly close above the market’s $383.06 high before a weekly close below $330; Q3… Theme leader · AI enterprise software · Physical AI & robotics analysed · ZENA ZenaTech, Inc. LOW ZenaTech's recovery case requires a priced commercial drone-service contract and a weekly close above the market's August 28 close of $1.71. A weekly close below $1.52 invalidates that case; September's development announcements have not… Defensive · Defense & aerospace · Cyclical industrials catalyst · ZURA Zura Bio Limited LOW Zura Bio’s pipeline-expansion story depends on positive Q4 2026 TibuSHIELD data before a weekly close below $4.90 breaks the setup. The September 11 close of $5.21 and RSI of 39.2 weaken the price evidence; clinical confirmation requires a… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics analysed · ZVRA Zevra Therapeutics, Inc. LOW The June patent re-rating fully reversed: EMA's CHMP issued a negative opinion on arimoclomol's EU application 2026-07-24 (efficacy not proven), and ZVRA gapped ~24% to the high-$9s, cutting through the $11.50 base. EU expansion is now… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics catalyst ·

Common questions

What is a FrontierPicks dossier?

A per-ticker research note written by a frontier language model: the current thesis, the archetype the name is trading as, the next dated catalyst, and an explicit kill line — the price level or event that would prove the pick wrong. Every dossier is dated and rewritten as the facts change.

How many stocks does FrontierPicks cover?

942 US tickers have a dossier right now. All 942 published dossiers carry the full shape: a dated thesis and the exact level that ends it. Coverage is earned rather than fixed: a name gets a dossier when the model has something to say about it beyond the price trend. The 61 names the model holds, has just exited, or that sit in a theme it is currently calling accelerating are re-read every trading day — every one of them was read in the current session. The wider 881-name coverage universe cycles behind them: its median name was last read 0 sessions ago, and no dossier is more than 8 sessions old.

Is AI-generated stock research reliable?

It should be judged the way any research is judged — on whether its stated confidence holds up against outcomes. FrontierPicks is built to make that measurable: every pick publishes a kill line before the outcome is known and is graded mechanically against it, and the resulting calibration record is recomputable from the published data rather than asserted. It is research to evaluate, not advice; no performance claim is made.

How often are the dossiers updated?

On a rolling cycle, not uniformly. The 61 names the model holds, has just exited, or that sit in a theme it is currently calling accelerating are re-read every trading day — every one of them was read in the current session. The wider 881-name coverage universe cycles behind them: its median name was last read 0 sessions ago, and no dossier is more than 8 sessions old. The model re-reads a covered name against fresh price, filing and news data and rewrites the dossier when the facts move; each page shows its own last-updated date rather than a sitewide timestamp, so the cadence is checkable name by name.